



The College *on* Problems
of Drug Dependence

84th Annual Scientific Meeting
June 11 - 15, 2022
Minneapolis, MN

PROGRAM BOOK

WWW.CPDD.ORG



HILTON MINNEAPOLIS

1001 MARQUETTE
AVENUE SOUTH
MINNEAPOLIS, MN
(612) 376-1000

Located in the heart of downtown Minneapolis, the hotel is directly connected by covered skyways to the Minneapolis Convention Center and the Minnesota Orchestra.


FLOOR MAP KEY

- Meeting/Conference Rooms
- Amenities
- Public Space
- Private
- Outdoor Space
- ⬆ Stairs and Escalators
- ⬆ Elevators


Lobby Level



Second Level



Third Level



GENERAL INFORMATION

Registration is located in the **Minneapolis Foyer** located on the 3rd floor of the hotel.

REGISTRATION HOURS:

- Saturday, June 11: 1:00 PM - 5:30 PM
- Sunday, June 12: 7:30 AM - 5:00 PM
- Monday, June 13: 7:30 AM - 5:00 PM
- Tuesday, June 14: 7:30 AM - 5:00 PM
- Wednesday, June 15: 7:30 AM - 3:00 PM

CPDD PHOTOGRAPHY POLICY



Please respect our presenters. CPDD does not permit photographs, videotaping, or audio taping of any session.

POSTER SESSIONS

The poster room is located on the 2nd floor in the **Marquette Ballroom**. Posters must be removed from boards immediately following the poster session.

- Sunday, June 12: 11:30 AM - 1:30 PM
- Monday, June 13: 8:00 AM - 10:00 AM
- Tuesday, June 14: 8:00 AM - 10:00 AM
- Wednesday, June 15: 8:00 AM - 10:00 AM

GENERAL INFORMATION

QUESTIONS

If you have questions during the conference, we encourage you to:

- 1) Stop by the registration desk located in the Minneapolis Foyer.
- 2) Email info@cpdd.org with additional questions or concerns or call (615) 432-0099.
- 3) Visit the Speaker Ready Room located in Red Wing for assistance with a presentation or presenter questions.

JOIN THE CONVERSATION

CPDD has gone social and we invite you to join the online conversation. Please be sure to follow/like the following CPDD social media accounts:

@CPDDorg



@CPDDmembers



@CPDD



And do not forget to use the hashtag #CPDD2022 if you post pictures or comments about the Meeting.

CPDD'S DISCLAIMER STATEMENT

Information obtained via CPDD channels, including webinars, conferences, websites, etc., is intended for only information and research purposes. CPDD cannot be held liable for the information consumed and may not reflect the opinions of CPDD or its members. The content and information shared should be used at the discretion of the consumer.

Funding for this conference was made possible (in part)
by 5 R13 DA 013192 - 15
from the National Institute on Drug Abuse

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

#CPDD2022

SAFETY PROTOCOLS

WEAR A MASK

Masks are strongly recommended at all CPDD events. Make sure and pack yours!



WEAR YOUR BADGE

A CPDD badge is required at all times for entry. Your badge indicates proof of vaccination.

GRAB A LANYARD

Magenta=Keep Your Distance
Yellow=Limited Contact
Green=Handshakes & High Fives



ATTENDEES THAT EXPERIENCE SYMPTOMS OR FEEL ILL
ONSITE SHOULD QUARANTINE IN THEIR GUESTROOM
AND CALL JESSE HOWARD AT 606-233-3049
TO RECEIVE NEXT STEPS.

CPDD 2021 - 2022

BOARD OF DIRECTORS

EXECUTIVE COMMITTEE

William Stoops, PhD
President

Amy Janes, PhD
President-Elect

Jack Bergman, PhD
Treasurer

Stacey Sigmon, PhD
Past-President

Sandra Comer, PhD
Public Policy Officer

BOARD MEMBERS

Sudie Back, PhD

Qiana Brown, PhD, MPH, MSW, LCSW

F. Ivy Carroll, PhD

Ziva Cooper, PhD

Kelly Dunn, PhD, MBA

Albert Garcia-Romeu, PhD, MA

Deborah Hasin, PhD

Angela Heads, PhD

Jermaine Jones, PhD

Frances R. Levin, MD

Wendy Lynch, PhD

Marco Pravetoni, PhD

James Rowlett, PhD

Dace Svikis, PhD

Michael Taffe, PhD

Erin Winstanley, PhD

2022 PROGRAM COMMITTEE

Chair: Kelly Dunn, PhD, MBA

MEMBERS

Matthew Banks, PhD, Pharm D

Eduardo Butelman, PhD

Mance Buttram, PhD

Kevin Freeman, PhD

Diann Gaalema, PhD

Scott Hadland, MD, MPH, MS

Jermaine Jones, PhD

Mikhail Koffarnus, PhD

Dustin Stairs, PhD

Justin Strickland, PhD

Jennifer Tidey, PhD

Denise Vidot, PhD

Heather Ward, MD

Reagan Wetherill, PhD

*thank
you*

2022 Schedule

SUNDAY, JUNE 12

8:00 AM	11:30 AM	Plenary, Eddy Lectures & Awards Ceremony*	Minneapolis D
11:00 AM	7:00 PM	Speaker Ready Room	Red Wing
11:30 AM	1:30 PM	Poster Session 1, Exhibits & Lunch	Marquette Ballroom
12:00 PM	1:00 PM	Drug and Alcohol Dependence and Drug and Alcohol Dependence Reports Journals Editorial Meeting	
1:30 PM	2:30 PM	Presidential Symposium*	Minneapolis D
2:30 PM	3:00 PM	Break	
3:00 PM	4:00 PM	Late-Breaking Oral Session 1**	Minneapolis D
3:00 PM	4:00 PM	Oral Communication: Advances in Contingency Management	Symphony Ballroom III
3:00 PM	4:00 PM	Oral Communication: Advancements in Monoclonal Antibodies	Conrad BC
3:00 PM	4:00 PM	Oral Communication: Role of Sex/Gender on SUDs	Orchestra AB
3:00 PM	4:00 PM	Workshop: Test of Two Implementation Science Strategies to Increase Medications for Opioid Use Disorders (MOUD) in Jail Settings**	Minneapolis ABC
3:00 PM	4:00 PM	Oral Communication: Prenatal Science I	Orchestra CD
4:00 PM	4:45 PM	Pre & Postdoctoral Networking	
4:30 PM	6:00 PM	Symposium: Beyond Delta-9-THC: The Blossoming of Minor Cannabinoids**	Minneapolis ABC
4:30 PM	6:00 PM	Symposium: Using Behavioral and Brain Biotypes to Enhance Treatment Outcomes in Addiction Medicine**	Minneapolis D
4:45 PM	5:45 PM	Oral Communication: Sexual Minority Health and SUDs	Conrad BC
4:45 PM	5:45 PM	Oral Communication: Alcohol and Psychiatric Comorbidities	Symphony Ballroom III
4:45 PM	5:45 PM	Oral Communication: How Do Flavorings Influence Nicotine Use Behaviors	Orchestra AB
4:45 PM	5:45 PM	Oral Communication: Choice Behaviors	Orchestra CD
6:00 PM	7:00 PM	Fischman Lecture Presented by Frances Levin, 2020 Fischman Awardee**	Minneapolis D
7:00 PM	8:30 PM	CPDD Presidential Reception	The Gallery
7:15 PM	9:15 PM	Workshop: Advantages and Challenges of Big Data Approaches to Detect Novel Biology Underlying Substance Use Disorders**	Minneapolis ABC
7:15 PM	9:15 PM	Workshop: Conducting Pragmatic Trials of Interventions to Improve Care for Substance Use in Medical Settings: Lessons From 4 Trials	Symphony Ballroom III
7:15 PM	9:15 PM	Workshop: Epidemiology and Public Health Research Methods	Orchestra AB
7:15 PM	9:15 PM	Workshop: News You Can Use: Media Relations 101	Orchestra CD
7:15 PM	9:15 PM	Workshop: Academic/Community Partnerships as a Strategy for Reducing Health Disparities in Substance Use**	Minneapolis D
7:15 PM	8:15 PM	Oral Communication: Trends in Polysubstance Use	Conrad BC

MONDAY, JUNE 13

8:00 AM	10:00 AM	Poster Session 2, Exhibits & Continental Breakfast	Marquette Ballroom
10:00 AM	11:30 AM	Symposium: The Best Offense is Defense! Blocking and Tackling Stimulants in the Periphery to Prevent CNS Action**	Minneapolis D
10:00 AM	11:30 AM	Symposium: The Importance of Gender, Culture and Intersectional Issues in Substance Use Interventions: Lessons in Health Disparity Research in South Africa and the U.S.**	Minneapolis ABC
10:00 AM	11:30 AM	Symposium: From Bench to Bedside to Policy: Updating Our Understanding of Kratom	Orchestra AB
10:00 AM	11:30 AM	Symposium: Dose-Dependent Subjective Effects of THC and Cannabis Concentrates: From Naturalistic Investigation to Population Analysis	Orchestra CD
10:00 AM	11:00 AM	Oral Communication: Social Environment and SUD Behaviors	Conrad BC
10:00 AM	11:00 AM	Oral Communication: Machine Learning Applications for SUDs	Symphony Ballroom III
11:30 AM	12:00 PM	Lunch On Own	N/A
12:00 PM	2:00 PM	Human Forum: Resuming Research on Substance Use Disorders After Lifting COVID-19 Distancing Measures: Challenges and Opportunities	Orchestra AB
12:30 PM	2:00 PM	CPDD Early Career Investigator Travel Awards Luncheon (By Invitation Only)	Minneapolis E
1:00 PM	2:00 PM	Mini-Symposium: Gabapentin, Friend or Foe? Emerging Trends, Use Behaviors, and Adverse Events**	Minneapolis D
1:00 PM	2:00 PM	Mini-Symposium: Catching up on Sleep: Insights Into the Bidirectional Relationship Between Drug Use and Sleep Impairments, and Relapse Potential**	Minneapolis ABC
1:00 PM	2:00 PM	Oral Communication: Methamphetamine Basic Science	Conrad BC
1:00 PM	2:00 PM	Oral Communication: Ecological Momentary Assessment Innovations	Orchestra CD
1:00 PM	2:00 PM	Oral Communication: Genetics of SUDs I	Symphony Ballroom III
2:15 PM	3:15 PM	Fischman Lecture Presented by Laura Bierut, 2022 Fischman Awardee**	Minneapolis D
3:45 PM	4:45 PM	Oral Communication: Neuroscience of SUDs I	Orchestra AB
3:45 PM	4:45 PM	Oral Communication: Cannabinoid Science	Orchestra CD
3:45 PM	4:45 PM	Oral Communication: The Role of Neighborhood on SUDs	Symphony Ballroom III
3:45 PM	5:15 PM	Symposium: "Extending" the Benefits of Extended (virtual and augmented) Reality to SUD Patients**	Minneapolis D
3:45 PM	5:15 PM	Symposium: Pain Relief Without Opioids: Is the Future Now?	Conrad BC
3:45 PM	5:15 PM	Symposium: NDEWS Methods to Detect New and Emerging Psychoactive Substances Presented by New and Emerging Scientists**	Minneapolis ABC
5:30 PM	6:30 PM	SBIR Poster Session (Small Business Innovation Research - SBIR)	Marquette Ballroom
6:00 PM	7:00 PM	Primm Singleton Reception	
7:00 PM	9:00 PM	Workshop: Early Career Member Committee: Navigating a Career in Addiction Science**	Minneapolis D
7:00 PM	9:00 PM	Workshop: 28th Annual Contingency Management Working Group	Orchestra AB
7:00 PM	9:00 PM	Workshop: Learnings From the Rural Opioid Initiative About Methods to Conduct Research With Rural PWUD	Orchestra CD
7:00 PM	9:00 PM	Workshop: A Path Less traveled: Becoming a Medical Device Developer for the Substance Use Disorders**	Minneapolis ABC
7:00 PM	9:00 PM	Workshop: Implementing Peer Recovery Coaches for Improving Recovery in People With Substance Use Disorders: Insights Form Researchers, Stakeholders, and Clinicians	Conrad BC
7:00 PM	8:00 PM	Oral Communication: The Neuroscience of Alcohol	Symphony Ballroom III

8:00 AM	10:00 AM	Poster Session 3, Exhibits & Continental Breakfast	Marquette Ballroom
10:00 AM	11:30 AM	Symposium: Circadian and Sleep Factors in Substance Use Disorders: Role of the Extracellular Matrix	Orchestra CD
10:00 AM	11:30 AM	Symposium: Innovative Approaches for Expanding Access to Pharmacotherapy for Opioid Use Disorder**	Minneapolis D
10:00 AM	11:30 AM	Symposium: Links Between Early Life Adversity and Addiction**	Minneapolis ABC
10:00 AM	11:30 AM	Symposium: Cross-Cultural Cannabis Science: Lessons Learnt and How to Move Forward	Conrad BC
10:00 AM	11:00 AM	Oral Communication: Behavioral Pharmacological Research	Orchestra AB
10:00 AM	11:00 AM	Oral Communication: Harm Reduction Efforts for SUDs	Symphony Ballroom III
11:30 AM	12:00 PM	Lunch (On Own)	N/A
12:00 PM	2:00 PM	Animal Forum: Getting the Word Out: Strategies for Effective Communication About Animals in Research	Orchestra AB
1:00 PM	3:00 PM	Policy Forum: Impact of COVID-19 Opioid Treatment Program Policy Relaxations on Patient Outcomes	Orchestra CD
2:00 PM	3:00 PM	Late-Breaking Oral Session 2**	Minneapolis D
2:00 PM	3:00 PM	Oral Communication: Cocaine Preclinical Science	Orchestra AB
2:00 PM	3:00 PM	Journals: Drug and Alcohol Dependence & Drug and Alcohol Dependence Reports	Minneapolis ABC
2:00 PM	3:00 PM	Oral Communication: Opioid Use in Justice-Involved Persons	Conrad BC
2:00 PM	3:00 PM	Oral Communication: Prenatal Science II	Symphony Ballroom III
3:30 PM	5:30 PM	Workshop: Event-Related Potentials and Substance Use Disorders: Identifying Clinically Relevant Metrics to Inform Therapeutics	Orchestra AB
3:30 PM	5:30 PM	Workshop: Did You Hear About the Looming Global Fentanyl Crisis?: A Quick Start for Addiction Scientists Across the World**	Minneapolis D
3:30 PM	5:30 PM	Workshop: Meeting the Demand: Expanding the Addiction Workforce From Programs to Peers	Orchestra CD
3:30 PM	5:30 PM	Workshop: Engaging Communities to Deliver Effective Opioid Use Programs for Native Americans**	Minneapolis ABC
3:30 PM	5:30 PM	Workshop: Advances in Adolescent Recovery Research and the Society for Adolescent Substance Abuse Treatment Effectiveness (SASATE)	Conrad BC
3:30 PM	4:30 PM	Oral Communication: Nicotine Co-Use	Symphony Ballroom III
4:45 PM	5:45 PM	Oral Communication: What is the Role of Diet in SUDs?	Symphony Ballroom III
5:45 PM	6:45 PM	CPDD Business Meeting	Minneapolis D
7:30 PM	9:30 PM	Dessert and Dancing	Minneapolis E

8:00 AM	10:00 AM	Poster Session 4, Exhibits & Continental Breakfast	Marquette Foyer
10:00 AM	11:30 AM	Symposium: The Orexin System in Addiction**	Minneapolis D
10:00 AM	11:30 AM	Symposium: Through the Looking Glass: Metacognition, Interoception, Hallucinogens, and Non-Ordinary States as Potential Avenues for Novel Addiction Treatments**	Minneapolis ABC
10:00 AM	11:30 AM	Symposium: Biopsychosocial Risk Processes Underlying Hazardous Cannabis Use and Cannabis Use Disorder	Orchestra CD
10:00 AM	11:30 AM	Symposium: Accounting for Older Adults in Substance Use Research, Treatment, and Policy: Current Findings and Future Considerations	Orchestra AB
10:00 AM	11:00 AM	Oral Communication: Genetics of SUDs II	Symphony Ballroom III
10:00 AM	11:00 AM	Oral Communication: Intersectionality Between SUDs and Suicidality	Conrad BC
11:30 AM	1:30 PM	Media Forum: Harnessing Your Expertise: CPDD Media Training With Reporting on Addiction	
12:00 PM	1:30 PM	Brunch With Champions	Minneapolis E
1:30 PM	2:30 PM	Oral Communication: Infectious Diseases and SUDs	Symphony Ballroom III
1:30 PM	2:30 PM	Oral Communication: Cocaine Clinical Research	Conrad BC
1:30 PM	2:30 PM	Oral Communication: Neuroscience of SUDs II	Orchestra AB
1:30 PM	2:30 PM	Oral Communication: Fentanyl: Focus on Toxicology	Orchestra CD
1:30 PM	2:30 PM	Mini-Symposium: Facilitating Compassionate and Consistent Care for Women and Neonates Affected by Opioids**	Minneapolis D
1:30 PM	2:30 PM	Mini-Symposium: Using Big Data to Optimize Benzodiazepine Prescribing and Deprescribing Across the Lifespan**	Minneapolis ABC
2:45 PM	3:45 PM	Oral Communication: Cravings and Cues in SUDs	Orchestra AB
2:45 PM	3:45 PM	Oral Communication: Fentanyl: Focus on Subjective/Affective Properties	Orchestra CD
2:45 PM	3:45 PM	Oral Communication: Towards Standardization of Clinical Trial Outcomes	Symphony Ballroom III
2:45 PM	3:45 PM	Oral Communication: Racial Disparities and SUDs	Minneapolis ABC
2:45 PM	3:45 PM	Oral Communication: The Role of Anxiety in SUDs	Conrad BC
2:45 PM	3:45 PM	Mini-Symposium: Use of Technology to Facilitate Translational Substance Use Disorder Research**	Minneapolis D
4:00 PM	5:00 PM	Oral Communication: Imaging Research With Nicotine	Orchestra AB
4:00 PM	5:00 PM	Oral Communication: Methamphetamine Clinical Research	Orchestra CD
4:00 PM	5:00 PM	Oral Communication: Alcohol and Coping Behaviors	Symphony Ballroom III
4:00 PM	5:00 PM	Oral Communication: Meaningful Interactions With Cannabinoids	Minneapolis D
4:00 PM	5:00 PM	Oral Communication: Behavioral Economics	Conrad BC
4:00 PM	5:00 PM	Oral Communication: Unique Challenges for SUDs in Rural Environments	Minneapolis ABC
5:00 PM	5:45 PM	Closing General Session - Sweepstakes Drawing	Minneapolis D

SUNDAY, JUNE 12, 2022

8:00 A.M. - 11:30 A.M.

PLENARY

WELCOME AND INTRODUCTION

William Stoops, University of Kentucky; CPDD 2022 President

RESEARCH ON DRUG ABUSE AND ADDICTION: PROGRESS, OPPORTUNITIES AND CHALLENGES

Nora Volkow, National Institute on Drug Abuse

Scientific advances continue to broaden our understanding of the biological, developmental, and environmental elements underlying drug use and addiction and to accelerate efforts to develop targeted strategies for their prevention and treatment. At the same time, the challenges confronting the field have grown both in number and in magnitude. This presentation will highlight such challenges as the growing use of fentanyl by itself or in combination with other opioids or stimulant drugs like cocaine and methamphetamine and the staggering number of overdose deaths that result. It will also focus on how NIH researchers have been using scientific advances to address the opioid crisis amidst the COVID pandemic, which includes the development of new medications and formulations to help treat opioid use disorders and overdoses; prevention strategies to mitigate an individual's vulnerability to addiction; and implementation science to guide optimal deployment of therapeutic interventions including the use of telehealth in diverse settings (healthcare, justice setting, rural communities). Also to be addressed is the disproportionate impact that the COVID-19 pandemic has had on some drug abusing populations; and some of the relevant policy and research initiatives currently being supported by NIDA and the National Institutes of Health (NIH) to help address some of the most pressing challenges the field has ever faced.

NIAAA UPDATE: CLOSING THE TREATMENT GAP

George Koob, National Institute on Alcohol Abuse and Alcoholism

Alcohol misuse and alcohol use disorder (AUD) cause an enormous amount of human suffering, loss of productivity and cost to our medical care system and the nation's economy all of which have been exacerbated by the COVID-19 pandemic. Recent developments include a 26% increase in alcohol-related deaths, 34% increase in the prevalence of hospital visits for alcohol withdrawal, and a 51% increase in hospitalizations for alcohol-associated hepatitis during the COVID-19 pandemic in the United States. In addition, there continues to be a significant treatment gap where less than 10% of individuals in need of treatment receive treatment for AUD and less than 2% receive one of the 3 FDA approved medications for treatment of AUD. Ongoing challenges include the increased drinking to cope with stress exacerbated by the COVID-19 pandemic, interaction of alcohol with mental health, the role of alcohol in women's health, alcohol and health in older adults, and research on recovery from AUD. Current priorities and challenges for closing the treatment gap include promoting medications development, expanding NIAAA resources for the public, development of a heuristic definition of recovery, expanding the uptake of screening, brief intervention and referral to treatment (SBIRT), exploring and expanding a role for telehealth in treatment, addressing stigma, addressing diversity, equity and health disparities in the alcohol field, and supporting the next generation of alcohol researchers. Addressing such challenges will facilitate the implementation of evidence-based treatment for AUD in primary care, mental health, and other health care settings.

**AWARD PRESENTATION: 2022 EDDY LECTURE
LEVERAGING THE REINFORCEMENT PROCESS TO PROMOTE HEALTH: APPLICATIONS TO SUBSTANCE
USE DISORDERS AND OTHER CHRONIC CONDITIONS**

Stephen Higgins, University of Vermont, 2022 Eddy Awardee

This presentation will underscore how the reinforcement process that plays such a fundamental role in the genesis and maintenance of substance use disorders can also be applied effectively to promote healthy behavior change. Research from clinical laboratory and randomized clinical trials will be reviewed. Interventions designed to impact the behavior of individual patients and populations will be discussed.

1:30 P.M. - 2:30 P.M.

PRESIDENTIAL SYMPOSIUM

William Stoops, University of Kentucky; 2022 CPDD President

THE HISTORICAL ROLE OF ANIMAL RESEARCH IN ADDICTION SCIENCE

Katherine Serafine, The University of Texas at El Paso

Animal research has served as an essential component in our understanding of substance use disorder, and factors that contribute to disease etiology, vulnerability, addiction liability and potential treatments. Understanding the historical impact of animal research in addiction science is essential for those advocating for continued investments in this life-saving field of study. This presentation will focus on an overview of the historical and current roles of animal research in exploring the neurobiology of addiction and vulnerability factors, as well as the development of effective pharmacotherapeutics for substance use disorders including methadone, naltrexone and varenicline. This presentation will also describe how these historical examples can be used to advocate for the critical role of animal research to further understand and treat human diseases, including substance use disorder.

THE FUTURE OF ANIMAL RESEARCH ON ADDICTIONS: PROMISE AND PERILS

J. David Jentsch, Binghamton University

Though animal research has been crucial to the effort to identify the mechanisms of action of drugs with addiction liability, the discovery of the pathophysiological mechanisms underlying addictions and the successful translation of those biological mechanisms into actionable treatment targets, there clearly is much left to do if we are to address many currently unmet needs. The animal research community is developing more powerful, rigorous and sophisticated approaches that have exceptional promise for closing the remaining gaps, yet a number of forces place those advances at risk. Because of the actions of animal rights extremist groups, politically connected lobbyists and elected officials themselves, this vital research is at peril. This presentation will focus on the future for animal research on addiction and the need for a broader set of actions we must all take to support it.

6:00 P.M. – 7:00 P.M.

FISCHMAN LECTURE: PURSUING A CLINICAL RESEARCH CAREER: LESSONS LEARNED FROM MARIAN FISCHMAN

Frances Levin, Columbia University Irving Medical Center/ New York State Psychiatric Institute, 2020 Fischman Awardee

Marian Fischman served as a role model to many young clinical investigators during her exceptional career. Her wisdom and support led to the success of many of the current leaders (and particularly women) in the addiction field. This talk will initially focus on “lesson learned” from my personal experience being mentored by Marian, followed by highlights of some of the research that I have conducted over the past 30+ years and additional “lessons learned.”

MONDAY, JUNE 13, 2022

2:15 P.M. - 3:15 P.M.

FISCHMAN LECTURE: JOIN ME ON THE ROAD TO PRECISION HEALTH FOR SUBSTANCE USE DISORDERS

Laura Bierut, Washington University School of Medicine, 2022 Fischman Awardee

The large-scale implementation of genetic knowledge represents one of the next major scientific challenges to improve health. Although much work to date has focused on using genetic information to identify diseases and define treatment options in fields such as cancer, the next frontier is to expand our genetic knowledge base to a wider range of disorders including substance use disorder. Smoking cessation is an ideal target for testing the implementation of a genetic intervention to enhance behavioral change. There remains a massive preventable burden of morbidity and mortality related to smoking and there are well identified genetic variants that drive smoking behaviors as well as smoking related diseases. A precision health effort focused on smoking behaviors will test the utility of a genetic informed intervention to drive behavioral change and study the implementation, optimization, and integration of smoking related genetic knowledge in the goal of improved population health. Personalized genetic results can inform individual health decisions, optimize treatment choices, and potentially motivate smoking cessation. Let’s challenge the dominant model of incremental, stepwise research questions and undertake multi-faceted efforts that test the effects of returning genomic information about smoking and smoking-related disease risk directly to individuals, in a manner that promotes future scalability to large-scale implementation.

SUNDAY, JUNE 12, 2022

3:00 P.M. - 4:00 P.M. WORKSHOP

1. TEST OF TWO IMPLEMENTATION SCIENCE STRATEGIES TO INCREASE MEDICATIONS FOR OPIOID USE DISORDERS (MOUD) IN JAIL SETTINGS

Chair: Faye Taxman, George Mason University

Co-Chair: Todd Molfenter, University of Wisconsin - Madison

This session describes the initial experiences of a trial testing use of NIATx Coaching and the ECHO model to increase use of medication for opioid use disorders (MOUDs) in jail settings located in California, Florida, Hawaii, Maine, Virginia, Wisconsin, and Washington. The NIATx model has been supported by 30+ research publications and used by community-based treatment provider settings to increase MOUD use. This session will describe the key operational components of the NIATx model and how the model was adjusted to accommodate jail workplace practices.

Project ECHO is a collaborative model of medical education that uses video-conferencing sessions, a panel of subject matter experts to provide short educational lectures, then participants present clinical cases and receive feedback from peers and experts. This model was utilized to offer education and support in the delivery of MOUD to health professionals from the participating trial sites. The session will describe the ECHO structure, the educational topics presented, a summary of cases presented, and preliminary lessons learned.

NIATx Coaching and ECHO asked participants to use workflow improvement strategies to increase use of MOUD. For workflow improvement, jails tended to follow the MOUD cascade of care model and focused on improving certain steps of the cascade. This session will describe the cascade of care and where the greatest opportunities to strengthen the cascade of care exist based on jail self-assessments. The session will conclude with a concentration on the role external coaching and ECHO can play in the jail MOUD policy setting and implementation process.

1.1 Project Echo for Dissemination of Clinical Education in Jail settings: Lessons Learned

Elizabeth Salisbury-Afshar, University of Wisconsin - Madison

1.2 Test of Two Implementation Science Strategies to Increase Medications of Opioid Use Disorders (MOUD) in Jail Settings.

Todd Molfenter, University of Wisconsin - Madison

1.3 Test of Two Implementation Strategies to Increase Medications for Opioid Use Disorder (MOUD) in Jail Settings

Lynn Madden, APT Foundation

4:30 P.M. - 6:00 P.M. SYMPOSIUM

2. BEYOND DELTA-9-THC: THE BLOSSOMING OF MINOR CANNABINOIDS

Chair: Jenny Wiley, RTI International

Co-Chair: Inna Belfer, Laboratory of Neurogenetics, NIAAA, NIH

The cannabis plant (*Cannabis sativa/indica*) has long been used for medicinal purposes. In addition to its major psychoactive constituent delta-9-tetrahydrocannabinol (THC), cannabis contains over 100 phytocannabinoids

as well as over 500 other identified chemicals, including the terpenoids that give cannabis its distinctive flavoring and aroma. The degree to which these minor plant constituents contribute to the psychoactive and medicinal effects of cannabis is under active investigation. The speakers in this symposium will provide an overview of their work with selected minor cannabinoids, ranging from molecular pharmacology to preclinical studies and clinical trials. The symposium will begin with an examination of interactions of minor cannabinoids with CB1 and CB2 receptors and continue with assessment of the effects selected cannabis constituents in a mouse model of THC-like subjective effects and in rodent models of pain and inflammation. A translational viewpoint will follow, linking an initial finding that the minor cannabinoid cannabidiol (CBD) showed promise in the treatment of heroin use disorder in an animal model with later supportive data from human clinical trials. A final presentation will focus on results of analysis of cannabinoid constituent profiles of products from medical cannabis patients enrolled in a longitudinal, observational study and will explore the potential impact of these profiles on clinical variables. The moderated discussion period will begin with a brief description of NCCIH programmatic priorities and funding opportunities for minor cannabinoids research. Together, these presentations will provide the audience with a broad overview of the pharmacology and potential medicinal uses of cannabis.

2.1 Minor Phytocannabinoid Interactions With CB1 and CB2 Receptors
Jenny Wiley, RTI International

2.2 Evaluation of Analgesic and Protective Effects of Minor Cannabinoids in Animal Models
Sara Jane Ward, Lewis Katz School of Medicine, Temple University

2.3 Translating Cannabidiol for Opioid Use Disorder and Related Phenotypes
Yasmin Hurd, Icahn School of Medicine at Mount Sinai

2.4 A Major Role for Minor Cannabinoids? Examining Real World Products From Medical Cannabis Patients
Staci Gruber, McLean Hospital, Harvard Medical School

4:30 P.M. - 6:00 P.M. SYMPOSIUM

3. USING BEHAVIORAL AND BRAIN BIOTYPES TO ENHANCE TREATMENT OUTCOMES IN ADDICTION MEDICINE

Chair: Amy Janes, National Institute on Drug Abuse

Co-Chair: Hamed Ekhtiari, University of Minnesota

Drug and alcohol use disorders are dynamic processes, affecting a wide variety of individuals for a wide variety of reasons. Despite widespread appreciation for this variability, our current treatment regimens are fairly uniform. In an effort to catalyze a new chapter in patient-tailored addiction treatment, this symposium will feature a group of experts who are working at the intersection of uniting behavioral and brain based phenotyping with improved pharmacological and neuromodulatory treatment outcomes. Dr. Witkiewitz will present data from three clinical trials on phenotypic variation in drinking motives in treatment-seeking individuals with Alcohol Use Disorder, who could be characterized into 'reward' or 'relief drinkers'. Each type responded best to differential pharmacological treatments, driven by distinct underlying learning mechanisms. Dr. Zilverstand will demonstrate that this framework extends to individuals with other SUD (e.g., cannabis, cocaine Use Disorder), by presenting an empirically derived addiction-general three domain model of neurobehavioral function. Individuals who use substances could be characterized as either 'reward', 'relief' and 'low functioning', demonstrating distinct behavioral profiles and brain function during resting-state. In addition

to using behavioral phenotypes to make decisions about pharmacological treatment, recent studies show that brain based phenotypes can influence brain stimulation treatment outcomes. Dr. Ekhtiari will demonstrate that it is possible to tailor transcranial electrical stimulation to individual patients through the use of brain functions and structure. Dr. Hanlon will bring these themes together by demonstrating unique brain activity patterns in “reward” and “relief” subtypes and that they differentially respond to transcranial magnetic stimulation strategies.

3.1 Phenotyping Individuals With Alcohol Use Disorder: Implications for Precision Medicine
Katie Witkiewitz, University of New Mexico

3.2 An Empirically Derived Neurobehavioral Three-Domain Model Underlying Addiction-General Subtypes: Implications for Personalized Addiction Medicine
Anna Zilverstand, University of Minnesota

3.3 Optimization in Transcranial Electrical Stimulation, Implications for Precision Addiction Medicine
Hamed Ekhtiari, University of Minnesota

3.4 Using Behavioral and Brain Biotypes to Influence TMS Protocol Selection
Colleen Hanlon, Wake Forest Health Sciences

7:15 P.M. - 9:15 P.M. WORKSHOP

4. ADVANTAGES AND CHALLENGES OF BIG DATA APPROACHES TO DETECT NOVEL BIOLOGY UNDERLYING SUBSTANCE USE DISORDERS

Chair: Susan Wright, NIDA/NIH

Incorporating data science as a tool for the study of substance use disorders is gaining popularity and plays a critical role in data-driven decision making. Advanced computational methods to extract knowledge and insights from increasingly large and/or complex datasets in addiction research improves our understanding of the genetic, chemical, neurobiological and behavioral mechanisms of drug use disorders and their long-term consequences and informs prevention and treatment. However, there are also some challenges, such as biases embedded in data or in machine learning algorithms, and ethical, legal, and social implications are important considerations. This session will highlight cutting-edge research such as the performance of different substance use outcome measures in predicting longer-term improvement in psychiatric and social functioning and algorithms and methods for high-dimensional and high-throughput -omics data, including artificial intelligence/machine learning approaches. This session will also caution how biases in both data and algorithms may inadvertently lead to racial disparities being perpetuated and exacerbated, which is of particular importance for addiction, which carries stigma and potential discrimination.

4.1 Empirically Identifying and Validating Predictors of Longer-Term Improvement in Patients With Substance Use Disorders
Laura Brandt, Columbia University Irving Medical Center and New York State Psychiatric Institute

4.2 Empirically Comparing Opioid Use Disorder Treatment Outcomes
Gabriel Odom, Florida International University

43 *Deep Learning for Genomic Discovery*
Soumya Kundu, Stanford University School of Medicine

4.4 *Genetic Data Can Lead to Medical Discrimination: Cautionary Tale of Opioid Use Disorder*
Alexander Hatoum, Washington University in St. Louis

7:15 P.M. - 9:15 P.M. WORKSHOP

5. CONDUCTING PRAGMATIC TRIALS OF INTERVENTIONS TO IMPROVE CARE FOR SUBSTANCE USE IN MEDICAL SETTINGS: LESSONS FROM 4 TRIALS

Chair: Morgan Justice Fuoco, Kaiser Permanente Washington Health Research Institute
Co-Chair: Judith Tsui, University of Washington

Few patients with substance use disorders (SUDs) receive treatment. Routine substance use screening, outreach, care management, and digital therapeutics may improve access and outcomes among the 90% of patients with SUDs who do not receive treatment. To understand whether these interventions reach patients and increase SUD care, each must be evaluated in real world settings with appropriate comparison groups, through pragmatic, implementation, or hybrid trials. Such trials are relatively new and can pose challenges in design, site recruitment and engagement, health systems partnerships, Institutional Review Board considerations, and implementation. They also rely on data for outcome measures from diverse secondary electronic sources, such as apps, patient-report measures in electronic health records, prescription monitoring programs, and health information exchanges. This symposium highlights lessons learned from four such studies. These include: 1) a study to improve primary care of teens using tobacco, alcohol, cannabis and other drugs, which will describe a 3-clinic pilot and a future pragmatic trial to evaluate implementation across 30 other clinics; 2) the DIGITS trial, which will share results of a pilot of reSET/reSET-O implementation in primary care and present the design of an ongoing cluster-randomized, hybrid type-III implementation trial; 3) the PROUD trial, which will highlight lessons from a cluster-randomized, hybrid type-III implementation trial of opioid use disorder (OUD) treatment in primary care; and 4) the MI-CARE trial of collaborative care for OUD and depression, which will describe the challenges of encouragement (Zelen) trials whereby patients are randomized before consent.

5.1 *Design and Pilot Implementation of Opportunistic Substance Use Screening into Routine Primary Care: Unique Challenges for Teens*
Gwen Lapham, Kaiser Permanente Washington Health Research Institute

5.2 *Digital Therapeutics for Opioids and Other Substance Use Disorders (DIGITS Trial) in Primary Care: Results of a Quality Improvement Pilot and Study Protocol for a Hybrid Type-III Implementation Trial*
Joseph Glass, Kaiser Permanente Washington Health Research Institute

5.3 *The Primary Care Opioid Use Disorders Treatment (PROUD) Trial: Strengths and Challenges of a Pragmatic, Cluster-Randomized, Hybrid Type III Implementation Trial Using Real World, Electronic Health Record Data*
Paige Wartko, Kaiser Permanente Health Research Institute

5.4 *More Individualized Care: Assessment and Recovery Through Engagement (MI-CARE) Trial: Lessons Learned Regarding Rigorous Design and Implementation of an Encouragement Trial*
Morgan Justice Fuoco, Kaiser Permanente Washington Health Research Institute

7:15 P.M. - 9:15 P.M. WORKSHOP

6. EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS

Chair: Howard Chilcoat, Indivior, Inc.

Co-Chair: Maria Parker, Indiana University - Bloomington

This proposal is for a continuation of the annual CPDD Epidemiology and Public Health Research Methods evening workshop series that was launched more than 10 years ago. These workshops have featured a series of methodologic approaches of interest to those conducting epidemiologic, prevention, and clinical research in the field of substance use and related disorders. This year's workshop will focus on methods that can be applied in behavioral economic research on drug substance use and how these methodologic approaches can be used in population-based research. Presentations will discuss on delay discounting as a key behavioral economic indicator related to substance use and associated behaviors,

*6.1 The Nuts and Bolts of Delay Discounting Assessment, and its Relevance for Substance Use Research
Richard Yi, University of Kansas*

*6.2 Behavioral Economic Methods to Understand Intersecting COVID-19 and Substance Use Epidemics
Justin Strickland, Johns Hopkins University School of Medicine*

*6.3 Statistical Methods for Subgroup Identification: An Application to Opioid Use Disorder Recovery
Allison Tegge, Virginia Tech Carilion Research Institute*

7:15 P.M. - 9:15 P.M. WORKSHOP

7. NEWS YOU CAN USE: MEDIA RELATIONS 101

Chair: Chelsea Shover, David Geffen School of Medicine at UCLA

Talking to the press can seem intimidating, but mass media is an excellent platform to get your research in front of a wider audience. Engaging with media is also an effective way to influence health policy. This workshop will demystify media relations for scientists, with an opportunity to practice via mock pitches and interviews. Dr. Shover, formerly a journalist, uses insight into media relations to amplify her work as an epidemiologist, most recently when her study was on the front page of the Los Angeles Times. Dr. Vest, a formerly incarcerated scholar, will discuss techniques to contribute to media that advances a public health - rather than criminal legal - response to substance use disorders. Presentations will cover best practices for pitching your work to news outlets, talking with reporters, evaluating interview requests, cultivating relationships with editors to become a go-to source, and working with public relations teams at your university or organization. We will cover your rights and expectations as someone being interviewed. This workshop will cover nuts and bolts like talking points, quote checks, when to go "off the record" versus "on background," and what to do if you get misquoted. We will also share tips of the trade to appear in your best light and make sure your work shines through compellingly and accurately. Attendees will then have the opportunity to practice in mock pitches (telling a media outlet why they should cover their work) and mock interviews (discussing your findings for a general audience).

7.1 Reporting With Conviction: A Formerly Incarcerated Scholars Perspective on Media Relations
Noel Vest, Stanford University School of Medicine

7.2 How's and Why's of Talking to Reporters
Chelsea Shover, David Geffen School of Medicine at UCLA

7:15 P.M. - 9:15 P.M. WORKSHOP

8. ACADEMIC/COMMUNITY PARTNERSHIPS AS A STRATEGY FOR REDUCING HEALTH DISPARITIES IN SUBSTANCE USE

Chair: A. Kathleen Burlew, University of Cincinnati
Discussant: Ayana Jordan, NYU Langone Medical Center

The integration of evidence-based interventions into racial/ethnic communities has often been challenging in part due to the lack of fit between the intervention and the target group. Community-engaged research leverages the knowledge and expertise of both community and academic members, can directly target community needs, and often results in more culturally relevant interventions. The aim of this workshop is to share alternative approaches for academic/community partnerships. Members of the Minority Interest Group of NIDA's Clinical Trials Network (CTN) will present on community engagement activities either conducted within or inspired by the CTN. These partnerships include work with community partners on recruitment (Dr. Haeny), prevention (Dr. McCuistian) and treatment (Dr. Cain). Dr. Haeny will describe a partnership with the community to recruit individuals who use cocaine into treatment. Dr. McCuistian will describe the formation of an academic/community partnership within a residential community that worked together on all phases of a project aimed at culturally adapting a prevention intervention to increase its effectiveness for Blacks. Dr. Cain will describe the development of a partnership with churches and other community sites to provide more effective substance use treatment for opioid users. Ms. Delanie Jordan, a peer recovery guide, will offer a community perspective.

Following the presentations, Dr. Ayana Jordan who collaborates with churches to provide more effective treatment, will serve as the discussant. She will also encourage audience discussion on other models for community engagement.

8.1 Using Community Engaged Approaches to Recruit Participants Who Self-Changed From Cocaine Use Disorder
Angela Haeny, Yale University School of Medicine

8.2 Collaborating With Community Members on Cultural Adaptation: Overview of the CCCA Model
Caravella McCuistian, University of California, San Francisco

8.3 Engaging a Diversity of Community Partners to Reduce Disparities in Substance Use Disorder Treatment
Gloria Cain, Howard University College of Medicine

8.4 Engaging a Diversity of Community Partners to Reduce Disparities in Substance Use Disorder Treatment
Dephanie Jordan, Howard University College of Medicine

MONDAY, JUNE 13, 2022

10:00 A.M. - 11:30 A.M. SYMPOSIUM

9. THE BEST OFFENSE IS DEFENSE! BLOCKING AND TACKLING STIMULANTS IN THE PERIPHERY TO PREVENT CNS ACTION

Chair: Katrina Foster, NIH/NIDA/DTMC

Co-Chair: David White, National Institute of Drug Abuse, National Institutes of Health

Stimulant use is a significant public health concern in the United States. In 2019, approximately 1.4 million persons age 18 and up reported past month stimulant use (2019 National Survey on Drug Use and Health). Further, there is an urgent need for reversal agents for stimulant overdose. According to CDC data, stimulants were involved in approximately 33,000 overdose deaths in 2019. There are currently no FDA-approved interventions for the treatment of stimulant use disorder (SUD) or overdose. The most effective treatment options available to clinicians treating patients with SUD are behavioral therapies, such as Cognitive Behavioral Therapy and Contingency Management. Yet, these interventions are only modestly effective with high rates of relapse. Additionally, patients presenting at emergency rooms with symptoms of a stimulant overdose are stabilized by treating only the symptoms but not the root cause(s). As traditional pharmacotherapeutic approaches have yet to yield effective SUD treatments, alternative approaches need to be given serious consideration. This symposium will provide exciting pre-clinical and clinical development efforts for treating SUD and stimulant overdose by preventing or reducing stimulant activity in the CNS.

9.1 A New Therapeutic Approach for Treating Methamphetamine Intoxication

Xinhua Li, Clear Scientific, Inc

9.2 AAV Gene Therapy for Cocaine Abuse

Kah-Whye Peng, Mayo Clinic

W. Michael Hooten, Mayo Clinic

9.3 Adenovirus-Based Vaccines for Addiction

Stephen Kaminsky, Weill Cornell Medical College

9.4 New Results From Phase 2 Trials of IXT-M200, a High Affinity METH Antibody

Brooks Gentry, InterveXion Therapeutics, LLC

10:00 A.M. - 11:30 A.M. SYMPOSIUM

10. THE IMPORTANCE OF GENDER, CULTURE AND INTERSECTIONAL ISSUES IN SUBSTANCE USE INTERVENTIONS: LESSONS IN HEALTH DISPARITY RESEARCH IN SOUTH AFRICA AND THE U.S.

Chair: Felicia Browne, RTI International

Co-Chair: Wendee Wechsberg, RTI International

There is a dearth of evidence-based interventions that explicitly address substance use for populations of African descent. Moreover, evidence has shown that interventions that are intersectional and more comprehensive have greater impact with substance use outcomes. The specific aims of the symposium are to (1) share the stages

of intervention research and lessons learned conducting NIH-funded cross-cultural and global collaborative research, including community and youth advisory boards and key populations who use substances, and (2) present the process and outcome evaluation data from evidence-based substance use interventions for young women, women who are pregnant and couples of African descent. In addition, this symposium will allocate time for an interactive discussion about how these projects have offered professional and career development for a diversity of investigators, students and staff.

The first presentation will report on a clustered randomized trial that reached female adolescents who use drugs in South Africa and have left school early and live in underserved communities.

The second presentation will discuss outcomes from a randomized trial in the U.S. South testing the delivery of a substance use intervention among African American women in emerging adulthood.

The third presentation will share formative research from a new study in South Africa reaching young couples who use drugs and alcohol to adapt a risk-reduction intervention for couples and address community stigma.

The fourth presentation will report findings from analysis of a study addressing maternal drug and alcohol use and preventing fetal alcohol spectrum disorders and adverse infant outcomes in South Africa.

10.1 Intervening With Teens in the Cape Flats in South Africa Who Use Alcohol and Other Drugs and Report Other Risk Behaviors: What Works?

Wendee Wechsberg, RTI International

10.2 Outcomes From a Randomized Trial Reaching Young African American Women Who Use Drugs and Alcohol

Felicia Browne, RTI International

10.3 Multilevel Strategies for Young Couples Who Use Alcohol & Other Drugs in Cape Town, South Africa: Formative Research Findings to Adapt a Biobehavioural Intervention for Couples and Address Community Stigma

Tara Carney, South African Medical Research Council

10.4 Addressing Maternal Alcohol and Substance Use and Preventing Adverse Infant Outcomes in South Africa

Yukiko Washio, RTI International

Moderator: Courtney Bonner, RTI International

10:00 A.M. - 11:30 A.M. SYMPOSIUM

11. FROM BENCH TO BEDSIDE TO POLICY: UPDATING OUR UNDERSTANDING OF KRATOM

Chair: Kirsten Smith, National Institute on Drug Abuse, Intramural Research Program

Co-Chair: Oliver Grundmann, University of Florida

Use of kratom, a botanical indigenous to Southeast Asia, has increased dramatically in the U.S. since 2006 with products proliferating rapidly. This is noteworthy, as kratom leaves contain bioactive alkaloids of which at least four act as partial, seemingly biased, agonists at mu opioid receptors and with activity at other neurotransmitter receptors. We are only just beginning to scientifically uncover kratom's therapeutic and effect profile, primarily through preclinical studies, self-report, and case presentations. Accumulating evidence is beginning to reveal that kratom produces clinically relevant opioid-like effects that have implications for policy decisions. This translational symposium will feature four talks from kratom experts focused on unique aspects of this complex psychoactive plant and its heterogeneous population of consumers. First, trends in real-world kratom use derived from survey and social media data, that include dependence and misuse, as well as clinical anecdote on kratom's use as an opioid substitute among persons with substance use disorders, will be discussed. Second,

an overview of kratom's role as a self-treatment for psychiatric and pain symptoms will be presented using national and international survey findings. Third, the molecular structure of kratom's best studied alkaloids, their pharmacological effects, and variability of kratom leaves and products will be reviewed. Lastly, kratom regulation and policy will be discussed in light of current scientific understanding and within the broader context of intersecting opioid, pain, and psychiatric health epidemics in the U.S. Discussion of key scientific and clinical considerations on kratom and attendee engagement will be facilitated by the symposium's moderator.

11.1 Real-World and Clinical Characteristics of Kratom Use

Kirsten Smith, National Institute on Drug Abuse, Intramural Research Program

11.2 The Who, Why, and What: Kratom User Profiles in the US

Oliver Grundmann, University of Florida

11.3 Alkaloid Chemistry and Pharmacology of Kratom

Christopher McCurdy, University of Florida

11.4 Kratom Policy in the Context of Abuse Potential and Public Health

Jack Henningfield, Pinney Associates, Inc.

Moderator: Kelly Dunn, Johns Hopkins University School of Medicine

10:00 A.M. - 11:30 A.M. SYMPOSIUM

12. DOSE-DEPENDENT SUBJECTIVE EFFECTS OF THC AND CANNABIS CONCENTRATES: FROM NATURALISTIC INVESTIGATION TO POPULATION ANALYSIS

Chair: Adrienne Wilson-Poe, Legacy Research Institute

Co-Chair: Ziva Cooper, UCLA Cannabis Research Initiative

The subjective and intoxicating effects of cannabis are well-established. However, much of this evidence relies on cannabis supplied by the National Institute on Drug Abuse, which has important chemical differences compared to cannabis products sold in regulated markets. Because of these differences, it is important to characterize the abuse liability and psychoactive effects of cannabis sold in regulated markets. The excessive use of cannabis is also well-characterized, and is associated with negative health outcomes such as psychosis-like symptoms, Cannabis Use Disorder, and cannabinoid hyperemesis syndrome. These negative outcomes are largely mediated by cannabis' primary psychoactive constituent, delta-9-THC, which is also involved in the euphoric and rewarding effects of cannabis. The THC potency of both regulated and illicit cannabis products around the world has been steadily increasing in recent years. In fact, cannabis concentrates (purified resin from the cannabis plant), which make up 9.5% of the regulated U.S. cannabis market, can contain 80% THC or more. Despite the increased prevalence and health risks of high-potency cannabis products, their subjective effects and safety are poorly characterized. This session will focus on the subjective effects of high potency cannabis products and cannabis concentrates, with an emphasis on young adults. Dose-dependent effects of THC will be discussed, as well as harm reduction opportunities to support public health. This symposium also features innovative data collection methods to characterize the effects of high potency cannabis products sold in state-regulated markets.

12.1 The Appeal and Use of Cannabis among Adolescents and Young Adults

Jessica Barrington-Trimis, University of Southern California

12.2 *Aroma, But Not THC Potency Mediates the Subjective Appeal of Cannabis Flower*
Adrienne Wilson-Poe, Legacy Research Institute

12.3 *Acute Effects of High Potency Cannabis Flower and Concentrates*
Carrie Cuttler, Washington State University

12.4 *Cannabis Concentrates: Cannabis Exposure & Intoxication*
L. Cinnamon Bidwell, University of Colorado Boulder

12:00 P.M. - 2:00 P.M. HUMAN FORUM

13. RESUMING RESEARCH ON SUBSTANCE USE DISORDERS AFTER LIFTING COVID-19 DISTANCING MEASURES: CHALLENGES AND OPPORTUNITIES

Chair: Omayma Alshaarawy, Michigan State University College of Human Medicine
Co-Chair: Elizabeth Santa Ana, Medical University of South Carolina and Charleston VAMC

The College on Problems of Drug Dependence Human Research Committee (HRC) presents a forum focusing on challenges and opportunities related to resuming research on substance use disorders after lifting many COVID-19 distancing measures. In 2020, the emerging pandemic necessitated the halting of all non-essential human subject research. This pause was the focus of the HRC 2021 forum, where ethical considerations related to retention of study participants, adapting research methodologies, and investigator burnout were discussed. In 2021, COVID-19 vaccines became widely available, significantly reducing risks associated with COVID-19 infection and allowing paused research programs to resume in-person activities. However, these rapidly shifting regulations have created additional challenges for investigators who need to re-adjust their protocols to protect participants and staff (e.g., mask policies, reducing interactions with participants, transition to virtual platforms, preference of some research participants to maintain the virtual format without face-to-face contact). In 2022, HRC forum speakers will present an overview of these adjustments, implementation barriers, and risk-benefit assessments. Furthermore, a wealth of COVID-19 misinformation has continued to spread, including the usefulness of masks or vaccines. Investigators engaged in human subject research are well placed to help counter falsehoods about the pandemic. Speakers will discuss opportunities for integrating SBIRV (Screening, Brief Intervention, and Referral for Vaccine) with substance use research. In summary, the forum will provide attendees with different perspectives and best practices to conduct substance use research in the era of global pandemics.

13.1 *Addressing Provider and System Level Barriers to Opioid Use Disorder Treatment via Telehealth: Findings From a Mixed-Methods Investigation in the Veteran's Health Administration*
Ursula Myers, Ralph H. Johnson VA Medical Center

13.2 *The Association Between COVID-19 and Alcohol Use Among a Trauma Exposed Sample: Future Directions for Participant Outreach in the Post Pandemic World*
Elizabeth Santa Ana, Medical University of South Carolina and Charleston VAMC

13.3 *The Challenges and Opportunities of Online-Only Trials in the Post-Covid Era*
Steven Ondersma, Michigan State University

13.4 *Screening, Brief Intervention and Referral for Vaccine for Researchers Engaged in Drug Use Research*
Maureen Reynolds, University of Pittsburgh

1:00 P.M. - 2:00 P.M. MINI-SYMPOSIUM

14. GABAPENTIN, FRIEND OR FOE? EMERGING TRENDS, USE BEHAVIORS, AND ADVERSE EVENTS

Chair: Matthew Ellis, Washington University in St. Louis

Co-Chair: Mance Buttram, University of Arkansas

Gabapentin is an anti-convulsant prescribed for the treatment of epilepsy and neuralgia, but off-label, its use is increasing in the treatment of opioid use disorder (OUD). Reports of non-medical use (NMU) and overdose involvement are growing, particularly in combination with opioids. The aim of this mini symposium is to describe newly emerging national trends related to polysubstance use involving gabapentin.

Data are drawn from three long-running nationally representative surveillance programs that will present a comprehensive picture of non-medical gabapentin use through different, yet linked, lenses. First, quantitative and qualitative data from newly admitted patients in treatment for opioid use disorder shed light on the concomitant NMU of gabapentin and opioid agonist therapies such as buprenorphine and methadone, including motivations, perceived benefits, and consequences. Second, data from US poison centers in 48 states will describe recent trends in gabapentin-involved poison center exposure cases, co-occurring substances present in each case, and related direct deaths. Finally, data from law enforcement agencies in 49 states who report diversion cases and use trends in their jurisdictions will report describe national rates of gabapentin diversion along with qualitative data from law enforcement investigators which describe polysubstance trends and behaviors in their justifications.

These presentations represent some of the first national-level reports of polysubstance trends involving gabapentin. Although gabapentin may have some harm reduction benefits in the self-treatment of OUD, negative consequences of NMU in combination with opioids can be severe and contribute to fatal overdoses. Continued surveillance of gabapentin in the context polysubstance use is needed.

14.1 Co-Occurring Use of Gabapentin and Opioid Agonist Therapies: Prevalence and Motivations

Matthew Ellis, Washington University in St. Louis

14.2 National Trends in Gabapentin Diversion and Qualitative Descriptions of Polysubstance Use

Mance Buttram, University of Arkansas

14.3 Perils of Polysubstance Use: Tales and Trends of Gabapentin From US Poison Centers

Janetta Iwanicki, Rocky Mountain Poison and Drug Safety

1:00 P.M. - 2:00 P.M. MINI-SYMPOSIUM

15. CATCHING UP ON SLEEP: INSIGHTS INTO THE BIDIRECTIONAL RELATIONSHIP BETWEEN DRUG USE AND SLEEP IMPAIRMENTS, AND RELAPSE POTENTIAL

Chair: Robert Gould, Wake Forest School of Medicine

Co-Chair: Lais Berro, University of Mississippi Medical Center

Substance use disorders (SUDs) show a high degree of comorbidity with sleep problems, with drug abuse profoundly impairing sleep at all phases of addiction. Conversely, sleep disruption also may affect the course of drug addiction: Individuals with a history of sleep problems are at higher risk for the development of substance use disorders and are more likely to relapse during treatment. Taken together, these observations suggest a bidirectional relationship between effects of drugs of abuse and sleep impairment that may be

critical for developing effective treatments. In this symposium, we will discuss recent studies indicating that SUDs and sleep disorders are intricately interconnected, including evidence across the translational pipeline. While decades of research have shaped our understanding of circuits/mechanisms regulating homeostatic sleep and neurobiological changes following chronic drug exposure, less research has demonstrated a causal relationship between the two. Speakers will cover topics including mechanisms underlying sleep and how neurobiological changes associated with SUD may contribute to altered sleep, pre-clinical and translational research investigating progressive and persistent sleep impairment in animals self-administering drugs, and clinical studies showing a clear role of sleep in SUDs. This symposium will cover a range of topics in a field that is of high relevance to both basic and clinical scientists.

15.1 Progressive Sleep Alterations Following Cocaine or Oxycodone Self-Administration in Rats.

Robert Gould, Wake Forest School of Medicine, Department of Physiology/Pharmacology

15.2 Sleep Disturbances and Dopamine Adaptations During Cocaine Abstinence

Rodrigo España, Drexel University College of Medicine

15.3 Nonhuman Primates as a Translational Model to Study the Effects of Methamphetamine on Sleep

Lais Berro, University of Mississippi Medical Center

3:45 P.M. – 5:15 P.M. SYMPOSIUM

16. “EXTENDING” THE BENEFITS OF EXTENDED (VIRTUAL AND AUGMENTED) REALITY TO SUD PATIENTS

Chair: Leonardo Angelone, DHHS/National Institute on Drug Abuse

Extended reality (XR) can be defined as an artificial environment which is experienced through sensory stimuli (such as sights and sounds) provided by a computer and in which one’s actions partially determine what happens in the environment. XR approaches are diverse and currently include augmented reality (AR), virtual reality (VR) and mixed reality (MR). While the use of XR as a therapeutic has been initially proposed over 20 years ago, only recently the technology has become robust enough to be applied to medical devices. Exponential improvement of computational and graphic capabilities and emergence of peer-reviewed XR research led to attempts to leverage this technology for surgical and radiology applications, and more recently as therapeutic solutions for pain and substance use disorders (SUDs).

XR-based products are characterized by broad flexibility of content, adaptable design to address diverse patient needs, ability to address high or low digital literacy, and a wide price range. Speakers will discuss ongoing research efforts in the XR as a medical device area, with specific attention to patient-centric study design. Panelists will also discuss existing regulatory hurdles for XR devices and opportunities to ensure that developed solutions are accessible to SUD patients of diverse socio-economic backgrounds, including underrepresented and vulnerable populations.

16.1 Opportunity for Self-Administered VRx to Reduce Opioid Use With Chronic Pain Sufferers

Matthew Stoudt, AppliedVR, Inc.

16.2 Virtual Reality for Opioid-Sparing Chronic Pain Management

Celine Tien, Tamade Inc. (dba Flowly)

16.3 *Augmented Reality Throughout the Patient Journey – Addressing the Pediatric Opioid Crisis*
Jenny Choi, SpellBound

16.4 *Medical Extended Reality: Applications and Evaluation Challenges*
Ryan Beams, FDA

3:45 P.M. – 5:15 P.M. SYMPOSIUM

17. PAIN RELIEF WITHOUT OPIOIDS: IS THE FUTURE NOW?

Chair: Nathan Appel, National Institute on Drug Abuse, National Institutes of Health

Co-Chair: Jane Acri, National Institute of Drug Abuse, National Institutes of Health

Opioid receptor agonists acting primarily at mu opioid receptors, are widely prescribed to treat pain. They are effective analgesics, but they carry liabilities that include dependence, tolerance, respiratory depression, nausea, somnolence, constipation, and abuse potential. Moreover, opioid analgesics are less effective for treating certain pain modalities such as inflammatory and neuropathic pain. The NIDA Medications Development Program in concert with the NIH HEAL (Helping to End Addiction Long-termSM) Initiative is supporting research to develop effective new analgesics that lack all, or some of the liabilities of mu opioid receptor agonists. In this symposium, we will present preclinical and clinical progress on NIDA-supported efforts to develop safer analgesics. Drs. Jane Acri and Nathan Appel will then moderate a discussion on how novel non-opioid analgesics can inform treatment and potentially reduce exposure to opioids for both new and existing patients with acute and chronic pain conditions.

17.1 *Arylepoaxamides: A New Class of Potent, Safer Analgesics*
Jeffrey Reich, Sparian Biosciences, Inc.

17.2 *Nav1.7 Selective Inhibitors for the Treatment of Acute and Chronic Pain*
John Hunter, Site One Therapeutics

17.3 *A Novel Chemical Entity That is an Effective, Safe, Non-Addictive Peripheral Anti-Hyperalgesic*
Paula Hoffman, University of Colorado Anschutz Medical Campus

17.4 *Agonist Targeting of TRPV1 for Pain Treatment*
Andrew Mannes, Clinical Center, NIH

3:45 P.M. - 5:15 P.M. SYMPOSIUM

18. NDEWS METHODS TO DETECT NEW AND EMERGING PSYCHOACTIVE SUBSTANCES PRESENTED BY NEW AND EMERGING SCIENTISTS

Chair: Linda Cottler, University of Florida

Co-Chair: Marsha Lopez, National Institute of Drug Abuse, National Institutes of Health

In 2020, NIDA funded the second iteration of the National Drug Early Warning System (NDEWS) to address the shifting landscape of drug use in the US, particularly the proliferation of new psychoactive substances (NPS) such as fentanyl and its analogs, synthetic cathinones, and synthetic cannabinoids. Real-time surveillance is needed to detect early signals of new and emerging drug trends and inform prevention efforts, and the new iteration

of NDEWS has established multiple data sources to provide an integrated and comprehensive characterization of drug use and availability. This workshop will discuss the NDEWS Scientific Advisory Group, Sentinel Sites, Weekly Briefings, and four methods for surveillance, including: 1) Rapid Street Reporting, on-the-ground rapid surveys of NPS use in Sentinel Site locations, pairing self-report methods with hair sampling; 2) assessment of real-time, substance-related 911 dispatch data; 3) collaborations with High Intensity Drug Trafficking Area (HIDTA) programs and RADARS for monitoring of drug seizures and exposures reported to national Poison Control Centers; and 4) real-time web monitoring of drug-related discussion forums. Trainees from the University of Florida NIDA T32 Predoctoral Training Program and Florida Atlantic University spearheading these NDEWS projects will present their methods and ongoing surveillance findings at this symposium. The audience will be asked to link to a brief survey at the end of the symposium to obtain feedback on the topics important to them.

18.1 Rapid Street Reporting: Identifying Emerging Drugs and Their Adverse Effects in the Field
Nae Won, University of Florida, College of Medicine

18.2 Drug Seizures and Poisoning Exposures: Collaborations with HIDTA and RADARS for Monitoring Trends in Drug Use and Availability in the U.S.
Nicole Fitzgerald, University of Florida

18.3 Real-Time 911 Dispatch Data to Monitor Overdose Events in the U.S.
Andrew McCabe, University of Florida

18.4 Web Monitoring of New Psychoactive Substance Trends in Drug Subreddit Discussion
Paul Morris, Center for Complex Systems and Brain Sciences, Florida Atlantic University

Moderator: Anna Wang, University of Florida

7:00 P.M. - 9:00 P.M. WORKSHOP

19. EARLY CAREER MEMBER COMMITTEE: NAVIGATING A CAREER IN ADDICTION SCIENCE

Chair: Lia Smith, University of Houston
Co-Chair: Denise Vidot, University of Miami

Despite the many career paths available to addiction scientists, the knowledge on how to navigate a given career can be limited. This gap in knowledge may often be a function of available mentorship and/or resources. Opportunities may exist for emerging addiction scientists that are suited for their skillsets or expertise but are otherwise inaccessible due to a lack of institutional knowledge on how to pursue certain career paths. The purpose of this workshop is to provide early career attendees the opportunity to hear from a diverse group of addiction scientists pursuing a range of professions in academia, industry, and government agencies. This workshop will provide valuable information to early career attendees about skill sets, experiences, and expertise required to be successful in various careers as addiction scientists. Our speakers include preclinical, clinical, and epidemiological addiction scientists with experience in industry (Pew Charitable Trust, Canopy Growth Inc.), government (FDA), and academic (research institute, teaching institute and clinic-based research) agencies. Presenters will share experiences that prepared them for success, describe their day-to-day work entails, and discuss available growth opportunities. The workshop will also include breakout groups with each speaker that will allow early career attendees to ask directed questions about specific career paths. CPDD is successful, in part, because of dedicated addiction scientists with careers in academia, industry, and government

who collaborate to advance the understanding of addiction science. This workshop will provide critical insights for early career attendees, facilitate unique networking opportunities, and will ultimately enrich the future membership of CPDD.

19.1 Navigating Substance Use Disorder Careers Outside of Academia
Alexandra Duncan, The Pew Charitable Trusts

19.2 Drug Abuse Research at a Primarily Undergraduate Institution: Balancing the Classroom and Laboratory
Ryan Lacy, Franklin and Marshall College

19.3 The “Ins” and “Outs” of a Typical Workday for a Regulatory Scientist on the FDA Controlled Substance Staff
Jovita Randall-Thompson, US Food and Drug Administration

19.4 The Role of the Psychiatrist in Academic Research
Denis Antoine, Johns Hopkins University School of Medicine

19.5 Trading Paces: One Perspective on the Journey From Academia to Industry
Erica Peters, Canopy Growth Corporation

7:00 P.M. - 9:00 P.M. WORKSHOP

20. 28TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP

Chair: Diann Gaalema, University of Vermont

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the discussion and dissemination of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 28th annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact. As the goal for this working group has always been to provide an informal outlet for discussion of CM data, names of presenters are not included with this submission. Rather, participants and topics will be chosen during the Spring of 2022 in order to capture the most current data in contingency management for presentation at our annual working group.

20.1 Contingency Management to Promote Health-Related Behaviors
Diann Gaalema, University of Vermont

20.2 Promoting Abstinence From Commonly Abused Drugs
Forrest Toegel, Northern Michigan University

7:00 P.M. - 9:00 P.M. WORKSHOP

21. LEARNINGS FROM THE RURAL OPIOID INITIATIVE ABOUT METHODS TO CONDUCT RESEARCH WITH RURAL PWUD

Chair: Richard Jenkins, National Institutes of Health

Discussant: Hannah Cooper, Emory University

Over the past 20 years, drug-related epidemics have expanded from metropolitan areas into rural areas. This workshop is designed to strengthen participants' capacities to plan and conduct rigorous research with people who use drugs (PWUD) and live in rural areas.

Methods to study drug use and drug-related harms were often created in, and for, cities, and so must be adapted or replaced in rural environments because of urban/rural differences in population dynamics, technology access and use, travel distances, and the distribution of resources. Venue-based sampling, for example, may encounter challenges because low densities of rural populations are usually accompanied by low densities of medical and public health organizations. Moreover, local knowledge and relationships may be required to identify and gain entrée to organizations serving PWUD because they are purposely hidden from populated areas. Further, the lack of history with research may make it more difficult to establish the relationships necessary to gain local knowledge and entrée.

We will draw on learnings from the first years of eight NIDA-funded Rural Opioid Initiative projects to share, and critically reflect on, promising strategies for engaging and studying PWUD in a variety of rural areas. Speakers will discuss COVID-era challenges to these strategies, and ways to overcome them.

Sessions:

- Historical and sociocultural drug-use contexts in rural America: a multi-site qualitative study
- Recruitment and Retention of Rural PWUD: Lessons from Appalachian Kentucky
- Epidemiologic, policy and vulnerability scans for rural opioid-related risks
- Maximizing benefits and avoiding pitfalls when collaborating with rural health departments for harm reduction

21.1 Historical & Sociocultural Drug-Use Contexts in Rural America: A Multi-Site Qualitative Study

Vivian Go, University of North Carolina

21.2 Recruitment & Retention of Rural PWUD: Lessons From Appalachian Kentucky

Thomas Stopka, Tufts University School of Medicine

21.3 Epidemiologic, Policy & Vulnerability Scans for Rural Opioid-Related Risks

Mai Pho, The University of Chicago

21.4 Maximizing Benefits & Avoiding Pitfalls When Collaborating With Rural Health Departments for Harm Reduction

William Zule, RTI International

21.5 Epidemiologic, Policy & Vulnerability Scans for Rural Opioid-Related Risks

April Young, University of Kentucky, College of Public Health

7:00 P.M. - 9:00 P.M. WORKSHOP

22. A PATH LESS TRAVELED: BECOMING A MEDICAL DEVICE DEVELOPER FOR THE SUBSTANCE USE DISORDERS

Chair: Leonardo Angelone, DHHS/National Institute on Drug Abuse

Co-Chair: Stephanie Carreiro, University of Massachusetts Medical School

The alarming increase of drug overdose-related deaths highlights the continuous public health emergency faced by patients, their families, and caregivers. There is an urgent need for safe and effective solutions for Substance Use Disorders (SUDs), not fully addressed by existing pharmacologic and psychological treatments. Medical devices offer promising means to monitor, diagnose, and treat SUDs. The paths to become a medical device developer in SUD field are often unexplored and unique for each investigator. The symposium offers the opportunity to learn from four speakers about their unique experience and journey to become a medical device developer. Panel members include executives and academic partners from some of the most disruptive and innovative companies in today's healthcare ecosystem. The speakers have exceptional and diverse background, including emergency medicine, toxicology, epidemiology, anesthesiology, computational neuroscience, and business administration. Their research interests include a broad spectrum of applications for SUD patients, such as digital biomarkers, wearables, mobile health, neurofeedback, or stochastic vibration used as therapy for neonatal abstinence syndrome. They are pioneers in their field, building an ecosystem that includes the scientific community, regulators, payers, and patients. And they share common goals: to develop novel safe and effective technologies for SUD patients, design these products to address specific needs of the patients and their caregivers, and ensure access to these novel solutions for all patient populations.

22.1 Using Smart Devices to Detect Opioid Overdose

Jacob Sunshine, University of Washington School of Medicine

22.2 A Curious Journey to Help Opioid-Exposed Newborns, My Benjamin Button Like Story

John Konsin, Prapela, Inc

22.3 From the University Lab to the Market: Digital Biomarker-Based SUD Intervention Development From the Academic Investigator's Perspective

Stephanie Carreiro, University of Massachusetts Medical School

22.4 Unplugged: Lessons Learned Taking Drug Craving Neuromarkers Out of the Lab and Into the Clinic

Scott Burwell, Neurotype Inc.

7:00 P.M. - 9:00 P.M. WORKSHOP

23. IMPLEMENTING PEER RECOVERY COACHES FOR IMPROVING RECOVERY IN PEOPLE WITH SUBSTANCE USE DISORDERS: INSIGHTS FORM RESEARCHERS, STAKEHOLDERS, AND CLINICIANS

Chair: Irene Pericot-Valverde, Clemson University

Co-Chair: Kaileigh Byrne, Clemson University

Approximately 20.4 million people aged 12 or older have a substance use disorder (SUD). Recent legislative efforts have been implemented in order to improve access to treatment among people with SUDs.

Unfortunately, most individuals living with a SUD do not receive treatment. Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with SUDs to achieve and maintain recovery. These services are provided by recovery coaches, individuals with lived experience with substance use and a successful recovery. Recent studies have shown the effectiveness of utilizing peer recovery services into different settings, including emergency department and outpatient settings. This workshop will bring together researchers, peer recovery specialists, and clinicians who will provide insight into the implementation of peer recovery services in a variety of settings including clinical trials, inpatient and outpatient services, and emergency departments. More specifically, Dr Pericot-Valverde will describe the implementation of peer recovery coaching in randomized clinical trials. Dr Roth will describe the implementation of peer recovery coaching in inpatient settings departments. Dr Byrne will describe the utilization of recovery coaching services in inpatient and outpatient settings. Finally, Ms. Melling will describe her experience as a specialist peer recovery coach. Focusing on prior experiences from a multidisciplinary team, the workshop will help researchers and clinicians interested in implementing peer recovery coaches for research and treatment purposes.

23.1 Results of Inpatient Linkage to Peer Recovery Coaching on Engagement in Recovery Outcomes and Hospital Utilization

Kaileigh Byrne, Clemson University

23.2 Implementation of Inpatient Peer Recovery Coaching Into the Hospital System

Prerana Roth, Prisma Health-Upstate

23.3 What Are Peer Recovery Coaches and What Do We Do? Input From a Peer Recovery Professional

Trisha Melling, Prisma Health

23.4 Applying Peer Recovery Coaching in Clinical Trials

Irene Pericot-Valverde, Clemson University

TUESDAY, JUNE 14, 2022

10:00 A.M. - 11:30 A.M. SYMPOSIUM

24. CIRCADIAN AND SLEEP FACTORS IN SUBSTANCE USE DISORDERS: ROLE OF THE EXTRACELLULAR MATRIX

Chair: Barbara Sorg, Legacy Research Institute

Co-Chair: Harry Pantazopoulos, University of Mississippi Medical Center

Sleep and circadian rhythms are disrupted in individuals with substance use disorders (SUDs). This session will cover recent findings showing that extracellular matrix components, including perineuronal nets, may serve as key mechanistic links between SUDs and disrupted sleep and circadian rhythms. Dr. Ryan Logan will discuss transcriptomic results in the prefrontal cortex (PFC) and nucleus accumbens (NAc) of humans with opioid use disorder (OUD), demonstrating association of rhythmic transcripts with changes in glutamatergic, GABAergic, and extracellular matrix signaling, and with sleep and insomnia. He will also present evidence for the role of microglia, proinflammatory cytokines, and ECM signaling in OUD. Dr. Harry Pantazopoulos will provide the first evidence of altered PNNs and PNN-surrounded parvalbumin neurons in the hippocampus of humans with SUDs and will discuss the link between these changes with altered expression of clock genes and synaptic markers. Dr. Barbara Sorg will discuss diurnal rhythms of PNNs and surrounded parvalbumin neurons. She will

also discuss how PNNs in the PFC guide cocaine-associated memories in a rodent addiction model, and how depleting PNNs in the PFC alters brain oscillations between the PFC and hippocampus. Dr. Jonathan Wisor will discuss the consequences of manipulating the sleep/wake cycle to address whether the diurnal pattern of PNNs is linked to or is independent of daily variations in the sleep/wake cycle. Collectively, this mini-symposium will highlight changes in the extracellular matrix as an important driver of altered plasticity that links SUDs with disrupted sleep and circadian rhythms.

24.1 Transcriptional Rhythms in Human Brain Reveal Roles for Extracellular Matrix and Microglia in Opioid Use Disorder

Ryan Logan, Boston University School of Medicine

24.2 Extracellular Matrix and Molecular Clock Abnormalities in the Hippocampus of Subjects With Substance Use Disorder

Harry Pantazopoulos, University of Mississippi Medical Center

24.3 Perineuronal Nets: Diurnal Changes and Cocaine Memories

Barbara Sorg, Legacy Research Institute

24.4 Sleep and Circadian Modulation of Perineuronal Nets

Jonathan Wisor, Washington State University

10:00 A.M. - 11:30 A.M. SYMPOSIUM

25. INNOVATIVE APPROACHES FOR EXPANDING ACCESS TO PHARMACOTHERAPY FOR OPIOID USE DISORDER

Chair: Stacey Sigmon, University of Vermont

Co-Chair: Sharon Walsh, University of Kentucky

Innovative approaches are desperately needed to continue the expansion of OUD treatment access. In this session, presenters will share their recent scientific efforts to develop and evaluate novel approaches for expanding delivery of pharmacotherapy and harm reduction. First, Dr. D'Onofrio will discuss innovative strategies for ED-initiated buprenorphine, including the options of high-dose buprenorphine and a 7-day injectable, extended-release buprenorphine formulation which may allow for immediate induction while concurrently surmounting logistic and other barriers that often impede uptake. Second, Dr. Lee will present on his team's efforts to expand MOUD in CJS settings and populations, which will include NIDA-funded research findings and real-world implementation efforts on recent and current clinical trials and MOUD expansion strategies focused on criminal justice facilities and re-entry populations. Thirdly, Dr. Freeman will discuss the role of pharmacists in substance use disorder treatment and harm reduction. This will include recent efforts by pharmacists to initiate dispensing of naloxone, establish opioid and alcohol use disorder treatment services with long-acting naltrexone injection, and sell syringes over-the-counter to persons who inject drugs. Finally, Dr. Sigmon will present primary outcomes from two recently-completed randomized clinical trials (1 rural, 1 non-rural setting) evaluating the efficacy of a technology-assisted buprenorphine treatment for reducing illicit opioid use and other risk behaviors. Dr. Walsh will moderate this session. Taken together, we aim to share updates on recent scientific efforts to expand avenues for increasing access to life-saving opioid treatment.

25.1 Innovative Strategies for ED-Initiated Buprenorphine

Gail D'Onofrio, Yale University School of Medicine

25.2 Expanding MOUDS in CJS Settings and Populations
Joshua Lee, New York University Grossman School of Medicine

25.3 Engaging Pharmacists in Substance Use Disorder Treatment and Harm Reduction
Patricia Freeman, University of Kentucky

25.4 Technology-Assisted, Low-Barrier Buprenorphine Treatment
Stacey Sigmon, University of Vermont

Moderator: Sharon Walsh, University of Kentucky

10:00 A.M. - 11:30 A.M. SYMPOSIUM

26. LINKS BETWEEN EARLY LIFE ADVERSITY AND ADDICTION

Chair: Lynn Oswald, University of Maryland School of Nursing
Co-Chair: Erin Winstanley, West Virginia University

Early life adversity (ELA) is a term that is being used to describe traumatic events that occur during childhood which have the potential to alter normal development and increase risks for a spectrum of physical and mental health in adulthood, including substance use disorders (SUDs). Accumulating evidence has shown associations between ELA and risk behaviors, drug misuse, more rapid transition from misuse to use disorders, and poor treatment outcomes in humans. These findings have mirrored those of preclinical studies demonstrating the consequences of early life manipulations on behaviors that reflect aspects of drug reward or tendency to relapse after abstinence. Nevertheless, ELA is only beginning to be taken into consideration in the development of individualized prevention and treatment strategies and there is a need for better understanding of the neurobiological processes that promote vulnerability or resilience in ELS-exposed individuals. This symposium will begin with a presentation by Dr. Khan who will discuss the role of ELAs in substance abuse risks, highlighting current findings on mediating pathways that may help to inform intervention strategies. Dr. al'Absi will then review evidence of neurobiological mechanisms that underlie risks for addiction, focusing on the physiological stress system. Dr. Nugent will present her findings showing effects of ELA on behavior depression and motivational properties of morphine and its relationship to habenula activity in a rat model. Finally, Dr. Hales will discuss the impact of ELA on nociception in mice and their response to morphine and its implications for opioid treatment of chronic pain.

26.1 The Role of Childhood Traumatic Events in Substance Use Risk Across the Lifecourse: Considerations of Mediating Paths and Intervention Possibilities
Maria Khan, New York University School of Medicine

26.2 Neurobiological Mechanisms of Early Adverse Experience, Blunted Stress Reactivity and Risk for Addiction
Mustafa al'Absi, University of Minnesota Medical School

26.3 Maternal Deprivation-Induced Lateral Habenula Dysfunction Promotes Anhedonia and Alters Morphine Self Administration Acquisition in Rats
Fereshteh Nugent, Uniformed Services University

26.4 The Impact of Early Life Adversity on Pain and Responses to Opioids
Tim Hales, University of Dundee

Moderator: Erin Winstanley, West Virginia University

10:00 A.M. - 11:30 A.M. SYMPOSIUM

27. CROSS-CULTURAL CANNABIS SCIENCE: LESSONS LEARNT AND HOW TO MOVE FORWARD

Chair: Janna Cousijn, Erasmus University Rotterdam

Co-Chair: Francesca Filbey, University of Texas at Dallas

Today's world is experiencing shifts towards lenient cannabis policies and similar shifts in public opinion. However, the knowledge base of both harms and benefits is still poor and integration of evidence is complicated by substantial variability in cannabis products, route of administration, and regional differences therein. For example, European cannabis users often smoke cannabis with tobacco, while this is uncommon in US users. Moreover, the strength of cannabis is highly variable between regions, and how others perceive cannabis use will likely impact the social problems a cannabis user experiences. This symposium will describe what we currently know about the impact of long-term cannabis use and dependence on brain and behaviour. Taking a cross-cultural and cross-jurisdictional perspective, we will critically evaluate the role of different user characteristics and the environment. We will discuss novel findings from neuroimaging research investigating the role of cannabis culture, as well as cannabis policy research. Moreover, we will discuss important knowledge gaps and evaluate novel tools to globally harmonise cannabis research.

27.1 Cannabis Use, Dependence and the Brain: What Do We know?

Janna Cousijn, Erasmus University Rotterdam, The Netherlands

27.2 The Role of Cannabis Cultural Attitudes and Norms on Cannabis Approach Tendencies in Individuals With Cannabis Use Disorder

Lauren Kuhns, University of Amsterdam

27.3 Assessing Cannabis Consumption and Policy-Relevant Outcomes at the Population Level

David Hammond, University of Waterloo

27.4 Bridging the Gaps: New Developments in Measuring Cannabis Use Across International and Multidisciplinary Settings

Valentina Lorenzetti, Australian Catholic University

12:00 P.M. - 2:00 P.M. ANIMAL FORUM

28. GETTING THE WORD OUT: STRATEGIES FOR EFFECTIVE COMMUNICATION ABOUT ANIMALS IN RESEARCH

Chair: James Rowlett, University of Mississippi Medical Center

Animal research plays a vital role in our understanding of substance use disorders (SUDs), contributing to topics ranging from genetic/molecular mechanisms to complex social interactions. As with most research endeavors with animals, misrepresentations about the importance of animal research in SUDs research has grown over the years due to the actions of animal rights extremists, who are remarkably effective at affecting public opinion. As an organization, CPDD supports animal research, and a key strategy for growing this support beyond the scientific community is to engage in effective communication that: (a) informs the public at large about the issues and misinformation propagated by the modern animal rights extremism movement, and (b)

informs the public at large about the factual role animal research plays in scientific advancement of the field. To discuss these issues, Dr. Sangeeta Panicker (American Psychological Association) will provide an overview of the strategies and recent successes of the animal rights movement in the modern era. Next, Dr. Allyson Bennett (University of Wisconsin—Madison) will discuss communication strategies for all scientists to engage both scientific and non-science audiences alike. The overall goal of this Forum is to make the membership aware of the urgent issues regarding the animal research environment and to provide important resources for addressing these critical issues.

28.1 Not Just Science: Talking About Ethics, Animals, and Public Benefit

Sangeeta Panicker, Public Responsibility in Medicine and Research (PRIM&R)

28.2 Why Are We Still Doing This? Making the Basic to Applied Relationship Clear

Allyson Bennett, University of Wisconsin-Madison

1:00 P.M. - 3:00 P.M. POLICY FORUM

29. IMPACT OF COVID-19 OPIOID TREATMENT PROGRAM POLICY RELAXATIONS ON PATIENT OUTCOMES

Chair: Sandra Comer, Columbia University and NYSPI

Co-Chair: Dennis McCarty, Oregon Health and Science University

Discussant: Gavin Bart, University of Minnesota

The 2022 CPDD Policy Forum examines the COVID-19 relaxation of methadone treatment regulations. In addition, the Policy Forum will include a Friends of NIDA update and a review of pending federal legislation.

Optimal Policies to Improve Methadone Maintenance Adherence Long-term (OPTIMMAL)

Arthur Robin Williams, MD

The study examined pre-pandemic OTP operations and patient outcomes (e.g., clinic dosing visits, take-home doses, retention in care) with post-pandemic operations and patient outcomes. Approximately 2,500 patient charts were reviewed across 10 OTPs participating in the National Drug Abuse Treatment Clinical Trials Network.

Multi-state Survey of Opioid Treatment Program Leaders Assessing COVID-19 Changes

Ximena Levander, MD

A multi-state survey of OTP leaders' responses to COVID-19 related policy changes assessed 1) how OTPs changed take-home methadone provisions, 2) factors considered in determining patient stability, and 3) concerns surrounding expanded take-homes. The two most common factors for determining stability were ongoing non-prescribed opioid use (52%) and sedative use (52%).

Impacts of COVID-19 Relaxation of Methadone Policies in Rural Oregon Opioid Treatment Programs (Oregon HOPE study)

Todd Korthuis, MD, MPH

Oregon's OTPs reported a 50% decline in patient visits and a 97% increase in take-home doses after implementation of relaxed policies. In two rural OTPs, the rate of opioid positive urine screens did not increase and interviews identified three themes: 1) patients felt trusted with increased responsibility; 2) repurposed time spent traveling to the clinic with other activities supportive of recovery; and 3) less exposure to individuals who hampered recovery.

29.1 *The Optimal Policies to Improve Methadone Maintenance Adherence Longterm OPTIMMAL CTN Study*
Arthur Robin Williams, Columbia University Division on Substance Use Disorders

29.2 *Multi-State Opioid Treatment Program Leader Survey of COVID-19 Policy Changes*
Ximena Levander, Oregon Health and Science University

29.3 *Impacts of COVID-19 Relaxation of Methadone Policies in Rural Oregon Opioid Treatment Programs (Oregon Hope Study)*
P. Todd Korthuis, Oregon Health and Science University

2:00 P.M. - 3:00 P.M. JOURNALS

30. JOURNALS: DRUG AND ALCOHOL DEPENDENCE AND DRUG AND ALCOHOL DEPENDENCE REPORTS

Steve Shoptaw, University of California Los Angeles
Teresa Franklin, University of Pennsylvania
Erin McClure, Medical University of South Carolina

In this one-hour Oral Session, the Editor-in-Chiefs for Drug and Alcohol Dependence (DAD; Dr. Steve Shoptaw) and Drug and Alcohol Dependence Reports (DADR; Dr. Teri Franklin) will make a brief presentation on their perspectives for the next year for the journals.

1. Vital stats of DAD and DADR: submission rate/acceptance rate/impact factor
2. Snapshots of the most important papers published over the last year in DAD and DADR
3. What puts a submission on track to be the 'best' published of the year?
4. What causes a submission to be rejected without review and authors' next steps
5. Role of reviewers: what makes a review helpful to authors; what can be learned by being a reviewer?
6. Ensuring diversity and inclusion in peer reviewed journals

30.1 *Gender Parity and Homophily in the Drug and Alcohol Dependence Editorial Process*
Erin McClure, Medical University of South Carolina

3:30 P.M. - 5:30 P.M. WORKSHOP

31. EVENT-RELATED POTENTIALS AND SUBSTANCE USE DISORDERS: IDENTIFYING CLINICALLY RELEVANT METRICS TO INFORM THERAPEUTICS

Chair: Vaughn Steele, Yale University School of Medicine
Co-Chair: Ingmar Franken, Erasmus University Rotterdam

Substance use disorders (SUDs) are exemplified by dysregulated cognitive functions such as heightened drug cue reactivity, attentional bias, and executive control. Uncovering the underlying mechanisms related to these cognitive functions is important for understanding the chronic, relapsing brain disease of SUDs necessary to develop effective therapeutics. Recent studies show exciting progress in this area and reveal how event-related potentials (ERPs) can inform our understanding of basic brain processes involved in SUD behaviors, predict the onset and development of these behaviors, and provide objective markers for treatment outcome evaluation. In the symposium we present state-of-the-art of ERP studies focused on how ERPs facilitate

prediction, prevention, treatment outcomes, and therapeutic development. Specifically, Dr. Parvaz will present results related to ERPs-based tracking changes in reactivity to cocaine-related cues in cocaine use disorder as a function of abstinence duration as well as with volitional down-regulation of the affective response to these cues. Mr. Butler will present time-frequency ERP measures of attentional processes dysregulated in SUD. Dr. Steele will present ERP measures of dysregulated response inhibition and error-monitoring and outline how these are targets for therapeutic interventions to treat SUDs. Finally, Dr. Franken will present recent and ongoing studies of error-processing in SUD as highlighted in a large-scale study of adolescents to predict the development of substance use disorders. Together, these presentations will highlight how robust and versatile ERP measures inform clinical outcomes and therapeutic development.

31.1 Electrophysiological Tracking of Drug Cue-Reactivity and Changes Therein With Abstinence and Self-Regulation
Muhammad Parvaz, Icahn School of Medicine at Mount Sinai

31.2 Delta and Theta Activity From an 3-Stimulus Oddball Task Provide Shared and Unique Sensitivity to Alcohol and Cocaine Use Disorders

Devin Butler, University of Maryland - College Park

31.3 Identifying Treatment Targets Related to Dysregulated Circuits in Substance Use Disorders With Event-Related Potential Measures of Response Inhibition and Error-Monitoring

Vaughn Steele, Yale University School of Medicine

31.4 Electrophysiological Indices of Error Processing in Substance Use Disorders

Ingmar Franken, Erasmus University Rotterdam

3:30 P.M. - 5:30 P.M. WORKSHOP

32. DID YOU HEAR ABOUT THE LOOMING GLOBAL FENTANYL CRISIS?: A QUICK START FOR ADDICTION SCIENTISTS ACROSS THE WORLD

Chair: Francesca Filbey, University of Texas at Dallas

Co-Chair: Dace Svikis, Virginia Commonwealth University

Illegally sourced fentanyl is no longer just a problem for the United States. Despite disruptions in supply chains for illicit drugs during the COVID-19 pandemic, we have witnessed an increase in fentanyl-related drug fatalities, and fentanyl is now also being shipped to Canada, Europe, and other destinations. How will these complex developments be different from the U.S. opioid epidemic and are there lessons learned that can be applied to evolving contexts and settings? What strategies from different countries can be effective in fending off an emerging global fentanyl crisis?

Towards the goal of providing current data and resources for an international audience to address this growing worldwide public health concern, this workshop will be structured in two parts. Part 1 (80 minutes) will consist of 20-minute panel presentations: (1) Thom Browne from the Colombo Plan will discuss various fentanyl compounds (and other novel synthetic opioids) and existing international controls; (2) Paul Griffiths from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) will present scientific evidence on the fentanyl crisis in the EU as well as the impacts of medical and legal policies; (3) Kim Johnson, Director of the International Consortium of Universities for Drug Demand Reduction (ICCUDDR) will describe how ICCUDDR's mission of supporting addiction professionals can be leveraged to meet the challenges of this global crisis; and (4) Steve Gust, Director of NIDA International Program, will describe existing NIDA mechanisms to advance international collaborations on addiction research. Part 2 (40 minutes) will be an interactive Q and A session.

32.1 Fentanyl's Role in the Polydrug Epidemic
Thom Browne, Colombo Plan Secretariat

32.2 The Impact of the Fentanyl Crisis on the EU: An Overview of the Current Situation
Paul Griffiths, European Monitoring Centre for Drugs and Drug Addiction

32.3 The Role of Addiction Professionals on the Global Crisis: Perspectives From the International Consortium of Universities for Drug Demand Reduction (ICCUDDR)
Kevin Mulvey, International Consortium of Universities for Drug Demand Reduction

32.4 Opportunities for Research Funding on the Global Fentanyl Epidemic
Steve Gust, Consultant NIDA International Program

3:30 P.M. - 5:30 P.M. WORKSHOP

33. MEETING THE DEMAND: EXPANDING THE ADDICTION WORKFORCE FROM PROGRAMS TO PEERS

Chair: Julie McCarthy, McLean Hospital, Harvard Medical School

Co-Chair: Jessica Chou, Drexel University

Among individuals with a current substance use disorder (SUD), 90% did not receive any substance use treatment in the past year. Despite the existence of evidence-based interventions addressing SUDs and their impact on the greater community, the availability of a well-trained workforce to deliver such services is severely limited. This workshop will educate participants on the latest efforts to develop and evaluate training initiatives designed to meet the demand for accessible evidence-based services that address SUDs. Dr. Jessica Chou will first present on a Health Resources and Services Administration (HRSA) Opioid Workforce Expansion Program (OWEP) to train graduate students to provide services to children, adolescents, and families impacted by opioid use disorder in Ohio and Pennsylvania, two states experiencing some of the highest rates of opioid fatalities in the United States. Dr. Paul Sacco will then present on the University of Maryland, Baltimore Behavioral Health Workforce Integration Service and Education (BHWISE) Fellowship programs, highlighting an interdisciplinary OWEP designed to train clinicians who are committed to working with underserved communities. Dr. Kenneth Carpenter will next present on a national parent-to-parent peer support network by describing the feasibility and acceptability of training parents of a child who has a substance use disorder in evidence-based principles and strategies who in turn provide phone coaching to other parents seeking help for their children. Finally, Drs. McCarthy and Chou will lead an interactive discussion on next steps to expand our ability meet the unmet need for addiction treatment.

33.1 Online Family Systems Training for Graduate Students Working With Adolescents & Families Impacted by Opioid Use Disorder
Jessica Chou, Drexel University

33.2 Training the Next Generation of Substance Use Disorder Clinicians Committed to Working With Underserved Communities
Paul Sacco, University of Maryland Baltimore

33.3 Parent-To-Parent Phone Coaching for Families Experiencing a Substance Use Disorder
Kenneth Carpenter, New York State Psychiatric Institute, Columbia University

3:30 P.M. - 5:30 P.M. WORKSHOP

34. ENGAGING COMMUNITIES TO DELIVER EFFECTIVE OPIOID USE PROGRAMS FOR NATIVE AMERICANS

Chair: Daniel Dickerson, UCLA Integrated Substance Abuse Programs

The opioid epidemic is having a profound impact on the health and well-being of American Indian/Alaska Native (AI/AN) people. Effective relationships between researchers, clinical delivery systems and Native American communities are needed in order to create a system of opioid treatment delivery that is sustainable and culturally appropriate.

The first part of this workshop will include brief presentations. First, Dr. Daniel Dickerson (Inupiaq) will describe the development of a new opioid prevention intervention for urban AI/AN emerging adults. Next, Dr. Claradina Soto (Najavo/Pueblo) will describe a comprehensive assessment of California Tribal Health Programs, Urban Indian Health Programs, and AIAN culturally centered residential treatment, and sober living facilities. Next, Dr. Carrie Johnson (Wahpeton Dakota), will provide a clinical perspective in the implementation and delivery of opioid prevention and treatment. Lastly, a community elder (to be determined) will provide a community perspective with regard to the delivery of opioid interventions for AI/ANs.

The second part of this workshop will include an interactive exercise that will involve the development of a new “hypothetical” opioid use treatment program for Native Americans. The audience will be separated into three groups: 1) an AI/AN community advisory board, 2) opioid use intervention researchers, and 3) clinic administrators and providers. Following a brief description of this community, each group will discuss potential strategies that may need to be considered. Lastly, a broader discussion with the whole group will be conducted to identify some potential collaborative strategies that can help develop this new program.

*34.1 The Development of a New Opioid Prevention Intervention for Urban Native American Emerging Adults
Daniel Dickerson, UCLA Integrated Substance Abuse Programs*

*34.2 An Overview of a Comprehensive Assessment of Opioid Treatment Programs for Native Americans in California
Claradina Soto, Keck School of Medicine University of Southern California*

*34.3 Engaging Communities to Deliver Effective Opioid Use Programs for Native Americans
Carrie Johnson, United American Indian Involvement*

*34.4 Engaging Communities to Deliver Effective Opioid Use Programs for Native Americans
George Funmaker, State of California, Department of Corrections and Rehabilitation*

3:30 P.M. - 5:30 P.M. WORKSHOP

35. ADVANCES IN ADOLESCENT RECOVERY RESEARCH AND THE SOCIETY FOR ADOLESCENT SUBSTANCE ABUSE TREATMENT EFFECTIVENESS (SASATE)

*Chair: Michael Dennis, Chestnut Health Systems
Co-Chair: Doug Smith, University of Illinois Urbana-Champaign*

The process of substance use disorder (SUD) recovery is difficult for adolescents and young adults. It often involves multiple episodes of treatment and relapse. While adolescents is the primary person of substance use

onsite and SUD prevalence peaks during young adult, treatment and recovery support systems are generally geared towards older adults. In the past two decades there has been a growing body of research on how to facilitate and sustain recovery. More recently this research has begun to focus on adolescents and youth adults. Presentations on recovery related research with adolescents and young adults and will include presentations by: Dr. Douglas Smith on, “Coming of Age in Recovery: The prevalence and correlates of recovery status among a large statewide sample of adolescents”; Dr. John Kelly on “Independent Effects of entering recovery as a young versus older adult on long-term functioning and quality of life: Results from a National Survey on Recovery”; Dr. Emily Hennessy on, “Social Influence in Youth Recovery and the use of Social Identity Mapping to Examine Recovery Processes”; Dr. Michael Dennis on “Preliminary Findings from the Smartphone Addiction Recovery Coach (SARC) experiment with Young Adults”; and Robert M. Vincent facilitating a discussion.

35.1 Coming of Age in Recovery: The Prevalence and Correlates of Recovery Status Among a Large Statewide Sample of Adolescents

Doug Smith, University of Illinois Urbana-Champaign

35.2 Social Influence in Youth Recovery and the Use of Social Identity Mapping to Examine Recovery Processes
Emily Hennessy, Massachusetts General Hospital and Harvard Medical School

35.3 Independent Effects of Entering Recovery as a Young Versus Older Adult on Long-Term Functioning and Quality of Life: Results From a National Survey on Recovery

John Kelly, Harvard Medical School

35.4 Preliminary Findings From the Smartphone Addiction Recovery Coach (SARC) Experiment With Young Adults
Michael Dennis, Chestnut Health Systems

Moderator: Robert Vincent, Substance Abuse and Mental Health Administration (SAMHSA)

WEDNESDAY, JUNE 15, 2022

10:00 A.M. - 11:30 A.M. SYMPOSIUM

36. THE OREXIN SYSTEM IN ADDICTION

Chair: Scott Lane, University of Texas Health Science Center, McGovern Medical School

Co-Chair: Mark Greenwald, Wayne State University

Accumulating evidence demonstrates that the hypocretin/orexin (ORX) neuropeptide system and its constituent CNS receptors play a significant role in the development and maintenance of substance use disorder (SUD). The biobehavioral components through which ORX contributes to SUD are still being elucidated; regulation of motivational, stress/anxiety, sleep and energy homeostasis systems are strongly implicated. The present symposium will provide an update on mechanisms and treatment interventions involving the ORX system in addiction. Presentations will include both preclinical and human studies and feature investigations covering a range of abused substances.

36.1 Cocaine-Suvorexant Interactions: A Human Laboratory Study
William Stoops, University of Kentucky

36.2 *Dual Orexin Receptor Antagonism During Opioid Withdrawal*
Andrew Huhn, Johns Hopkins University School of Medicine

36.3 *The Orexin System in Addiction*
Brooke Schmeichel, East Tennessee State University, James H. Quillen College of Medicine

36.4 *Orexin System Plasticity Following Cocaine in Rats: Therapeutic Opportunities*
Morgan James, Rutgers University

10:00 A.M. - 11:30 A.M. SYMPOSIUM

37. THROUGH THE LOOKING GLASS: METACOGNITION, INTEROCEPTION, HALLUCINOGENS, AND NON-ORDINARY STATES AS POTENTIAL AVENUES FOR NOVEL ADDICTION TREATMENTS.

Chair: Albert Garcia-Romeu, Johns Hopkins University School of Medicine

Metacognition issues in addiction lead to problems in social functioning and may contribute to low treatment success rate and high levels of relapse. Research into the role of interoception in drug and alcohol use is also growing. Interoceptive “fingerprints” could be a part of predisposition endophenotype, and also may change under the influence of drugs and alcohol, or through targeted treatment. Data on emerging treatment modalities using hallucinogens suggest the potential for rapid insight and behavior change, possibly through inducing non-ordinary states that can alter metacognition and interoceptive processes. These interventions may present novel avenues to overcoming barriers in addiction treatments, while improving social cognition and functionality.

37.1 *Moderated Discussion: Hallucinogens and Non-ordinary States in Addiction Treatment*
Albert Garcia-Romeu, Johns Hopkins University School of Medicine

37.2 *Metacognition in Mental health: A Hierarchical and Transdiagnostic Framework*
Tricia Seow, UCL, London

37.3 *Interoceptive Correlates of Alcohol Administration and Future Clinical Avenues*
Mateo Leganes-Fonteneau, Center of Alcohol and Substance Use Studies, Rutgers University

37.4 *Down a Rabbit Hole? The Role of Metacognition and Interoception in Establishing Addiction Phenotypes*
Lori Keyser-Marcus, Virginia Commonwealth University

37.5 *Interrupted by the Ineffable: The Role of Ketamine-Occasioned Non-Ordinary Experiences in Facilitating Cognitive, Perceptual, and Existential Reappraisal in SUDs*
Elias Dakwar, Columbia University

10:00 A.M. - 11:30 A.M. SYMPOSIUM

38. BIOPSYCHOSOCIAL RISK PROCESSES UNDERLYING HAZARDOUS CANNABIS USE AND CANNABIS USE DISORDER

Chair: Emily Ansell, Penn State University

Co-Chair: Stephanie Wemm, Yale School of Medicine

Cannabis is the most commonly used federally illicit drug in the United States (U.S.) (SAMHSA, 2019) and the prevalence of cannabis use and cannabis use disorder (CUD) has increased in the US over the past two decades, but the majority of users do not develop CUD. High levels of exposure to cannabis increases the likelihood that young adults will experience deleterious psychosocial and behavioral consequences, as well as substance use disorders. Given widespread legalization and increased rates of use, it is important to identify the biopsychosocial risk processes that are most relevant to distinguishing those who will develop hazardous use and/or cannabis use disorder. This symposium will present findings on neurophysiological, biological, and psychosocial risk factors for hazardous use and cannabis use disorder. Research presented will employ multiple modalities including laboratory paradigms of stress reactivity, EEG, cue reactivity, intensive repeated measurement of stress biomarkers and self-report, and longitudinal designs over 3-6 months that will highlight key risk factors in the process of increasingly hazardous cannabis use, consequences from cannabis use, and cannabis use disorder. The aim of this session is to review several biopsychosocial risk processes with a focus on modalities of cannabis use, stress and cannabis cue motivation, and sex differences in cannabis users that may underlie patterns of problematic use. Implications for prevention of risk and treatment will be discussed.

38.1 Associations Between Modes of Cannabis Use in Daily Life With Concurrent and Longitudinal Hazardous Use and Consequences

Margaret Bedillion, Penn State University

38.2 Electrophysiological Markers of Cannabis Cue Reactivity in Regular Cannabis Users: Impact of CUD Severity and Acute Stress

Richard Macatee, Auburn University

38.3 Investigating Real-World Subjective Responses and Cortisol in Individuals With Cannabis Use Disorder Relative to Recreational Cannabis Users: An In-Field, Within-Person Intensive Monitoring Study

Stephanie Wemm, Yale School of Medicine

38.4 Sex Differences in Risk Mechanisms Underlying Hazardous Cannabis Use

Emily Ansell, Penn State University

Moderator: Margaret Haney, Columbia University Irving Medical Center

10:00 A.M. - 11:30 A.M. SYMPOSIUM

39. ACCOUNTING FOR OLDER ADULTS IN SUBSTANCE USE RESEARCH, TREATMENT, AND POLICY: CURRENT FINDINGS AND FUTURE CONSIDERATIONS

Chair: Bethea Kleykamp, BAK and Associates, LLC

Co-Chair: Benjamin Han, University of California - San Diego

The number of adults age \pm 65 years is expected to more than double over the next 30 years and for the first time ever older adults will make up nearly a quarter of the US population. At the same time, there is evidence that substance use disorders (SUDs) among older adults are increasing including drug-related overdoses. Older adults who use psychoactive substances are at heightened risk for harm including exacerbation of chronic health issues such as cardiovascular disease and cancer.

The primary aim of this symposium is to promote discussion around how to increase the representation of older adults who use psychoactive substances in research, treatment, and health policy and the special considerations pertaining to an older adult population. Four presentations will 1) provide critical analysis of tobacco smoking prevalence in the US across over last 30+ years using data from the National Health Interview Survey, 2) present survey data characterizing cannabis use, risk perceptions, and symptom management among patients with a cancer diagnosis, 3) describe patterns of comorbidities and healthcare utilization among older adults with opioid use disorder, and 4) critically examine co-occurring opioid use, cannabis use, and dual-use of these substances among older adults with chronic pain. Given the broad focus of this symposium across methods and substances of use, we expect that it will be of great interest to clinical researchers, healthcare providers, and health policy organizations to promote the inclusion of older adults in all areas of SUD research and treatment.

39.1 Age and Race Disparities in Tobacco Smoking Prevalence in the United States: Over 50 Years and Counting

Bethea Kleykamp, BAK and Associates, LLC

39.2 Opioid Use Disorder Among Older Adults: Addressing Multimorbidity and Geriatric Conditions

Benjamin Han, University of California - San Diego

39.3 Characterizing Chronic Pain and Co-Occurring Substance Use in a Community Sample of Younger and Older Adults

Marilyn Horta, University of Florida

39.4 Assessing Patterns of Cannabis Use, Risk Perceptions, and Symptom Management Among Older Adults With a Cancer Diagnosis

Margaret Fahey, Medical University of South Carolina

11:30 A.M. - 1:30 P.M. MEDIA FORUM

40. MEDIA FORUM - HARNESSING YOUR EXPERTISE: CPDD MEDIA TRAINING WITH REPORTING ON ADDICTION

Chair: Bethea Kleykamp, BAK and Associates, LLC

Mainstream news media perpetuates many problematic narratives about drug use and addiction that increase stigma, discrimination, and bad policy. One way to address these shortcomings is to increase the coverage of evidence-based approaches to addiction treatment and recovery, including well-designed research studies, in the news through collaborative efforts with subject matter experts. However, many experts are not trained to interact with journalists in today's media environment. Thus, this forum is designed to offer customized, in-person training that can help support effective interactions between CPDD attendees and The Media.

The Media Forum will be open to all attendees, including graduate-level and early career CPDD attendees for whom this forum could serve as a valuable training experience. The 120-minute forum will be broken down into three components: 1) how The Media works (30 minutes); 2) how you can work with the media (30 minutes); 3) trainer-led small-group didactic and practice sessions (one hour). The small-group trainer sessions will help attendees generate social media-friendly video content for CPDD to promote the sharing of cutting-edge research in the field. Topics covered include how to prepare for interviews, how to disseminate press releases, and how to pitch ideas or op-eds to The Media. In addition, in the weeks following the annual conference, Reporting on Addiction, a cutting-edge collaboration designed to facilitate the communication of substance use research findings, will promote this content to journalists interested in the topic areas covered.

*40.1 Media Forum - Harnessing Your Expertise: CPDD Media Training With Reporting on Addiction
Ashton Marra, Reporting on Addiction*

*40.2 Reporting on Addiction - A Collaborative Approach to Working With the Media to Reduce Stigma
Jonathan Stoltman, Opioid Policy Institute*

1:30 P.M. - 2:30 P.M. MINI-SYMPOSIUM

41. FACILITATING COMPASSIONATE AND CONSISTENT CARE FOR WOMEN AND NEONATES AFFECTED BY OPIOIDS

*Chair: Dennis Hand, Thomas Jefferson University
Co-Chair: Ekaterina Burduli, Washington State University*

Opioid use during pregnancy remains a significant public health concern with 8.2:1000 births including an opioid-related diagnosis. Whether perinatal opioid use consists of a medication for opioid use disorder (OUD) or unauthorized use, all mothers and neonates deserve compassionate and highest quality care. The voices of perinatal women with OUD must be heard to understand their needs and to address stigmatization and discrimination that undermine health during the vulnerable perinatal period. Healthcare providers have frequent interactions with mother-child dyads in the perinatal period and their needs, barriers, and facilitators must be understood to improve the care provided. The studies in the present symposium include qualitative and quantitative analyses of feedback from perinatal women with OUD and the providers who care for them and their neonates. In the first study, pregnant women and nurses identified barriers and facilitators to care, such as compassion fatigue and burnout when seeking medication for OUD. In the second, perinatal women

and healthcare providers identified the importance of self-advocacy while navigating the healthcare and social systems and the importance of communicating expectations in a way which is empowering women. In the final study, nurses and caregivers tested a digital therapeutic care diary with embedded decision support for improving consistency of care in two forms of neonatal abstinence syndrome care, the Finnegan Neonatal Abstinence Scoring Tool and Eat, Sleep Console. Overall, these studies provide critical information for researchers designing educational and technological interventions to improve care for perinatal women with OUD and their neonates.

41.1 Primary Stakeholder Evaluation of Acute Care Induction Period Women Entering Substance Use Treatment
Meghan Gannon, Thomas Jefferson University

41.2 Supporting Perinatal Women With Opioid Use Disorder and Their Newborns Experiencing Neonatal Abstinence Syndrome: Impressions From Perinatal Women and Providers
Ekaterina Burduli, Washington State University

41.3 Development of a Neonatal Abstinence Syndrome (NAS) Primer, Reference and Decision Support Tool
Crystal Smith, Washington State University

1:30 P.M. - 2:30 P.M. MINI-SYMPOSIUM

42. USING BIG DATA TO OPTIMIZE BENZODIAZEPINE PRESCRIBING AND DEPRESCRIBING ACROSS THE LIFESPAN

Chair: Kevin Xu, Washington University School of Medicine
Co-Chair: Laura Bierut, Washington University School of Medicine

This mini-symposium will illustrate the potential for large-scale administrative claims research (“big data”) to examine important clinical questions across the lifespan that are difficult to study via conventional clinical trials, such as the prescribing of benzodiazepines. While benzodiazepines are powerful short-term treatments for anxiety disorders and insomnia, they are associated with longer-term addictive potential and overdose risk, culminating in a September 2020 boxed warning by the FDA. A major gap in the research base is that real-world studies examining the long-term risks of prescribing are lacking, especially in vulnerable populations such as children, geriatric patients, and people with opioid use disorder. Thus, the overarching goal of this mini-symposium is to highlight state-of-the-art research shedding light on benzodiazepine prescribing and overdose risk in these understudied groups. Leading pharmaco-epidemiologists will present new data encompassing 1) adolescents and young adults (“Leveraging Healthcare Claims Data to Study Benzodiazepine Overdose Risk in Adolescents and Young Adults”), 2) adolescents and adults with opioid use disorder (“Novel Methods for Comparative Effectiveness Research: Towards Rational Benzodiazepine Prescribing in Adolescents and Adults with Opioid Use Disorder”), and 3) older adult populations (“Prescription Characteristics Associated with Increased Overdose Event Risk Among Older Adults Prescribed Benzodiazepines”). The use of datasets such as Medicaid, Medicare, and IBM MarketScan commercial claims will be discussed, in addition to cutting-edge analytical methods such as parallel cohort analyses, propensity score estimation, and case-crossover study design.

42.1 Novel Methods for Comparative Effectiveness Research: Towards Rational Benzodiazepine Prescribing in Opioid Use Disorder
Kevin Xu, Washington University School of Medicine

42.2 *Leveraging Healthcare Claims Data to Study Benzodiazepine Overdose Risk in Adolescents and Young Adults*
Greta Bushnell, Rutgers University

42.3 *Prescription Characteristics Associated With Increased Overdose Event Risk Among Older Adults Prescribed Benzodiazepines*
Donovan Maust, University of Michigan

2:45 P.M. - 3:45 P.M. MINI-SYMPOSIUM

43. USE OF TECHNOLOGY TO FACILITATE TRANSLATIONAL SUBSTANCE USE DISORDER RESEARCH

Chair: Kathryn Polak, Virginia Commonwealth University
Co-Chair: Dace Svikis, Virginia Commonwealth University

Technology-based tools have demonstrated feasibility with various Substance Use Disorders (SUDs), populations (from pregnant women to individuals with chronic pain), providers (from case managers to medication-assisted treatment prescribers), and settings (from primary care clinics to out-of-treatment direct-to-consumer). Use of technology as part of SUD treatment can promote access to care, personalized medicine, measurement-based care, recovery, and wraparound care. This symposium will explore novel and innovative utilization of technologic tools to serve in addictions healthcare. First, Dr. Polak will present recent findings examining efficacy of a fully-automated contingency management app targeting self-monitoring of pain symptom severity and prescription opioid use in a sample of individuals with chronic pain. Next, Dr. Ingersoll will discuss the application of an mHealth platform deployed by HIV care clinics to increase treatment engagement in substance users vs. non substance users. Finally, Dr. Ondersma will discuss the development and implementation of a digital platform facilitating tailored SUD interventions.

43.1 *Use of Technology to Facilitate Translational Substance Use Disorder Research*
Kathryn Polak, Virginia Commonwealth University

43.2 *CIAS: A Digital Intervention Development Platform for Accelerating Translational Science*
Steven Ondersma, Michigan State University

43.3 *Comparison of 3 Year HIV Clinical Outcomes Among mHealth Platform Users for People With and Without Substance Use Histories: A Clinical Quality Improvement Project*
Karen Ingersoll, University of Virginia School of Medicine

SUNDAY, JUNE 12, 2022

POSTER SESSION 1

S1. Association of Phosphatidylethanol (PEth) Levels With Severity of Dependence in Alcohol Dependent Patients- A Cross-Sectional StudyAbhishek Gupta*¹, Raka Jain¹, Biswadip Chatterjee¹¹AIIMS DELHI**S2. Associations Among Perceived Risk, Age of Marijuana and Alcohol Onset, and DSM-IV Alcohol Use Disorder and Marijuana Use Disorder in a Sexual Minority Population**Corrine M. Schwarting*¹, Sean Esteban McCabe², Sterling M. Hubbard¹, Brenna Klesel¹, Brooke Arterberry¹**S3. Driving Under the Influence of Alcohol, Marijuana, and Select Illegal Drugs by Sexual Identity and Gender**Raymond Moody*¹, Justin Knox², Dustin Duncan¹, Silvia Martins²¹Columbia University, Mailman School of Public Health, ²Columbia University**S4. Longitudinal Patterns and Demographic, Family History, and Psychopathology Predictors of Substance Use Initiation in the ABCD Study Cohort**Ryan Sullivan*¹, Natasha Wade², Alexander Wallace¹, Christine Kaiver¹, Mary Heitzeg³, Krista Lisdahl¹¹University of Wisconsin-Milwaukee, ²University of California, San Diego, ³University of Michigan**S5. Sex-Specific Associations in Patients With Alcohol Use Disorder Admitted for Hospital Detoxification**Daniel Fuster*¹, Xavier Garcia-Calvo², Ferran Bolao³, Paola Zuluaga², Julia Casado², Anna Hernández-Rubio², Robert Muga¹¹Hospital Universitari Germans Trias i Pujol, ²Internal Medicine Service. Hospital Universitari Germans Trias i Pujol, ³Internal Medicine Service. Hospital Universitari Bellvitge.**S6. The Effect of Comorbid Alcohol Use Disorder on Major Depressive Disorder Treatment Outcomes: A STAR*D Analysis**Victor Tang*¹, Dengdeng Yu², Cory Weissman³, Brett Jones⁴, Guan Wang⁵, Daniel Blumberger⁶, Zafiris Daskalakis³, Bernard Le Foll⁴, Daphne Voineskos⁶¹University of Toronto, Centre for Addiction and Mental Health, ²University of Texas at Arlington, ³UC San Diego Health, ⁴University of Toronto, ⁵Dalla Lana School of Public Health, University of Toronto, ⁶Centre for Addiction and Mental Health**S7. Alcohol Use Disorder is Associated With Lower Receipt of Direct-Acting Antiviral Hepatitis C Treatment: A Cohort Study**Lamia Haque*¹, David Fiellin¹, Denise Esserman¹, Debika Bhattacharya², Adeel Butt³, Stephen Crystal⁴, E. Jennifer Edelman¹, Adam Gordon⁵, Joseph Lim¹, Christopher Rentsch⁶, Jeanette Tetrault¹, Emily Williams⁷, Kendall Bryant⁸, Amy Justice⁹, Vincent Lo Re III¹⁰, Janet Tate⁹, Kathleen McGinnis¹¹¹Yale University School of Medicine, ²David Geffen School of Medicine, University of California, Los Angeles, ³Weill Cornell Medical College, ⁴Rutgers University, ⁵University of Utah School of Medicine; Veterans Affairs Salt Lake City Healthcare System, ⁶London School of Hygiene and Tropical Medicine, Veterans Affairs Connecticut Healthcare System, ⁷University of Washington School of Public Health; Veterans Affairs Puget Sound Health Services Research and Development, ⁸National Institute of Drug Abuse, National Institutes of Health, ⁹Yale University School of Medicine; Veterans Affairs Connecticut Healthcare System, ¹⁰Perelman School of Medicine, University of Pennsylvania, ¹¹VA Connecticut Healthcare System

S8. Harms From Other's Drinking: Risk Factors and Help-Seeking Behaviors in Taiwan

Ren-Hao Chen*¹, I-An Wang², Wei J. Chen³, Chuan-Yu Chen¹

¹National Yang Ming Chiao Tung University, ²Center of Neuropsychiatric Research, National Health Research Institutes, ³National Taiwan University College of Public Health

S9. High-Throughput LC-QTOF-Mass Method for Determination of Phosphatidylethanol (PEth) in Whole Blood for Monitoring Alcohol Consumption in Alcohol Dependent Subjects

Raka Jain*¹, Abhishek Gupta², Sachin Rana², Biswadip Chatterjee², Arun Kumar²

¹All India Institute of Medical Sciences, ²National Drug Dependence Treatment Centre, All India Institute of Medical Sciences

S10. Negative Mood Symptoms and Alcohol Use in Firefighters: The Moderating Effects of Drinking Motives

Krista Miloslavich*¹, Margaret Wardle¹, Anka Vujanovic²

¹University of Illinois at Chicago, ²University of Houston

S11. Perceived Stigma, Self Stigma and Barriers to Treatment in Alcohol Dependent Individuals

Richa Tripathi*¹, Samant Singh¹, Manoj Prithviraj¹, Amit Nair¹

¹All India Institute of Medical Sciences

S12. Races, ACEs, and Places: The Interaction Effects of Race, Childhood Adversity, and Neighborhood Disadvantage on Alcohol Use Disorder

Skye Bristol*¹, Elzbieta Wiedbusch¹, Enya Vroom², Micah Johnson¹

¹University of South Florida, ²University of Florida

S13. Correlates and Consequences of Anxiety and Depressive Symptom Trajectories During Early Treatment for Alcohol Use

Jill Rabinowitz*¹, Jennifer Ellis², Justin Strickland², Jonathan Wells³, Andrew Huhn², Brion Maher¹

¹Johns Hopkins Bloomberg School of Public Health, ²Johns Hopkins University School of Medicine, ³Virginia Commonwealth University

S14. Fine Particulate Matter Exposure in Neighborhood is Associated to Early Substance Use Initiation in Youth

Julia Harris*¹, Gabriella Navarro¹, Evelyn Doan¹, Ryan Sullivan¹, Krista Lisdahl¹

¹University of Wisconsin-Milwaukee

S15. Nicotine Does Not Speed the Development of Recovery-Like Behavior in a Rat Model of Alcohol Use and Recovery Following Chronic Ethanol Exposure

Haley DeWitt*¹, Lyra Seaborn², Richard J. Lamb¹, Brett Ginsburg¹

¹University of Texas Health Science Center at San Antonio, ²Davidson College, Davidson NC

S16. Racial Differences in the Effects of Parent and Sibling Alcohol Misuse on the Odds of Alcohol Misuse Among Justice-Involved Adolescents

Elzbieta Wiedbusch*¹, Micah Johnson¹, Enya Vroom², Skye Bristol¹, Zahra Akbari¹, James-Angelo Suarez¹

¹University of South Florida, ²University of Florida

S17. Racial Differences in the Relationship Between Treatment Completion and Optimism Among Opioid Users in the Juvenile Justice System

Angitha Reji*¹, Micah Johnson¹

¹University of South Florida

S18. Reductions in Blood Alcohol Concentration During the First 90 Days of a Telehealth Program for Alcohol Use Disorder

Gantt Galloway*¹, Kevin Hallgren², Katie Witkiewitz³, Paul Linde¹, Robert Nix¹, Tom Nix¹, John Mendelson¹
¹Ria Health, ²University of Washington, ³University of New Mexico

S19. A Casual Model of Risk Factors Underlying Onset of Alcohol Use in Childhood

Andrea Maxwell*¹, Gregory Niklason¹, Leyla Bruçar¹, Reed Evers¹, Karina Quevedo¹, Anna Zilverstand¹
¹University of Minnesota,

S20. A Rapid Procedure to Assess Shifts in Discriminative Control Over Drinking During Recovery-Like Behavior

Acacia Nawrocik-Madrid*¹, Richard Lamb¹, Brett Ginsburg¹
¹The University of Texas Health Science Center at San Antonio

S21. Open Board

S22. Perspectives of Health Consumers With HIV on Integration of Pharmacological Mental Health and Substance Use Treatment in HIV Care

Erin Cox¹, Suzanne Singer², Felicia Browne¹, Wendee Wechsberg¹, Courtney Bonner*¹
¹RTI International, ²University of North Carolina Chapel Hill

S23. US Treatment Admissions for Alcohol Use Disorder by Gender and Reproduction 2015-2019

Mishka Terplan*¹, Kelly Young-Wolff², Karen Alexander¹, Erin Kelty³, Elizabeth Krans⁴, Sara Wallhed-Finn⁵
¹Friends Research Institute, ²Kaiser Permanente Northern California, ³The School of Population and Global Health, The University of Western Australia, ⁴University of Pittsburgh, ⁵Karolinska Institute

S24. Evaluation of the Adverse Effects of Synthetic Cathinones in Mice: Dependence and Toxicity

Masahiko Funada*¹, Tomiyama Kenichi²
¹National Institute of Mental Health, ²National Center of Neurology and Psychiatry

S25. Contraceptive Literacy and Utilization Among Illegal Drugs-Involved Women in Community

Rosetta Siew*¹, I-An Wang², Chuan-Yu Chen¹
¹National Yang Ming Chiao Tung University, ²Center of Neuropsychiatric Research, National Health Research Institutes

S26. Methylone Pre-Exposure Differentially Impacts the Aversive Effects of MDMA, MDPV and Fluoxetine in Male and Female Sprague-Dawley Rats

Hayley Manke*¹, Katharine Nelson², Shihui Huang¹, Jacob Bailey¹, Sara Bowman¹, Robert Jones¹, Sydney Cervený¹, Kenner Rice³, Anthony Riley⁴
¹American University, ²Medical University of South Carolina, ³National Institute of Drug Abuse, National Institutes of Health, ⁴The American University

S27. Trends in Drug Use Among Nightclub/Festival Attendees as a Potential Bellwether for Drug-Related Outcomes in the General Population

Joseph Palamar*¹, Austin Le²
¹New York University School of Medicine, ²New York University College of Dentistry

S28. Methodological Considerations for the Human Abuse Potential Evaluation of Emerging Drug Therapies With Psychedelic Properties

Beatrice Setnik*¹, Denise Milovan¹, Megan Shram², Cynthia Arons³, Talar Hopyan⁴, Catherine Mills¹, Himanshu Upadhyaya⁵, Thomas Hudzik⁶, Michael Klein⁷

¹Altasciences, ²Altreos Research Partners Inc.; University of Toronto, ³Pfizer, ⁴Syneos Health, ⁵Eli Lilly and Company, ⁶BlueRock Therapeutics, ⁷Controlled Substance Scientific Solutions LLC

S29. Use of Plant-Based Hallucinogens and Dissociative Agents: U.S. Time Trends, 2002-2019

Claire Walsh*¹, Ofir Livne², Dvora Shmulewitz³, Deborah Hasin³

¹Columbia University and New York State Psychiatric Institute, ²Columbia University Mailman School of Public Health, ³Columbia University

S31. Exploring the Heteromeric Interface of the Serotonin 5-HT_{2A}:5-HT_{2C} Receptor Complex In Vitro

Joshua Zamora*¹, Scott Gilbertson², Noelle Anastasio¹, Kathryn Cunningham¹

¹University of Texas Medical Branch, ²University of Houston

S32. Open-Access Clinical Care and Intervention in the Setting of Overprescribing of Benzodiazepines in a Community Sample

Gretchen Hermes*¹, Dexter Louie¹, Olayinka Olaniyi¹, Fabiola Arbelo-Cruz¹, Scott Farnum², Declan Barry¹, Kathryn Eggert², Kimberly DiMeola², Erica Cannata², Lynn Madden²

¹Yale University School of Medicine, ²APT Foundation, Inc.

S33. Human Abuse Potential Study Results in the Context of Abuse Detected Postmarketing

Yohanka Caro*¹, Silvia Calderon¹, Ling Chen¹, Saranrat Wittayanukorn¹, Sara Karami¹, Sheheryar Muhammad¹, Modupeola Adereti¹, Rajdeep Gill¹, Rose Radin¹, E. Gregory Hawkins¹, Chad J. Reissig¹, Dominic Chiapperino¹

¹US Food and Drug Administration

S34. Ketamine Non-Medical Use Versus Medical Use in the United States' General Population

Alexis Krause*¹, Annika Czizik¹, Joshua Black¹, Paula Bernander¹, Richard Dart¹, Janetta Iwanicki¹

¹Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority

S35. Perspectives of People Who Use Illicit Stimulants on Prospective Pharmaceutical Stimulant Substitution Treatments: A Qualitative Study

Taylor Fleming*¹, Andrew Ivsins², Allison Barker², Manal Mansoor², Ryan McNeil³

¹The University of British Columbia, ²British Columbia Centre on Substance Use, ³Yale University School of Medicine

S36. Abuse Potential of Zuranolone in Nondependent, Recreational Users of Central Nervous System Depressants: A Randomized, Double-Blind, Active- and Placebo-Controlled, Crossover Study

Joi Dunbar*¹, Robert Lasser¹, Nilanjana Rana¹, Haihong Li¹, Naama Levy-Cooperman², James Doherty¹, Kathleen Brady³

¹Sage Therapeutics, ²Altreos Research Partners Inc., ³Medical University of South Carolina

S37. The Association Between Childhood Trauma, Intimate Partner Violence and Perceived Parental Competence Among Women Abusing Amphetamine Type Stimulant

Suzaily Wahab*¹, Rubini Sivarajah², Amirul Danial Azmi¹, Norliza Chemi², Raynuha Mahadevan¹

¹Universiti Kebangsaan Malaysia Medical Centre, ²Kajang Hospital, Selangor

S38. The Risk Factors of One-Year Relapse Among Methamphetamine Users Referred From Criminal Justice System for Mandatory Treatment

Lian-Yu Chen*¹, Su-Chen Fang², Ming-Chyi Huang¹

¹Taipei City Hospital, ²Mackay Medical College

S39. The Safety and Feasibility of Lisdexamfetamine for the Treatment of Acute Methamphetamine Withdrawal: Preliminary Results of an Open Label Pilot Study

Liam Acheson*¹, Nadine Ezard¹, Nicholas Lintzeris², Adrian Dunlop³, Jonathan Brett¹, Craig Rodgers¹, Anthony Gill¹, Michael Christmass⁴, Rebecca McKetin⁵, Michael Farrell⁵, Steve Shoptaw⁶, Krista Siefried⁷

¹St. Vincents Hospital, ²South Eastern Sydney Local Health District, ³Hunter New England Local Health District, ⁴Next Step Drug and Alcohol Services, ⁵National Drug and Alcohol Research Centre, UNSW, ⁶University of California, Los Angeles, ⁷The National Centre for Clinical Research on Emerging Drugs (NCCRED)

S40. Trajectories of Prescription Stimulant Misuse and Substance Use Disorder Symptoms From Ages 18 to 50: US National Panel Data

Sean Esteban McCabe¹, John E. Schulenberg¹, Ty S. Schepis¹, Rebecca J. Evans-Polce¹, Timothy E. Wilens¹, Vita V. McCabe¹, Philip Veliz*¹

¹Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing

S41. What's Driving the Increases in Methamphetamine Overdose Deaths That Do Not Involve Opioids?

Dalia Khoury*¹, William Zule¹, Caitlin Hennessy¹

¹RTI International

S42. Is Age of Onset and Duration of Stimulant Medication Therapy for ADHD Associated With Stimulant Misuse During Adolescence? A Multi-Cohort National Study

Sean Esteban McCabe*¹, Olivia Figueroa¹, Vita V. McCabe¹, Ty S. Schepis¹, John E. Schulenberg¹, Phil T. Veliz¹, Kennedy S. Werner¹, Timothy E. Wilens¹

¹Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing

S43. Novel Pharmacotherapies for Young People With Methamphetamine Use Disorder: The MASKOT and CALM Studies

Alexandre Guerin*¹, Edward Mullen², Emily Karanges¹, Amelia Quinn¹, Orli Schwartz¹, Shalini Arunogiri³, Colleen Loo⁴, Andrew Chanen¹, Enrico Cementon², Paul Amminger¹, Gillinder Bedi¹

¹University of Melbourne, ²Orygen, ³Monash University, ⁴University of New South Wales

S44. Prevalence of Stimulant Use Disorder and Co-Occurring Substance Use Disorders Among Medicaid Enrollees With Stimulant Use Disorder in 2017-2018

Thanh Lu*¹, Sean Murphy¹

¹Weill Cornell Medical College

S45. Open Board

S46. Risk and Preventive Factors Associated With Illicit Drug Use Among Male Methamphetamine Users on Probation in Japanese Criminal Justice System: A One-Year Prospective Cohort Study

Ayumi Takano*¹, Takashi Usami², Yuka Kanazawa², Yousuke Kumakura², Toshihiko Matsumoto²

¹Tokyo Medical and Dental University, ²National Institute of Mental Health, National Center of Neurology and Psychiatry

S47. The Influence of Cocaine Use Disorder, Drug Cues and Sex on Decision-Making

Miranda Ramirez*¹, Joshua Lile², Joshua Beckmann³, Joseph Alcorn³, Skylar Mays², Craig Rush³, William Stoops², Preston Tolbert², Michael Wesley³

¹University of Kentucky, College of Arts and Sciences, ²University of Kentucky, College of Medicine,

³University of Kentucky

S48. Central Nervous System Activity of Kappa Opioid Receptor Ligands 5'- And 6'-Guanidinonaltrindole

Michelle Morochnik*¹, Yuli Kim¹, Brian Reed¹

¹The Rockefeller University

S49. Prevalence and Correlates of Active Amphetamine-Type Stimulants (ATS) Use Among Full-Service Women Sex Workers in Malaysia

Courtney J. Pedersen¹, Jeffrey A Wickersham², Antoine Khati³, Francesca Maviglia², Frederick A. Altice², Adeeba Kamarulzaman⁴, Kaveh Khoshnood², Britton A. Gibson⁴, Roman Shrestha*³

¹Brown University, ²Yale University, ³University of Connecticut, ⁴University of Malaya

S50. Psychosocial and Drug Use Characteristics of Individuals With Stimulant Use Disorder in New York City

Gabriella Horton*¹, Suky Martinez¹, Allen Yang¹, Jermaine Jones¹

¹Columbia University and New York State Psychiatric Institute

S51. Risk of First Episode Psychosis or Mania With Prescription Amphetamine Use

Lauren Moran*¹, Joseph Skinner², Ann Shinn¹, Kathryn Nielson¹, Vinod Rao³, S. Trevor Taylor⁴, Talia Cohen², Ian Baptiste², Jaisal Merchant², Cemre Erkol², Christin Mujica², Roy Perlis³, Dost Ongur¹

¹Harvard Medical School, McLean Hospital, ²McLean Hospital, ³Harvard Medical School, Massachusetts General Hospital, ⁴Harvard Medical School, Massachusetts General Hospital/McLean Hospital

S52. Treatments for the Fourth Wave: Association of Bupropion, Naltrexone, and Opioid Agonist Therapies With Stimulant-Related Events in Opioid Use Disorder

Kevin Xu*¹, Carrie Mintz¹, Ned Presnall¹, Laura Bierut¹, Richard Grucza²

¹Washington University School of Medicine, ²St. Louis University School of Medicine

S53. Utilizing a Nonhuman Primate Model to Examine the Importance of Sleep/Wake Architecture in Treating Substance Use Disorder

Christina LaValley*¹, Robert Gould¹, Michael Nader¹

¹Wake Forest School of Medicine

S54. Voluntary Exercise Prevents Long-Term Incubation of Cocaine Craving in Female and Male Rats

Marilyn Carroll*¹

¹University of Minnesota

S55. Addiction Severity and Language-Based Temporal Perspective in Cocaine Use Disorder

Jennifer Hoots*¹, Christopher Holden², Scott Lane³, Joy Schmitz⁴, Margaret Wardle¹

¹University of Illinois Chicago, ²University of Illinois College of Medicine, ³University of Texas Health Science Center, McGovern Medical School, ⁴University of Texas Health Science Center

S56. Associations Between Prescription and Illicit Opioid and Stimulant Use in the United States, 2015-2019

Riley Shearer*¹, Abenaa Jones², Benjamin Howell³, Joel Segel², Tyler Winkelman⁴

¹The University of Minnesota, ²Penn State, ³Yale University School of Medicine, ⁴Health, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute

S57. Causal Association Between Recent Methamphetamine Use and Unsuppressed HIV Viral Load Among People Living With HIV Who Inject Drugs in Hai Phong, Vietnam

Jonathan Feelemyer*¹, Don Des Jarlais², Nicolas Nagot³, Huong Duong Thi⁴, Oanh Khuat Thi Hai⁵, Pham Minh khue⁴, Giang Hoang Thi⁴, Thanh Nham Thi Tuyet⁶, Charles Cleland¹, Kamyar Arasteh², Ellen Caniglia⁷, Yu Chen¹, Gavin Bart⁸, Jean-Pierre Moles³, Vinh Vu Hai⁹, Roselyne Vallo³, Catherine Quillet³, Delphine Rapoud³, Mai Le Sao¹⁰, Laurent Michel¹¹, Didier Laureillard³, Maria Khan¹

¹New York University School of Medicine, ²New York University School of Global Public Health, ³University of Montpellier, ⁴Hai Phong University of Medicine and Pharmacy, ⁵Centre of Supporting Community and Development Initiatives, ⁶SCDI, ⁷Perelman School of Medicine, University of Pennsylvania, ⁸University of Minnesota, ⁹Infectious Diseases Department, Viet Tiep Hospital, ¹⁰Mental Health Department, ¹¹Centre Pierre Nicole

S58. Elevated Brain Lactate Levels in Female Methamphetamine Users

Young-Hoon Sung*¹, Xianfeng Shi¹, Yasmin Peralta¹, Deborah Yurgelun-Todd², Perry Renshaw², Douglas Kondo²

¹The University of Utah, ²The University of Utah, Rocky Mountain VISN 19 MIRECC

S59. Impact of Ketamine or Propranolol During a Novel Retrieval Session on Cue-Induced Reinstatement of Cocaine Self-Administration in Rats

Angela Gonzalez*¹

¹Washington State University, Vancouver

S60. Motivation for Change and Duration of Inpatient Treatment Among Patients With Cocaine Use Disorder

Kristine Chestnut¹, Bonnie Starkes¹, Kyle Kampman*¹

¹University of Pennsylvania

S61. Observed Increase in Methamphetamine Use Risk Among Vietnamese Methadone Patients: 2018-2021 Repeated Surveys

Trang Nguyen*¹, Diep Bich Nguyen¹, Thuy Dao¹, Anh Vu¹, Van Hoang¹, Michael Li², Steve Shoptaw², Giang Le¹

¹Hanoi Medical University, ²University of California, Los Angeles

S62. Pilot Study Testing the Feasibility, Acceptability, and Initial Efficacy of a Remote Caffeine Reduction Intervention

Dustin Lee*¹, Mary Sweeney¹, Labos Breanna¹, Roland Griffiths²

¹Johns Hopkins University School of Medicine, ²Johns Hopkins University

S63. Open Board

S64. Beliefs About Medications for Opioid Use Disorder Among Healthcare Practitioners and Community Stakeholders in Rural New England

Sarah Heil*¹, Nathaniel Schafrick¹, Julia Shaw¹, Valerie Harder¹, Andrea Villanti¹, Mary Smith², Jeanne Ryer³, Stacey Sigmon¹

¹University of Vermont, ²University of Southern Maine, ³University of New Hampshire

S65. Body Image Dissatisfaction Among Patients Receiving Methadone Maintenance Treatment

Zachary Mannes*¹, Meagan Carr², Lindsay Oberleitner³, David Oberleitner⁴, Mark Beitel⁵, Marina Gaeta Gazzola⁵, Lynn Madden⁵, Xiao Zheng⁵, Declan Barry⁵

¹Columbia University, Mailman School of Public Health, ²Yale University School of Medicine, ³Yale University School of Medicine, The APT Foundation, Oakland University William Beaumont School of Medicine, ⁴University of Bridgeport, The APT Foundation, ⁵Yale University School of Medicine, The APT Foundation

S66. Characterizing Opioid Withdrawal Experiences Among a Sample of Opioid Using People Who Inject Drugs (PWID)

Kelsey Simpson*¹, Maria Bolshakova¹, Matt Kirkpatrick¹, Ricky Bluthenthal¹

¹University of Southern California, Keck School of Medicine

S67. Differences in Sociodemographic Profiles and Drug Use Patterns of Individuals With Current Opioid Use Disorder Depending on Opioid Use Preference

Allen Yang*¹, Suky Martinez², Gabriella Horton¹, Sandra Comer³, Jermaine Jones⁴

¹Columbia University and New York State Psychiatric Institute, ²Columbia University Vagelos College of Physicians and Surgeons, ³Columbia University Irving Medical Center and the New York State Psychiatric Institute, ⁴Columbia University Irving Medical Center

S68. Disparities in Opioid Use Disorder Related Hospital Use Among Postpartum Virginia Medicaid Members

Caitlin Martin*¹, Erin Britton¹, Hannah Shadowen¹, Chethan Bachireddy², Ashley Harrell², Xue Zhao¹, Peter Cunningham¹

¹Virginia Commonwealth University, ²Virginia Department of Medical Assistance Services

S69. Emergency Department Initiated Buprenorphine/Naloxone Intervention for Problematic Opioid Use: Retention Rates and Predictors, and Health Outcomes at 3 and 6 Months

Nathan Schwab*¹, Nicholas Ferrigno¹, Roz King¹, Miles Lamberson¹, Richard Rawson², Daniel Wolfson¹, Sanchit Maruti¹, Scott Mackey¹

¹University of Vermont College of Medicine, ²UCLA Integrated Substance Abuse Programs

S70. Evaluating the Rate of Reversal of Fentanyl-Induced Respiratory Depression Using cNLX-NP, a Novel Long-Acting Naloxone Nanoparticle

Michael Raleigh*¹, Andrew Kassick², Diego Luengas¹, Pedro Silva¹, Marco Pravetoni³, Saadyah Averick²

¹University of Minnesota, ²Allegheny-Singer Research Institute Center for Neurosciences Research, ³University of Minnesota Medical School

S71. Factors Associated With COVID-19 Testing Among People Who Inject Drugs: Missed Opportunities for Reaching Those Most at Risk

Samantha Yeager*¹, Daniela Abramovitz¹, Alicia Harvey-Vera¹, Carlos Vera¹, Angel Algarin¹, Laramie Smith², Maria Gudelia Rangel Gomez³, Irina Artamonova¹, Thomas Patterson¹, Angela Bazzi¹, Emma Brugman¹, Steffanie Strathdee¹

¹University of California - San Diego, ²University of California - San Diego, School of Medicine, ³Comisión de Salud Fronteriza México-EEUU, Sección México

S72. Fentanyl's Rising Presence in Oregon's Drug Supply and Knowledge, Attitudes, and Behaviors Among People Who Use Drugs

Kate LaForge*¹, Sarah Shin¹, Erin Stack¹, Gillian Leichtling¹, Christopher Blazes², Dan Hoover², Andrew Seaman², P. Todd Korthuis²

¹Comagine Health, ²Oregon Health and Science University

S73. Frequency of Opioid Response Network Technical Assistance Requests Addressing Substance Use Disorder Stigma

Jermaine Jones*¹, Brent Moore², Holly Hagle³, Michael Knabel³, Nathan Driskill³, Nicholas Canning⁴, Laurie Krom³, Shelby Webb³, Zuleyma Serpas⁴, Zoey Logan⁴, Kerri Hayes⁴, Michele Baker³, Frances Levin⁵, Kathryn Cates-Wessel⁴

¹Columbia University Irving Medical Center, ²Yale University School of Medicine, ³University of Missouri-Kansas City, ⁴Opioid Response Network, American Academy of Addiction Psychiatry, ⁵Columbia University Irving Medical Center/ New York State Psychiatric Institute

S74. Health-Related Quality of Life in Patients With Opioid Use Disorder Initiating Medication Assisted Treatment in Primary Care

Michelle Lent*¹, Karen Dugosh², Emily Rey¹, Hannah Callahan¹, Richard Saitz³

¹Philadelphia College of Osteopathic Medicine, ²Public Health Management Corporation, ³Boston University School of Public Health

S75. Impact of Anxiety Severity on Retention in Opioid Agonist Therapy: A Secondary Analysis of the Optima Trial

Anees Bahji*¹, Paxton Bach², Eugenia Socias²

¹University of Calgary, ²University of British Columbia

S76. Impact of COVID-19-Related Health Care Disruptions and Regulatory Changes on Nationwide Access to Buprenorphine

Payel Roy*¹, Katherine Kim², Katie Suda², Jing Luo¹, Xiaoming Wang³, Jane Liebschutz¹

¹UPMC/University of Pittsburgh, ²University of Pittsburgh, ³National Institute on Drug Abuse

S77. Long-Term Mortality Among Hospitalized Medical Patients Seen by a Substance Use Disorder (SUD) Consultation Service

Jan Gryczynski*¹, Courtney Nordeck², Christopher Welsh³, Shannon Mitchell¹, Robert Schwartz¹

¹Friends Research Institute, ²Johns Hopkins Bloomberg School of Public Health, ³University of Maryland School of Medicine

S78. Modelling Buprenorphine Mitigation of Fentanyl-Induced Respiratory Depression

Celine Laffont*¹, Erik Olofsen², M. Hyke Algera², Laurence Moss³, Robert Dobbins¹, Geert Jan Groeneveld³, Monique van Velzen², Marieke Niesters², Albert Dahan²

¹Indivior, Inc., ²Leiden University Medical Center, ³Leiden University Medical Center; Centre for Human Drug Research

S79. New Federal Guidelines for Buprenorphine DEA-30 Patient Waivers: Will the States Support?

Anita Silwal*¹, Jeffery Talbert², Jordan Kelsch³, Christopher Cook³, Michelle Lofwall⁴

¹University of Kentucky, College of Communication and Information, Substance Use Priority Research Area, ²University of Kentucky College of Medicine, College of Pharmacy, ³University of Kentucky, Substance Use Priority Research Area, ⁴University of Kentucky, College of Medicine, Center on Drug and Alcohol Research (CDAR)

S80. Opioid Agonist Treatment for Prescription Opioids Dependence: An Updated Systematic Review and Meta-Analysis

Suzanne Nielsen*¹, Wai Chung Tse¹, Briony Larance², Louisa Degenhardt³

¹Monash University, ²University of Wollongong, ³UNSW Sydney

S81. Opioid and Alcohol Inpatient Treatment Admissions During the COVID-19 Pandemic

Mohammad Sibai*¹, Vartika Parashar¹, Gail Koshorek¹, Joshua Smith¹, Mark Greenwald², Timothy Roehrs¹
¹Henry Ford Health System, ²Wayne State University, Dept of Psychiatry and Behavioral Neurosciences

S82. Preliminary Findings From a Tool for Calculating the Effects of Replacing High Dead Space Syringes in Naloxone Kits With Reduced Dead Space Alternatives

William Zule*¹, Dalia Khoury¹, Caitlin Hennessy¹, Delesha Carpenter², Bayla Ostrach³, Georgiy Bobashev¹
¹RTI International, ²University of North Carolina, ³Boston University School of Medicine

S83. Prescription Drug Monitoring Program and the Opioid Use Disorder Cascade of Care Model: Opportunities for West Virginia

Anthony Eller*¹, Elizabeth DiDomizio², Kimberly Johnson³, Lynn Madden⁴, Jennifer Oliva⁵, Frederick Altice¹
¹Yale University School of Medicine, ²Yale University, ³University of South Florida, ⁴APT Foundation, ⁵Seton Hall University

S84. Preventing Opioid Relapse Among American Indian Women: A Community Based Participatory Approach to Develop a Facebook Intervention

Sydney Kelpin*¹, Anne Roche², Pamela Sinicropo², Gavin Bart³, Lisa Marsch⁴, Aimee Campbell⁵, Kamilla Venner⁶, Cuong Pham⁷, Antonia Young², Nicole Reinicke², Corinna Sabaque², Christi Patten²
¹Behavioral Health Research Program, ²Health Research Program, Mayo Clinic, ³Hennepin Healthcare, ⁴Dartmouth College, ⁵Columbia University Irving Medical Center and New York State Psychiatric Institute, ⁶Center on Alcohol, Substance Use and Addictions, University of New Mexico, ⁷University of Minnesota

S85. Proximity to Treatment and Post-Release Treatment Engagement Rates Among Adults Who Participated in a Comprehensive MOUD Program at the Rhode Island Department of Corrections, 2016-2018

Ariel Hoadley*¹, Gerald Stahler², Jeremy Mennis², Courtney DelaCuesta¹, Jennifer Clarke³, Rosemarie Martin⁴
¹Brown University, ²Temple University, ³Rhode Island Department of Health, ⁴Brown University School of Public Health

S86. Readmission and Comorbidities Associated With Patient-Directed Discharges Among Surgical Patients With and Without Opioid Use Disorder

Rachel French*¹, Ashish Thakrar¹, Peggy Compton², Matthew McHugh³, J. Margo Brooks Carthon³
¹University of Pennsylvania, ²University of Pennsylvania, School of Nursing, ³University of Pennsylvania, Center for Health Outcomes and Policy Research

S87. Recent Opioid Use Impedes Range Adaptation in Reinforcement Learning in Human Addiction

Maëlle Gueguen*¹, Hernan Anlló², Darla Bonagura¹, Julia Kong¹, Sahar Hafezi¹, Stefano Palminteri³, Anna Konova¹
¹UBHC, and Brain Health Institute, Rutgers University – New Brunswick, ²School of Fundamental Science and Engineering, Waseda University - Tokyo, ³Institut National de la Santé et Recherche Médicale, and Ecole Normale Supérieure - Paris

S88. Relative Risk of Opioid-Involved Death Following Exposure to Treatments for Opioid Use Disorder, Connecticut, 2017

Robert Heimer*¹, Anne Black¹, Hsiu-ju Lin², Benjamin Howell³, Grau Laurretta⁴, David Fiellin³, Gail D'Onofrio³, Kathryn Hawk¹, William Becker¹
¹Yale University, ²State of Connecticut, ³Yale University School of Medicine, ⁴Yale School of Public Health

S89. Risks of Overdose Events for Patients Undergoing Opioid Use Disorder Treatment

Laura Brandt¹, Mei-Chen Hu², Ying Liu², Felipe Castillo³, Gabriel Odom⁴, Raymond Balise⁵, Daniel Feaster⁶, Edward Nunes³, Sean Luo^{*2}

¹Columbia University Irving Medical Center, ²Columbia University, ³Columbia University and New York State Psychiatric Institute, ⁴Florida International University, ⁵University of Miami, ⁶University of Miami Miller School of Medicine

S90. Running to Stand Still: Exaggerated Aversive Salience in Individuals With Opioid Use Disorder

Jennifer Stewart^{*1}, Chrysantha Davis¹, Mary Kate Dykes¹, Natosha Markham¹, Tulsa 1000 Investigators¹, Rayus Kuplicki¹, Martin Paulus¹

¹Laureate Institute for Brain Research

S91. Concordance Between Self-Report and Hair Analysis in the ABCD Study: Self-Report With Hair Analysis Detects Additional 10% of Substance Users

Natasha Wade^{*1}, Ryan Sullivan², William Pelham¹, Krista Lisdahl², Susan Tapert¹, Marilyn Huestis³, Frank Haist¹

¹University of California, San Diego, ²University of Wisconsin-Milwaukee, ³National Institute of Drug Abuse, National Institutes of Health

S92. Considerations for Defining a Modified Completer Population in Human Abuse Potential Studies

Ling Chen^{*1}, Shalini Bansil¹, Qianyu Dang¹, Joshua Lloyd¹, Dominic Chiapperino¹

¹US Food and Drug Administration

S93. Prospective Effects of Financial Insecurity on Frequency of Substance Use

Sarah Gutkind^{*1}, Deborah Hasin¹

¹Columbia University

S94. Reinforcer Pathology's Anhedonia Hypothesis: An Examination Among Those in Recovery From Substance Use Disorder

Devin Tomlinson^{*1}, Liqa Athamneh², Roberta Freitas-Lemos¹, Allison Tegge², Warren Bickel³

¹Fralin Biomedical Research Institute at Virginia Tech Carilion, ²Virginia Tech Carilion Research Institute,

³Fralin Biomedical Research Institute at VTC

S95. Cannabis Use and Mental Health Among Transition Age Youth Receiving Care in a Large Urban Healthcare System 2019-2020

Marjan Javanbakht^{*1}, Howard Padwa², Whitney Akabike³, Lawrence Dardick³, Yu-Hsiang Lin³, Steve Shoptaw³, Lillian Gelberg³

¹University of California Los Angeles, Fielding School of Public Health, ²University of California Los Angeles, Integrated Substance Abuse Programs, ³University of California Los Angeles

S96. Shifting State-Level Cannabis Policies and Health Equity for Racial and Ethnic Minority Young People: A Qualitative Exploration

Morgan Philbin^{*1}, Heather Wurtz¹, Adrian Guta², Benjamin Lane³, Pia Mauro¹

¹Columbia University Mailman School of Public Health, ²University of Windsor, ³Columbia University Irving Medical Center

S97. Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration: 2005-2019

Deborah Hasin*¹, Andrew Saxon², Carol Malte³, Katherine Keyes⁴, Mark Olfson⁵, Melanie Wall⁵

¹Columbia University, ²Veterans Affairs Puget Sound Healthcare System, ³Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Puget Sound Health Care System, ⁴Columbia University Mailman School of Public Health, ⁵Columbia University and NYSPI

MONDAY, JUNE 13, 2022

POSTER SESSION 2

M1. Augmenting a Low-Level Implementation Strategy to Address Co-Occurring Substance Use and Mental Health Disorders: Outcomes From the Adaptive Implementation of Effective Programs Trial (ADEPT)

Andria Eisman*¹, E. Whitney Moore¹, Michaila Paulateer¹, Shawna Smith², Amy Kilbourne³

¹Wayne State University, ²University of Michigan, ³University of Michigan Medical School

M2. Open Board

M3. COVID Wariness, Protective Behaviors, Smoking, and Cigarette Purchasing Patterns Among Vulnerable Populations

Rhiannon Wiley*¹, Janice Bunn¹, Anthony Barrows¹, Jennifer Tidey², Dustin Lee³, Stacey Sigmon¹, Diann Gaalema¹, Sarah Heil¹, Andrea Villanti¹, Stephen Higgins¹

¹University of Vermont, ²Brown University, ³Johns Hopkins University School of Medicine

M4. Flavor Compounds Modulate Oral Nicotine Consumption and Preference in Mice

Ketki S. Pawaskar¹, Shaydel Engel*¹, Cassandra Win¹, Fayzeh K. El Banna¹, Anna M. Lee¹

¹University of Minnesota

M5. Interactive Effects of Financial Strain and Distress Tolerance on Pre-Quit Tobacco Withdrawal Symptoms in Smokers Preparing to Initiate a Quit Attempt

Mariel Bello*¹, Raina Pang², Suzanne Colby³, Adam Leventhal⁴, Michael Zvolensky⁵, Kirsten Langdon⁶

¹Brown University, Alpert Medical School, ²University of Southern California, ³Brown University Center for Alcohol and Addiction Studies, ⁴Keck School of Medicine, University of Southern California, ⁵University of Houston, ⁶Rhode Island Hospital

M6. Pattern of Tobacco Use and Nicotine Dependence in Patients With Psychiatric Disorders

Amit Nayak*¹, Richa Tripathi¹

¹All India Institute of Medical Sciences

M7. Youth Susceptibility to Tobacco-Free Oral Nicotine Products in Comparison to Cigarettes and E-Cigarettes

Erin Vogel*¹, Jessica Barrington-Trimis¹, Alyssa Harlow¹, Melissa Wong¹, Junhan Cho¹, Dae-Hee Han¹, Adam Leventhal¹, Alayna Tackett¹

¹University of Southern California

M8. Association Between Electronic Cigarette and Combustible Cigarette Use With Cardiometabolic Risk Biomarkers Among U.S. Adults

Emeka Okafor*¹, Nkechinyere Okafor², Catherine Kaliszewski¹, Liang Wang¹

¹Baylor University, ²Essen Healthcare

M9. Changes in Smoking From 2018 to 2020 Among Older Adults in the US: Implications for COVID-19

Pia Mauro*¹, Sarah Gutkind¹, Erin Annunziato², Daniel Giovenco¹

¹Columbia University, ²Columbia Mailman School of Public Health

M10. Characterization of Nicotine Pharmacokinetics and Pharmacodynamics During Use of Five Commercially Available Nicotine Pouches and Two Nicotine Lozenges in Adult Cigarette Smokers

Jesse Rensch¹, Jianmin Liu¹, Jingzhu Wang¹, Andrea Vansickel¹, Jeffery Edmiston*¹, Maria Gogova¹, Mohamadi Sarkar¹, Joshua Karelitz¹

¹Altria Client Services LLC

M11. Pulsed Intravenous Nicotine Infusions as Model for Inhaled Tobacco Use in Humans

Joao De Aquino*¹, Ralitzia Gueorguieva¹, Mehmet Sofuoglu²

¹Yale University School of Medicine, ²Yale University

M12. The Relationship Between Nonsystematic Delay Discounting and Low-Quality Survey Responses in a Sample of Smokers: ROC Curve Analysis

Yu-Hua Yeh*¹, Devin Tomlinson¹, Roberta Freitas-Lemos¹, William Craft¹

¹Fralin Biomedical Research Institute at Virginia Tech Carilion

M13. Tobacco, Alcohol, Cannabis, and Other Drug Use in the U.S. Before (2016-2019) and During (2020) the COVID-19 Pandemic: Findings From the Path Study

Kerry Flannagan*¹, Marushka Silveira¹, MeLisa Creamer¹, Heather Kimmel¹, Moana Kanel¹, Carlos Blanco¹, Wilson Compton¹

¹National Institute on Drug Abuse/NIH

M14. White Matter Integrity Among Early Nicotine Exposure in Early-Adolescence: An Adolescent Brain Cognitive Development (ABCD) Study

Hailey Wirtz*¹, Ryan Sullivan¹, Krista Lisdahl¹

¹University of Wisconsin-Milwaukee

M15. Open Board

M16. Characterizing Prevalence of Tobacco Product Type and Effects on Abstinence Among Individuals With Serious Mental Illness Enrolled in a Pragmatic Randomized Trial

Joanna Streck*¹, Kristina Schnitzer², Kevin Potter², Lindsay Neilson², Anne Eden Evins²

¹Harvard Medical School, ²Massachusetts General Hospital/Harvard Medical School

M17. Discrepancies in the Relation Between Smoking and Performance Across Different Tests of Executive Function

Brian Katz*¹, Diann Gaalema¹, Jennifer Tidey², Stacey Sigmon¹, Sarah Heil¹, Dustin Lee³, Michael DeSarno¹, Stephen Higgins¹

¹University of Vermont, ²Brown University, ³Johns Hopkins University School of Medicine

M18. Does Risky Substance Use Modify the Relationship Between Intensity of Nicotine Dependence and Motivation to Stop Smoking During COVID-19?

Jesse Boggis*¹, Elizabeth Saunders¹, Lisa Marsch¹, Nico Agosti¹, Alan Budney¹, Shea Lemley¹

¹Geisel School of Medicine at Dartmouth

M19. Loss Aversion, Substance-Free Reward, and Risk for Cigarette Smoking and Other Substance Use

Eric Thrailkill*¹, Michael DeSarno¹, Stephen Higgins¹

¹University of Vermont

M20. Pilot Study Investigating Rapid Visual Information Processing Task Assessment of Nicotine Delivery Via Oral Nicotine Pouch Products

Brandon Newmyer¹, Joshua Karelitz*², Jeffery Edmiston², Diana McKinney², Elizabeth Becker², Stephanie Plunkett², Mohamadi Sarkar²

¹Formally Altria; now JUUL, ²Altria Client Services

M21. Sexual Identity Differences in Perceived Risk of Tobacco and Marijuana Use Among U.S. Young Adults

Rebecca Evans-Polce*¹, Megan Schuler²

¹University of Michigan, ²RAND

M22. Validating Self-Reported Electronic Nicotine Delivery System Use With Biochemical and Topographical Measures

Merideth Addicott*¹, Eryn Matich², Katherine Wallis², Ping-Ching Hsu²

¹Wake Forest University, School of Medicine, ²University of Arkansas for Medical Sciences

M23. An Exploratory Analysis of Tobacco Use and Demographic Characteristics Among Treatment-Seeking Adult Dual Users Who Prefer to Quit Cigarettes Only Vs. Cigarettes and E-Cigarettes Simultaneously

Marc Jerome Feinstein*¹, Shaun Meyers¹, Joan Skelly², Elias Klemperer¹

¹Univ. of Vermont College of Medicine, ²Univ. of Vermont

M24. Assessment of Actual Use Behavior for Flavored Nicotine Pouches Relative to Original Nicotine Pouches

Hui Cheng*¹, Jennifer Lewis¹, Lai Wei¹, Elizabeth Becker¹

¹Altria Client Services, LLC

M25. Graphic Images for Cigarette Packs: Effects on Cigarette Purchases and Ventilation Status

Roberta Freitas-Lemos*¹, Allison N. Tegge¹, Jeffrey S. Stein¹, Warren K. Bickel¹

¹Fralin Biomedical Research Institute at Virginia Tech Carilion

M26. Prevalence and Correlates of Tobacco-Free Oral Nicotine Product Use Among Adolescents in Southern California

Alyssa Harlow*¹, Erin Vogel¹, Alayna Tackett¹, Junhan Cho¹, Dae-Hee Han¹, Melissa Wong¹, Adam Leventhal², Jessica Barrington-Trimis¹

¹University of Southern California, ²Keck School of Medicine, University of Southern California

M27. Racial Disparities in Awareness of Cigar Health Warnings by Cigar Type

Alisha Crump*¹, Brian Fairman¹

¹University of Arkansas for Medical Sciences

M28. Risk Factors Associated With E-Cigarette Use Among Adults in North Central Florida

Andrew McCabe*¹, Linda Cottler¹

¹University of Florida

M29. Social Media Use and Subsequent E-Cigarette Susceptibility and Initiation Among US Adolescents: Results From the Population Assessment of Tobacco and Health (PATH) Study Waves 4 (2016-2018) and 5 (2018-2019)

Juhan Lee*¹, Suchitra Krishnan-Sarin¹, Grace Kong¹

¹Yale University School of Medicine

M30. Tobacco Free Nicotine E-Cigarette Use Among Young Adults

Danielle Davis*¹, Krysten Bold¹, Meghan Morean¹, Deepa Camenga¹, Grace Kong¹, Asti Jackson¹, Juhan Lee¹, Lavanya Rajesh-Kumar¹, Patricia Simon¹, Suchitra Krishnan-Sarin¹

¹Yale University School of Medicine

M31. Young Adults' Interest in Using Tobacco-Free Nonmedicinal Oral Nicotine Products to Quit Vaping

Dae Hee Han*¹, Alyssa Harlow¹, Junhan Cho¹, Jessica Barrington-Trimis¹, Alayna Tackett¹, Erin Vogel¹, Melissa Wong¹, Adam Leventhal¹

¹University of Southern California

M32. Clouding up Cognition: Secondhand Cannabis and Tobacco Exposure Related to Cognitive Functioning in Youth

Alexander Wallace*¹, Connor McCabe², Marybel Gonzalez³, Eunha Hoh⁴, M. Infante³, Margie Hernandez Mejia⁵, Frank Haist³, Natasha Wade³

¹University of Wisconsin-Milwaukee, ²University of Washington, ³University of California, San Diego, ⁴San Diego State University, ⁵San Diego State University/University of California, San Diego

M33. Craving: An Early and Predictive Marker of Addiction? Baseline Results of a Prospective Study

Emmanuelle Baillet*¹, Fuschia Serre¹, Sarah Moriceau¹, Lucie Fournet¹, Marc Auriacombe¹

¹University of Bordeaux

M34. Fluctuations of Clinical Insight in Daily Life Influences Craving Intensity in Addiction

Laura Lambert*¹, Léa Donnadiou¹, Bérangère Thirioux², Nematollah Jaafari², Marc Auriacombe¹, Fuschia Serre¹

¹University of Bordeaux, ³Université de Poitiers

M35. Delay Discounting Predicts Remission Mediated by Regulatory Flexibility in Substance Use Disorder Recovery

Candice Dwyer*¹, Allison Tegge², Liqa Athamneh², Devin Tomlinson³, Warren Bickel⁴

¹Virginia Tech, ²Virginia Tech Carilion Research Institute, ³Fralin Biomedical Research Institute at Virginia Tech Carilion, ⁴Fralin Biomedical Research Institute at VTC

M36. Diminished Error-Related Negativity and Error Positivity in Adults With Addiction Problems and Disorders: A Meta-Analysis on Error Processing

Miranda Lutz*¹, Rianne Kok¹, Ilse Verveer¹, Marcelo Malbec¹, Susanne Koot², Pol van Lier², Ingmar Franken¹

¹Erasmus University Rotterdam, ²Vrije Universiteit Amsterdam

M37. Predicting Choice From Response Latencies: A Potential Treatment Target for Behavioral Allocation Disorders

Haidyn Stark*¹, Dhariye Dave¹, Richard Lamb¹, Brett Ginsburg¹

¹University of Texas Health Science Center at San Antonio

M38. Population Exposure to Marijuana and Illicit Drugs is Increasing While Exposure to Prescription Pain Relievers is Decreasing in the United States

Joshua Black*¹, Stevan Severtson¹, Richard Dart¹, Janetta Iwanicki¹

¹Rocky Mountain Poison and Drug Safety

M39. An Online Survey of the Impact of the COVID-19 Pandemic on Drug and Alcohol Use, Employment, and Mental Health

Matthew Novak*¹, August Holtyn¹, Justin Strickland¹, Matthew Johnson¹, Hillary Jackson¹, Albert Garcia-Romeu¹

¹Johns Hopkins University School of Medicine

M40. Effects of the COVID-19 Pandemic on New Cases of Drug Diversion in the United States

Kristen Bernal*¹, Stevan Severtson¹, Mance Buttram², Richard Dart¹, Janetta Iwanicki¹

¹Rocky Mountain Poison and Drug Safety, ²University of Arkansas

M41. Religiosity, Spirituality and Substance Use Disorders in Young Adulthood: A Developmental Approach

David Saunders*¹, Cristiane Duarte²

¹College of Physicians and Surgeons, Columbia University and NYSPI, ²Columbia University and NYSPI

M42. The Impact of Gender-Neutral and -Specific Normative Perceptions on Substance Use and Other Risky Behavior Among Emerging Adults

Kanila Brown*¹, Devin Banks¹, Katie Lawson²

¹University of Missouri- St. Louis, ²Ball State University

M43. Gender-Responsive Digital Intervention for Young Adult Women With Substance Use and Co-Occurring Psychiatric Disorders

Dawn Sugarman*¹, Callie Wang², Shelly Greenfield¹

¹McLean Hospital - Harvard Medical School, ²McLean Hospital

M44. LGBTQ Microaggressions and Substance Use Among University Students: The Moderating Role of Mindfulness

Ian Carson*¹, Tamika Zapolski¹

¹Indiana University Purdue University Indianapolis

M45. Gateway to Drugs: Poor School Encouragement as a Pipeline to Substance Use Disorder Among Latinx Adolescents

James-Angelo Suarez*¹, Zahra Akbari¹, Enya Vroom², Elzbieta Wiedbusch¹, Skye Bristol¹, Micah Johnson¹

¹University of South Florida, ²University of Florida

M46. Racial Differences in the Association Between Consequential Thinking and Substance Use Disorder Treatment Adherence Among Justice-Involved Adolescents

Zahra Akbari*¹, Enya Vroom², Skye Bristol¹, Elzbieta Wiedbusch¹, James-Angelo Suarez¹, Micah Johnson¹

¹University of South Florida, ²University of Florida

M47. Assessing Whether a Survey-Driven Tablet-Based Intervention Increased Willingness of Black Women With Substance Use to Attend a Prep Clinic Following an Emergency Department Visit

Mandy Hill*¹, Angela Heads², Robert Suchting², Charles Green¹, Angela Stotts¹

¹University of Texas Health Science Center, ²The University of Texas Health Science Center at Houston

M48. Emerging Sex Differences in Adolescent Substance Use

Devika Bhatia*¹, Susan Mikulich-Gilbertson¹, Crystal Natvig¹, Joseph Sakai¹

¹University of Colorado School of Medicine

M49. Sex Differences in Military Workplace Victimization and Drug Use Among U.S. Army Reserve/National Guard Service Members

Jessica Kulak*¹, Kimberly Kamper-DeMarco², D. Lynn Homish³, Gregory Homish³

¹University at Buffalo, ²Buffalo State College, ³State University of New York at Buffalo

M50. Open Board

M51. Assessing Recovery Coach Roles and Responsibilities in Substance Use Recovery

Matt Webster*¹, Amanda Fallin-Bennett¹, Martha Tillson¹, Jennifer Becan², Kevin Knight², Michele Staton¹

¹University of Kentucky, ²Texas Christian University

M52. Climate Change and Harmful Substance Use – A Risk Pathway Framework

Francis Vergunst*¹, Helen Berry², Kelton Minor³, Nicholas Chadi⁴

¹University of Montreal, ²University of Sydney, ³University of Copenhagen, ⁴Sainte-Justine University Hospital Centre

M53. Examining Factors Associated With “Lack of Readiness to Stop Using” Among U.S. Adults Needing but Not Receiving Substance Use Treatment

JaNiene Peoples*¹, Christine Doroshenko², Philip Baiden³, Erin Kasson², Nina Kaiser², Patricia Cavazos-Rehg²

¹Brown School of Social Work, Washington University in St. Louis, ²Washington University School of Medicine, ³The University of Texas at Arlington, School of Social Work

M54. Lessons Learned From Adapting Screening and Brief Intervention (SBI) to Prevent Substance Use Dependence Among Primary Care Patients in the New Age of Telehealth

Lillian Gelberg*¹, Stephanie Sumstine¹, Melvin Rico¹, Leticia Cazares¹, Quynh Vo¹, Natalie Martinez¹, Whitney Akabike¹, Dallas Swendeman¹

¹University of California Los Angeles,

M55. Principles and Metrics for Evaluating Oregon’s Drug Decriminalization Measure: Centering the Voices of People Who Use Drugs

Alex Kral*¹, Jules Netherland², Riona Morgan², Danielle Ompad Ompad³, Corey Davis⁴, Haven Wheelock⁵, Ricky Bluthenthal⁶, Nabarun Dasgupta⁷, Michael Gilbert⁸, Theshia Nadoo²

¹RTI International, ²Drug Policy Alliance, ³New York University, ⁴National Health Law Program, ⁵Outside In, ⁶University of Southern California, ⁷University of North Carolina, ⁸Booz Allen Hamilton

M56. Telehealth Services for Substance Use Disorders

Siara Sitar*¹, Kate Gliske², Justine Welsh¹, Jackie Braughton², Lance Waller³, Quyen Ngo²

¹Emory University School of Medicine, ²Hazelden Betty Ford Foundation, ³Emory University Rollins School of Public Health

M57. Characterizing Behavioral Addiction Symptoms in Adults Receiving Inpatient Substance Use Disorder Treatment

Andrew Peckham*¹, R. Kathryn McHugh², Margaret Griffin¹, Hannah Shapiro², Roger Weiss²

¹Harvard Medical School/McLean Hospital, ²McLean Hospital

M58. The Impact of National Drug Policy on the Perceptions of Psychoactive Drugs Among Psychiatrists in the United States

Alan Davis*¹, Adam Levin¹, Paul Nagib¹, Selina Deiparine¹, Tom Gao¹, Justin Mitchell¹

¹The Ohio State University

M59. A Qualitative Observational Study of Implementing Trauma-Informed Care as a Prevention/Intervention Strategy for Substance Use and Related Problems Among Juvenile Justice Youth

Yang Yang*¹, Elizabeth Joseph¹, Elaine Tinius¹, Lillyan Shelley¹, Erin Razurin¹, Danica Knight¹

¹Texas Christian University

M60. An Intervention to Address the Self-Stigma of Substance Use and Criminal Involvement: Feasibility, Acceptability, and Preliminary Effectiveness

Diamond Allen*¹, Shania Siebert¹, Jason Luoma², Kelly Moore¹

¹East Tennessee State University, ²Portland Psychotherapy Clinic, Research, and Training Center

M61. Associations Between Automated Session Elements and Gold Standard Ratings of Motivational Interviewing

Matisyahu Shulman*¹, Kenneth Carpenter², Mei-Chen Hu³, Paul Amrhein⁴, Edward Nunes²

¹College of Physicians and Surgeons, Columbia University/NYSPI, ²New York State Psychiatric Institute, Columbia University, ³Columbia University, ⁴Columbia University and Montclair State University

M62. Factors Associated With Recovery Housing Availability for Justice-Involved Individuals in the Community

Amy Mericle*¹, Katherine Karriker-Jaffe², Deidre Patterson¹, Meenakshi Subbaraman¹, Faye Taxman³

¹Alcohol Research Group, ²RTI, International, ³George Mason University

M63. Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models in the United States for Hepatitis C Virus Medications

Samantha Auty¹, Kevin Griffith*², Paul Shafer¹

¹Boston University School of Public Health, ²Vanderbilt University

M64. Infant Caregiving and Postpartum Substance Use: A Review of the Literature

Alicia Allen*¹, Linnea Linde-Krieger¹, McKenna Nelson¹, Stacey Tecot¹, Lela Williams²

¹University of Arizona, ²Arizona State University

M65. Transition to Virtual Addiction Treatment After Onset of the COVID-19 Pandemic Among Adults With Drug Use Problems in an Integrated Healthcare System

Vanessa Palzes*¹, Felicia Chi¹, Stacy Sterling¹, Asma Asyyed², Kathryn Erickson-Ridout¹, Cynthia Campbell¹

¹Center for Addiction and Mental Health Research, Kaiser Permanente Northern California, ²Northern California Addiction Medicine and Recovery Services, The Permanente Medical Group

M66. "Tired of Lying About Who I Was": A Grounded Theory of Drug Use Disclosure in Research Settings Among Drug Use Researchers

Danielle Ompad*¹, Cho-Hee Shrader², Kyle Snyder¹, Ingrid Walker³

¹New York University School of Global Public Health, ²ICAP at Columbia University, ³University of Washington, Tacoma

M67. Barriers to Implementation of Substance Use Disorder Care Within a Local Veteran's Health Administration System

Kenisha Nisbett*¹

¹Kaiser Permanente

M68. Availability of HIV, HCV, Substance Use Disorder Treatment and Other Medical Services at U.S. Syringe Service Programs

Czarina Behrends*¹, Don Des Jarlais², Xinlin Lu², Grace Corry¹, Sara Glick³, Shashi Kapadia¹, David Perlman⁴, Bruce Schackman¹

¹Weill Cornell Medical College, ²New York University School of Global Public Health, ³University of Washington, ⁴Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai

M69. Syringe Service Program Staff Experiences and Wellbeing During the COVID-19 Pandemic

Angela Bazzi*¹, Andrea Wang², Raagini Jawa³, Sarah Mackin⁴, Liz Whynott⁵, Connor Buchholz⁶, Ellen Childs⁷
¹University of California, San Diego, ²Boston University School of Medicine, ³Boston Medical Center, ⁴Access, Harm Reduction, Overdose Prevention and Education (AHOPE), ⁵Tapestry, ⁶Boston University School of Public Health, ⁷Abt Associates

M70. Determinants of Willingness to Pay for a Drug/Alcohol Problem-Free Day Over Time, Among HIV+ Individuals Who Use Drug/Alcohol in South Africa

Techna Cadet*¹, Jessica Magidson², Jennifer Belus Belus³, Thanh Lu¹, Sean Murphy¹

¹Weill Cornell Medicine, ²Massachusetts General Hospital, Harvard Medical School, ³Swiss Tropical and Public Health Institute

M71. Screening in Trauma for Opioid Misuse Prevention (STOMP): Results From a Prospective Cohort of Victims of Traumatic Injury

Randall Brown*¹, Brienna Deyo¹, Christopher Nicholas¹, Amelia Baltes¹, Scott Hetzel¹, Alyssa Tilhou², Joseph Glass³, Ann O'Rourke¹, Suresh Agarwal⁴

¹University of Wisconsin School of Medicine and Public Health, ²Boston University, ³Kaiser Permanente Washington Health Research Group, ⁴Duke University

M72. Similarity of Engagement Across Age Groups of Patients Treated With a Prescription Digital Therapeutic for Opioid Use Disorder

Brian Pfister*¹, Emily Peckham¹, Maxine Stitzer², Heather Shapiro¹, Robert Gerwein¹, Stephen Braun¹, Gigi Shafai¹, Brendan Hare¹, Yuri Maricich¹, Maria Sullivan¹

¹Pear Therapeutics, ²Friends Research Institute

M73. The Impact of Opioid Agonist Treatment on Hospitalisations for Injecting-Related Diseases: A Retrospective Data Linkage Study

Samantha Colledge*¹, Nicola Jones¹, Sarah Larney², Amy Peacock¹, Dan Lewer³, Thomas Brothers⁴, Matthew Hickman⁵, Michael Farrell¹, Louisa Degenhardt¹

¹National Drug and Alcohol Research Centre, ²Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, ³UCL Collaborative Centre for Inclusion Health, ⁴Dalhousie University, ⁵Bristol Medical School, University of Bristol

M74. The Revolving Prison Door for the Newly Released Heroin-Related Offenders in Taiwan: The Role of Community-Based Healthcare

An-Jou Chen*¹, I-An Wang², Sheng-Chang Wang³, Chuan-Yu Chen¹

¹National Yang Ming Chiao Tung University, ²Center of Neuropsychiatric Research, National Health Research Institutes, ³National Health Research Institutes

M75. Transition of Patients Established on Long-Term Transmucosal Buprenorphine Atreatment to Monthly Buprenorphine Injection

Frank Gray*¹, Bret Ryder¹, Celine M. Laffont¹

¹Indivior, Inc.

M76. Factors Driving Treatment Retention Among People With Opioid Use Disorder and HIV in Vietnam: A Qualitative Study

Linh Taylor*¹, Thanh Thuy Dinh², Hang Nguyen³, Patrick Brown⁴, Dana Button⁴, Gavin Bart⁵, Kim Hoffman³, P. Todd Korthuis⁶

¹School of Medicine Oregon Health and Science University, ²Hanoi Medical University, ³Portland State University - Oregon Health and Science University School of Public Health, ⁴Oregon Health and Science University, ⁵University of Minnesota and Hennepin Healthcare, ⁶Oregon Health and Science University

M77. A Novel Toll-Receptor 7/8 Adjuvant Increases the Immunogenicity of an Anti-Fentanyl Vaccine and Its Efficacy at Attenuating the Reinforcing Effects of Fentanyl in Rats

Mark LeSage*¹, Peter Muelken¹, Bethany Crouse², Shannon Miller³, Jay Evans³, Marco Pravetoni²

¹Hennepin Healthcare Research Institute, ²University of Minnesota Medical School, ³University of Montana

M78. A Statewide Evaluation of the Implementation and Effectiveness of Medications for Opioid Use Disorder in Vermont Correctional Facilities and the Impact of COVID-19

Elias Klemperer*¹, Laura Wreschnig², Abigail Crocker³, Jessica King-Mohr⁴, Annie Ramniceanu⁴, Liz Evans⁵, Richard Rawson¹

¹University of Vermont College of Medicine, ²Vermont Agency of Human Services, Blueprint for Health, ³University of Vermont, College of Engineering and Mathematical Sciences, ⁴Vermont Agency of Human Services, ⁵University of Massachusetts Amherst

M79. Analyzing Quality of Life Measures Collected in People With Opioid Use Disorder From the NIDA Data Share Initiative: The Implications for Cost-Effectiveness Evidence in Resource Allocation Decisions

Thomas Patton*¹, Jan Boehnke², Steffanie Strathdee¹, Annick Borquez¹

¹University of California, San Diego, ²University of Dundee

M80. Assessing Changes in Cognitive Functioning in Individuals With Opioid Use Disorder Enrolled in a Residential Treatment Program

Jennifer Marton*¹, Daniel Farmer¹, Autumn Long¹, Erin Winstanley¹, Victor Finomore¹, Ali Rezaei¹, James Mahoney¹

¹West Virginia University School of Medicine/Rockefeller Neuroscience Institute

M81. Barriers and Facilitators to No-Cost Pharmaceutical Alternatives to Illicit Drugs During Intersecting COVID-19 and Overdose Health Emergencies in British Columbia, Canada: A Qualitative Study

Ryan McNeil*¹, Taylor Fleming², Samara Mayer², Allison Barker², Manal Mansoor², Alex Betsos², Tamar Austin², Sylvia Parusel², Andrew Ivsins², Jade Boyd²

¹Yale University School of Medicine, ²British Columbia Centre on Substance Use

M82. Buprenorphine Adherence and Its Association With Illicit Opioid Use

Elenore Bhatraju*¹, Andrea C. Radick², Brian G. Leroux², Theresa Kim³, Jeffrey Samet⁴, Judith Tsui²

¹Harborview, ²University of Washington, ³Boston Medical Center, ⁴Boston University School of Medicine

M83. Clinically Significant Loneliness Among Individuals With Opioid Use Disorders

Lisham Ashrafioun*¹, Tracy Stecker², Nicholas Allan³, Jonathan Umansky¹, Tamara Bilinski¹

¹University of Rochester, ²VA Center of Excellence for Suicide Prevention; Medical University of South Carolina, ³Ohio University

M84. Early-Onset Prescription Opioid Misuse in Indiana Youth

Maria Parker*¹, Tamika Zapolski², Mary Waldron³

¹Indiana University - Bloomington, ²Indiana University Purdue University Indianapolis, ³Indiana University School of Education

M85. First in Human Trial of the Non-Opioid Selective Orexin-1 Antagonist INDV-2000 in Healthy Volunteers

Robert Dobbins*¹, Martin Kankam², Rana Al-Awam¹, Malcolm Young¹

¹Indivior Inc., ²AltaSciences

M86. How Has Ecological Momentary Assessment Been Used With People Who Are in Medication-Based Treatment for Opioid Use Disorder?

Karen Alexander*¹, Mishka Terplan¹, Pilar Sanjuan², Kenzie Preston³

¹Friends Research Institute, ²University of New Mexico, ³National Institute of Drug Abuse Intramural Research Program

M87. Improving Linkage and Ongoing Engagement With Outpatient Treatment in Patients Initiating Medication for Opioid Use Disorder While Hospitalized at an Urban Safety Net Hospital: Results From Project HOUDINI LINK

D. Andrew Tompkins*¹, Emily F. Dauria², Alexandra Haas¹, Hannah Snyder¹, Paula J. Lum¹, J. Konadu Fokuo³, Valerie A. Gruber¹

¹University of California, San Francisco, School of Medicine, ²University of Pittsburgh Graduate School of Public Health, ³University of Illinois At Chicago College of Medicine

M88. Initial Safety and Feasibility of Rapid-Induction Buprenorphine Extended-Release Following Opioid Overdose

Taylor Ochalek*¹, Brandon Wills¹, Lori Keyser-Marcus¹, Kirk Cumpston¹, Tamas Gal¹, F. Gerard Moeller¹

¹Virginia Commonwealth University

M89. Injection Partnership Characteristics and Hepatitis C Status Associations With Syringe and Equipment Sharing Among People Who Inject Drugs

Mary Mackesy-Amiti*¹, Leslie Williams², Carl Latkin³, Maggie Kaufmann², Basmattee Boodram²

¹University of Illinois at Chicago, School of Public Health, ²University of Illinois at Chicago, ³Johns Hopkins School of Public Health

M90. Is Naloxone Distribution Risky? Attitudes About Naloxone Distribution at the Start of Medical School and Two Years Later

Tabitha Moses*¹, May Chammaa¹, Eva Waineo¹, Mark Greenwald²

¹Wayne State University School of Medicine, ²Wayne State University

M91. Lack of Effect of Different Pain-Related Manipulations on Opioid Self-Administration, Reinstatement of Opioid Seeking, and Opioid Choice in Rats

Sarah Claypool*¹, E Andrew Townsend², Javier Orihuel¹, Sarah V Applebey¹, Matthew L Banks², Yavin Shaham¹, S Stevens Negus², David J Reiner¹

¹National Institute on Drug Abuse, ²Virginia Commonwealth University

M92. Long-Term Recovery From Opioid Use Disorder: Identification of Recovery Subgroups and Their Association With Opioid Use, Treatment, and Quality of Life

Allison Tegge*¹, William Craft², Hwasoo Shib³, Diana Keith⁴, Liqa Athamneh¹, Jeff Stein¹, Marco Ferreira³, Howard Chilcoat⁵, Anne Le Moigne⁵, Angela DeVeauh-Geiss⁵, Warren Bickel⁶

¹Virginia Tech Carilion Research Institute, ²Fralin Biomedical Research Institute at Virginia Tech Carilion, ³Virginia Tech, ⁴Fralin Biomedical Research Institute at VTC, Roanoke, VA, ⁵Indivior, Inc., ⁶Fralin Biomedical Research Institute at VTC

M93. Multidimensional Assessment of Access to Medications for Opioid Use Disorder Across Urban and Rural Communities: A Scoping Review

Paul Joudrey*¹, Tanner Bommersbach¹, Marissa Justen¹, Amanda Bunting², Melissa Funaro¹, Erin Winstanley³

¹Yale University School of Medicine, ²New York University School of Medicine, ³West Virginia University

M94. Prevalence of Mental Disorders Among People With Opioid Use Disorder: A Systematic Review and Meta-Analysis

Thomas Santo*¹, Gabrielle Campbell², Natasa Gisev¹, Daniel Martino-Burke¹, Jack Wilson³, Samantha Colledge¹, Brodie Clark¹, Lucy Thi Tran¹, Louisa Degenhardt¹

¹National Drug and Alcohol Research Centre, UNSW Sydney, ²University of the Sunshine Coast, ³The Matilda Centre, University of Sydney

M95. Project RIDE: Accessible and Acceptable Mobile Strategy for Community-Based Moud Engagement

Cecile Denis*¹, Kyle Kampman¹, Jose Benitez², Karen Dugosh³, David Metzger¹

¹University of Pennsylvania, ²Prevention Point Philadelphia, ³Public Health Management Corporation

M96. Prospective Associations of Tobacco Use With Prescription Drug Misuse Among Young People

Moriah Harton*¹, Ivana Nguyen¹, Rebecca Evans-Polce², Maria Parker¹

¹Indiana University, ²University of Michigan

M97. The Use of PICC Lines for Treatment of Serious Infections in People Who Inject Drugs: Review and Commentary

Victoria Weaver*¹, Mary Clare Kennedy²

¹University of British Columbia, Faculty of Medicine, ²The University of British Columbia

SBIR POSTER SESSION (SMALL BUSINESS INNOVATION RESEARCH - SBIR)

Novel Digital and Behavioral Health Platform That Combines Opioid Compliance Protocols to Improve Prescriber Confidence, Reduce Liability, and Improve Patient Outcomes

Amy Elliott*¹, John Bowman², Abraham Hartzema¹

¹University of Florida, ²SureMed Compliance

Development of a Digital Application for Patient Self-Management of Opioid Use Disorder: KIOS

Tara Karns-Wright*¹, Van King², Gregg Seigel³, H. Richard Priesmeyer⁴, Leslie Seigel³, Jennifer Potter²

¹The University of Texas Health Science Center At San Antonio, ²University of Texas Health San Antonio, ³Biomedical Development Corporation, ⁴St. Mary's University

Development of CP-Analogs as Novel Treatments for Opioid Use Disorder

Jeffrey Reich*¹, Susruta Majumdar², Jay McLaughlin³, Annie Pasternak¹

¹Sparian Biosciences, Inc., ²St. Louis College of Pharmacy/Washington University, ³University of Florida

Rae (Realize, Analyze, Engage): A Digital Detection and Intervention for Individuals in Recovery from Substance Use Disorder

Stephanie Carreiro*¹, Rebecca Leach², Sloke Shrestha³, Joshua Stapp³, Melissa Taylor², Megan Reinhardt⁴, Nicole Gilbertson⁴, Premananda Indic³

¹University of Massachusetts Medical School, ²University of Massachusetts Chan Medical School, ³University of Texas at Tyler, ⁴RAE Health

Introduction to NIDA's Office of Translational Initiatives and Program Innovations (OTIPI)

Christopher Conrad*¹, Julia Berzhanskaya¹, Sara Lioi¹, Stacie Gutowski¹, Tamara Slipchenko¹, Tam Nguyen¹, Yordan Kostov¹, Victor Prikhodko¹, Leonardo Angelone¹, Elena Koustova¹

¹DHHS/National Institute on Drug Abuse

Mobile Brain Sensing Platform for Detection of Opioid Craving and Treatment Response

Scott Burwell*¹, Justin Anker²

¹Neurotype Inc., ²University of Minnesota

Integrating Augmented Reality (AR) and Immersive Learning Simulation (ILS) for Healthcare Training: Towards a Transmedia Solution to Address the Opioid Crisis

Douglas Nelson*¹, Anya Andrews², Analia Castiglioni²

¹Lumis Corp., ²University of Central Florida College of Medicine

Risk and Protective Factors for Initial Training Completion Among Substance Use Disorder Peer Worker Trainees

Sierra Castedo de Martell*¹, J. Michael Wilkerson², Jason Howell³, Sheryl McCurdy⁴

¹UTHealth School of Public Health, ²The University of Texas Health Science Center at Houston,

³RecoveryPeople, ⁴University of Texas Health Science Center

Identification of Epigenetic Biomarkers Associated With Prenatal Exposure to Substances of Abuse

Aileen Baldwin*¹

¹United States Drug Testing Laboratories, Inc.

Innovative Animal Experiment Design Tool

Ben Fitzpatrick*¹, Yun Wang¹, Kristin Holmbeck-Cannell¹

¹Tempest Technologies

Multivalent Vaccine Strategies Against Polydrug Use in Opioid Use Disorder

Daihyun Song*¹, Bethany Crouse¹, Jennifer Vigliaturo¹, Stefano Persano¹, Marco Pravetoni¹

¹The University of Minnesota

Overdose Deaths Involving Non-Bzd Hypnotic/Sedatives in the USA: Trends Analyses

Vitor Tardelli*¹, Marina Costa Moreira Bianco², Rashmika Prakash³, Luis Segura³, João Castaldelli-Maia³, Thiago Fidalgo², Silvia Martins³

¹Universidade Federal de Sao Paulo/Centre for Addiction and Mental Health - University of Toronto,

²Universidade Federal de Sao Paulo, ³Columbia University Mailman School of Public Health

Technology Assisted Motivational Interviewing: Developing a Scalable Framework for Promoting Engagement With Tobacco Cessation

Jason Satterfield*¹, Joannalyn Delacruz¹, Ahson Saiyed², John Layton¹, Catherine Bexley¹, Jing Cheng¹, Tatyana Kanzaveli², Maksim Tsvetovat², Brian Borsari¹

¹University of California, San Francisco, ²Open Health Network

Small Business Program: Patient Uptake and Use of a Technological Solution to Support Treatment for Opioid Use Disorder in the Primary Care Setting

Mariah Kalmin*¹, Bengisu Tulu², Omar Nieto¹, Li Li¹, Dominic Trupiano³, Alycia Quick³, Steve Jenkins³, Steve Shoptaw¹

¹University of California, Los Angeles, ²Worcester Polytechnic Institute, ³Q2i

Virtual Opioid User: Reproducing Opioid Use Phenomena With a Control Theory Model

Alexander Preiss*¹, Georgiy Bobashev¹

¹RTI International

TUESDAY, JUNE 14, 2022

POSTER SESSION 3

T1. Arkansas Treatment Admission Trends From 2000 to 2020 for Dual Opioid-Methamphetamine or Opioid-Cocaine Use Problems

Alison Oliveto*¹, Jeff Thostenson¹, Mary Bollinger¹, Ronald Thompson, Jr.¹, Michael Mancino¹

¹University of Arkansas for Medical Sciences

T2. Childhood Neglect Predicts Perceived Quality of Care in Patients With Co-Occurring Substance Use and Mental Disorders

Karling R. Luciani*¹, Karina A Thiessen¹, Thomas Wen-Chi Chao¹, Christian Schütz¹

¹University of British Columbia

T3. Craving-Manager App Designed to Manage Craving and Individual Predictors of Substance Use / Addictive Behavior in Addiction: A Randomized Controlled Trial Study Protocol

Fuschia Serre*¹, Sarah Moriceau¹, Léa Donnadieu¹, Jean Pierre Daulouede², Maurice Dematteis³, Nematollah Jaafari⁴, David Mete⁵, Philippe Nubukpo⁶, Marc Auriacombe¹

¹Universite de Bordeaux, ²Bizia, ³Université de Grenoble, ⁴Université de Poitiers, ⁵CHU de La Reunion, ⁶CH Esquirol de Limoges

T4. Development of the Stop Covid Today Intervention to Increase SARS-CoV-2 Vaccination Among People Who Inject Drugs

Ian Aronson*¹, Alexander Bennett¹, Mary-Andrée Ardouin-Guerrier¹, German Rivera-Castellar¹, Brent Gibson², Brittney Vargas-Estrella², Sam Santoscoy²

¹New York University, ²New York Harm Reduction Educators

T5. Difficulty in Emotional Regulation is Associated With HIV Risk Related to Drug Use

Fatumastar Adan*¹, Jeremiah Bertz², Shireen Husami¹, Landhing Moran³, Megan Dwyer², Leigh Panlilio¹, David Epstein¹, Kenzie Preston¹, Karran Phillips⁴

¹NIDA, Intramural Research Program, ²National Institute on Drug Abuse, ³NIDA - Center for Clinical Trials Network, ⁴National Institute of Drug Abuse, National Institutes of Health

T6. Efficacy of Screening and Referral to Targeted Prevention That is Founded on the Liability-Threshold Model

Ty Ridenour*¹, Daniel Shaw², Chardee Galan³

¹RTI International, ²University of Pittsburgh, ³University of Southern California

T7. Gender Differences in Prescription Medication Misuse in Primary Care

Taylor Crouch*¹, Caitlin Martin², Kathryn Polak², Wally Smith², Pamela Dillon², Steven Ondersma³, Dace Svikis²

¹Virginia Commonwealth University, School of Medicine, ²Virginia Commonwealth University, ³Michigan State University

T8. HIV Education, Awareness, and Referral and Treatment for Substance Use Disorders (HEARTS): A New Generation of Substance Use Treatment

Adrienne Gilmore-Thomas*¹, Mandy Hill¹, Jane Hamilton², Angela Heads²

¹University of Texas Health Science Center, ²University of Texas Health Science Center Houston

T9. Health Service Utilization Among Hospitalized Patients Experiencing Homelessness in a Randomized Clinical Trial of Patient Navigation Services

Courtney Nordeck*¹, Robert Schwartz², Shannon Mitchell², Christopher Welsh³, Kevin O'Grady⁴, Jan Gryczynski²

¹Johns Hopkins, Bloomberg School of Public Health, ²Friends Research Institute, ³University of Maryland School of Medicine, ⁴University of Maryland

T10. Illegal Drug Use in Adolescents: A Missed Opportunity for Intervention in Taiwan

Enoch Lee*¹, An-Jou Chen¹, I-An Wang², Chuan-Yu Chen¹

¹National Yang Ming Chiao Tung University, ²Center of Neuropsychiatric Research, National Health Research Institutes

T11. Non-Engagement in Substance Use Treatment Among Women With Substance Use Disorders: A Latent Class Analysis on Multidimensional Barriers

Hannah Apsley*¹, Alexis Santos-Lozada¹, Kyler Knapp¹, Joy Gray¹, Gregory Hard², Abenaa Jones¹

¹Pennsylvania State University, ²MGH Institute of Health Professions

T12. Non-Opioid Substance Use Among Patients Receiving Office-Based Buprenorphine Treatment

Karen Dugosh*¹, Michelle Lent², Brook Burkley¹, Conor Millard¹, James McKay³, Kyle Kampman³

¹Public Health Management Corporation, ²Philadelphia College of Osteopathic Medicine, ³University of Pennsylvania

T13. One Person's Needs is Someone Else's Need Too: Attitudes Towards Harm Reduction and Low-Threshold Healthcare During COVID-19 Among People Who Use Drugs in Rural Southern Illinois

Alex Rains*¹, Mary York², Jerel Ezell³, Lawrence J Ouellet⁴, Wiley Jenkins⁵, Mai T Pho⁶

¹University of Chicago, Pritzker School of Medicine, ²Southern Illinois University, ³Africana Studies and Research Center, Cornell University, ⁴School of Public Health, University of Illinois Chicago, ⁵SIU School of Medicine, ⁶University of Chicago

T14. Patients With a History of Foster Care Are at Higher Risk for Drug Overdose

Tanise Teale*¹, Thomas Wen-Chi Chao¹, Christian Schütz¹

¹University of British Columbia

T15. Prevalence of Substance Abuse Among Out-Of-School Youth in Motor Parks in Ikeja Local Government Area of Lagos State

Olanrewaju Onigbogi*¹, Modupe Onigbogi²

¹University of Lagos, College of Medicine, ²University of Texas Health Sciences Houston

T16. The Association Between Socioeconomic Status, Delay Discounting, and Recovery From Substance Use Disorders

Liqia Athamneh*¹, Allison Tegge¹, Roberta Freitas-Lemos², Warren Bickel²

¹Virginia Tech Carilion Research Institute, ²Fralin Biomedical Research Institute at Virginia Tech Carilion

T17. "See The Need, Meet The Need:" Attitudes Toward Trauma-Informed Care Among Juvenile Justice Staff

Elizabeth Joseph*¹, Lillyan Shelley¹, Yang Yang¹, Danica Knight¹

¹Texas Christian University

T18. Addictive Characteristics of Patients With Cluster Headache

Kelly Hyves*¹, Fuschia Serre², Marc Auriacombe², Virginie Corand³

¹Bordeaux 2 University, ²Universite de Bordeaux, ³Pain Clinic, CHU Bordeaux

T19. COVID-19 Vaccination Status and Concerns Among People Who Use Drugs in Oregon

Erin Stack*¹, Sarah Shin¹, Kate LaForge¹, Gillian Leichtling¹, Christopher Blazes², Dan Hoover², Andrew Seaman², P. Todd Korthuis²

¹Comagine Health, ²Oregon Health and Science University

T20. Determination of the Cause and the Manner of Death in Post-Mortem Cases in the West Bank in the Years 2011-2021: Mortality Related to Drugs and Toxic Substance Use in Post-Mortem Cases

Ammar Thabaleh*¹, Rayan Al Ali², Rami Zagha³, Seraj Tijani¹, Omar Saffarini¹, Basma Damiri³

¹School of Medicine and Health Sciences, An-Najah National University, ²Forensic Medicine Institute, An-Najah National University, ³An-Najah National University

T21. Estimating the Impact of Stimulant Use on Initiation of Medication for Opioid Use Disorder Among Treatment-Seeking U.S. Adults

Ryan Cook*¹, Canyon Foot¹, Judith Tsui², Kara Rudolph³, Sean Luo⁴, P. Todd Korthuis¹

¹Oregon Health and Science University, ²University of Washington, ³Columbia University Mailman School of Public Health, ⁴Columbia University

T22. Feasibility of Using Social Media to Deliver an Evidence-Based HIV Prevention Intervention Among Rural Appalachian Women Who Use Drugs

Megan Dickson*¹, Erika Pike¹, Sean Young², Michele Staton³

¹University of Kentucky, ²University of California, Los Angeles, ³University of Kentucky, College of Medicine

T23. Low Intensity Focused Ultrasound Targeting the Nucleus Accumbens as a Potential Adjunctive Treatment for Substance Use Disorder

James Mahoney*¹, Marc Haut¹, Jeffrey Carpenter¹, Wanhong Zheng¹, James Berry¹, Jennifer Marton¹, Manish Ranjan¹, Victor Finomore¹, Ali Rezaei¹

¹West Virginia University School of Medicine/Rockefeller Neuroscience Institute

T24. Methamphetamine Use and Risky Sex Among Justice-Involved Women With a History of Opioid Use Disorder (OUD)

Michele Staton¹, Martha Tillson*², Matt Webster², Carl Leukefeld², Kathryn McCollister³, Carrie Oser², Sarah Johnson⁴, Katherine Marks²

¹University of Kentucky, College of Medicine, ²University of Kentucky, ³University of Miami Miller School of Medicine, ⁴KY Department of Corrections

T25. Model-Based Decision Making is Related to Reflection Impulsivity: Findings From Exploratory Correlational Analyses Between Computational and Traditional Impulsivity Outcomes

Laura Schmid*¹, Thomas Wen-Chi Chao¹, Stefanie Todesco¹, Karina Thiessen¹, Christian Schütz¹

¹University of British Columbia

T26. Predictors of Post Release Service Utilization Among the Formerly Incarcerated With Substance Use Disorders

Sara Beeler-Stinn*¹, Brett Drake², Kathleen Bucholz³, Vetta Sanders Thompson², Tonya Edmond², Tanya Renn⁴, Chris Veeh⁵, Carrie Pettus⁶

¹Jane Addams College of Social Work, UIC, ²Washington University in St. Louis, Brown School, ³Washington University School of Medicine, ⁴College of Social Work, Florida State University, ⁵School of Social Work, The University of Iowa, ⁶Florida State University

T27. Prevalence of Comorbid Health Diagnoses by Body Systems of Persons Presenting in Texas Hospitals With a Substance Use Diagnosis

J. Michael Wilkerson*¹, Cecilia M Ganduglia Cazaban¹, Randa Hamden¹, Kathryn R. Gallardo¹, David Adzrago¹, Henry S Brown¹, James J Yang¹, Sheryl McCurdy¹

¹The University of Texas Health Science Center at Houston

T28. Serious Psychological Distress, Substance Use Disorders, and the COVID-19 Pandemic: An Examination of Multiple Mental Health and Social Issues Among Men and Women in the United States in 2020

Joy Gray*¹, Alexis Santos-Lozada¹, Gregory Hard², Hannah Apsley¹, Deirdre O'Sullivan¹, Abenaa Jones¹

¹Pennsylvania State University, ²MGH Institute of Health Professions

T29. Sex Differences in Neural Responses to Stress and Drug Cues is Predictive of Future Substance Use Disorder Relapse Severity

Keisha Smith*¹, Cheryl Lacadie², Verica Milivojevic¹, Rajita Sinha¹

¹Yale University School of Medicine, ²Yale University

T30. Sex Work and Overdose Risk Among Women Who Use Drugs in Vancouver, Canada

Miriam Harris*¹, Shira Goldenberg², Michelle Cui³, Nadia Fairbairn⁴, M-J Milloy⁴, Kanna Hayashi⁵, Jeffrey Samet⁶, Alexander Walley⁶, Seonaid Nolan⁴

¹Boston University, ²San Diego State University, ³British Columbia Centre on Substance Use, ⁴University of British Columbia, ⁵Simon Fraser University, ⁶Boston University School of Medicine

T31. Suicidal Ideation, Planning, and Attempts in Adolescents and Adults During the COVID-19 Pandemic: The Role of Substance Use Disorders and Sex/Gender

Gregory Hard*¹, Alexis Santos-Lozada¹, Joy Gray¹, Abenaa Jones¹, Hannah Apsley¹

¹Pennsylvania State University

T32. Survey of Substance Use and Characteristics Associated to Problematic Use in a French Community Structure for People With Mental Disorders

Jean-Marc Alexandre*¹, Frederique Doneche², Marc Auriacombe¹

¹University of Bordeaux, ²Adapei 65

T33. Adolescent Behavioral Responses to COVID-19 and the Development of the Pandemic Response Index

Laura Monico*¹, Kevin O'Grady², Jan Gryczynski¹, Kaitlyn Garrison¹, Tyler Ross¹, Shannon Mitchell¹

¹Friends Research Institute, ²University of Maryland

T34. An Evaluation of Change in Coping Skills From Clinician- Versus Computer-Delivered CBT

Brian Kiluk*¹, Shannon Schrader¹, Tami Frankforter¹

¹Yale University School of Medicine

T35. Association of Unhealthy Alcohol and Drug Use With Healthcare Utilization Among Adult Primary Care Patients

Leah Hamilton*¹, Aimee Wahle², Margaret Kline², Sarah E. Wakeman³, Timothy Wilens³, Joseph Kannry⁴, Richard Rosenthal⁴, Keith Goldfeld⁵, Angeline Adam⁵, Sarah Farkas⁵, Carmen Rosa⁶, Seth Pitts², John Rotrosen⁷, Jennifer McNeely⁸

¹Kaiser Permanente, Washington Health Research Institute, ²The Emmes Corporation, ³Massachusetts General Hospital, ⁴Icahn School of Medicine at Mount Sinai, ⁵New York University School of Medicine, ⁶National Institute of Drug Abuse, National Institutes of Health, ⁷NYU Langone School of Medicine, ⁸New York University Grossman School of Medicine

T36. Causal Relationships Between High Levels of Substance Use, Emotions, and Social Support

Katherine Harrison*¹, Andrea Maxwell¹, Anna Zilverstand¹

¹University of Minnesota

T37. Distinguishing Differences in Polysubstance Use by Sex Among Persons Who Use Cocaine

Anna Wang*¹, Nicole Fitzgerald¹, Yiyang Liu¹, Barry Setlow¹, Lori Knackstedt¹, Catherine Striley¹, Linda Cottler¹

¹University of Florida

T38. Gender Differences in Substance Use, Eating, and Other Addictive Behaviors Among Bariatric Surgery Patients

Rachel Arnold*¹, Jaclyn Sadicario¹, Hayley Bray¹, Abirami Marimuthu¹, Navilia Gottipati¹, Leila Islam², Mary Loos¹, Dace Svikis¹

¹Virginia Commonwealth University, ²VCU Health

T39. Incarcerated Individuals With Co-Occurring Stimulant and Opioid Use Disorder in Rural Massachusetts: Needs and Use of Medications to Treat Opioid Use Disorder

Amelia Bailey*¹, Calla Harrington¹, Liz Evans²

¹University of Massachusetts, ²University of Massachusetts Amherst

T40. Treatment Retention, Return to Use, and Recovery Support Following Post-COVID-19 Relaxation of Methadone Take-Home Dosing in Two Rural Opioid Treatment Programs: A Mixed Methods Analysis

Kim Hoffman*¹, Canyon Foot¹, Ximena Levander¹, Ryan Cook¹, Javier Ponce Terashima², John McIlveen³, P. Todd Korthuis¹, Dennis McCarty¹

¹Oregon Health and Science University, ²University Hospitals Cleveland Medical Center, ³Oregon Health Authority

T41. Patterns of Past-Month and Lifetime Polysubstance Use are Associated With Co-Occurring Psychosocial Stress, Co-Occurring Psychiatric Disorders, and Overdose in Persons Seeking Treatment for Substance Use Disorders

Jennifer Ellis*¹, Jill Rabinowitz², Orrin Ware¹, Jonathan Wells³, Kelly Dunn¹, Andrew Huhn¹

¹Johns Hopkins University School of Medicine, ²Johns Hopkins Bloomberg School of Public Health, ³Virginia Commonwealth University

T42. Perceived Impact of COVID-19 on Substance Use and Mental Health in People Who Use Opioids (PWUO) in Syringe Services Programs (SSPs) in Southeast U.S. Cities

Mary Hatch¹, Tanja Laschober², Melissa Ertl^{*3}, Margaret Paschen-Wolff³, Lynette Wright⁴, Daniel Feaster⁵, Susan Tross⁶

¹University of Washington, ²University of Washington, Addictions, Drug and Alcohol Institute, ³Columbia University Medical Center, ⁴University of Washington Alcohol and Drug Abuse Institute, ⁵University of Miami Miller School of Medicine, ⁶Columbia University

T43. Psychoactive Substance Use and Road Traffic Accidents Among Commercial Passenger Vehicle Drivers: A Scoping Review Protocol

Tekendra Rai^{*1}, Nae Won¹, Nancy Schaefer², Linda Cottler³

¹University of Florida, College of Medicine, ²University of Florida, Health Science Center Libraries, ³University of Florida

T44. Religiosity, Religious Coping and Substance Use for Young Black Men After Trauma

Carolyn Bazan^{*1}, Alexandria Bauer¹

¹Rutgers University

T45. Social-Emotional Skills and Polysubstance Use Patterns Among Adolescents in Detention Facilities

Samay Shah^{*1}, Sami Habboub¹, Micah Johnson¹

¹University of South Florida

T46. Substance Use Treatment Utilization Among Individuals With Substance Use Disorders in the United States During the COVID-19 Pandemic: The Role of Polysubstance Use Criminal Justice Involvement

Abenaa Jones^{*1}, Hannah Apsley¹, Joy Gray¹, Gregory Hard¹, Alexis Santos-Lozada¹

¹Pennsylvania State University

T47. The Association Between Drug Use, Stressful Life Events, and Chaos With Participant Enrollment in Health Research: A Comparison of Two Person-Centered Approaches

Nicole Fitzgerald^{*1}, Krishna Vaddiparti¹, Catherine Striley¹, Linda Cottler¹

¹University of Florida

T48. Trends in the Concurrent Use of Nicotine and Cannabis Among Adults, United States, 2013-2019

Danielle Smith^{*1}, Cheryl Rivard¹, Erin McClure², Pete Driezen³, Shannon Gravely³, Karin Kasza¹, David Hammond³, Andrew Hyland¹

¹Roswell Park Comprehensive Cancer Center, ²Medical University of South Carolina, ³University at Waterloo

T49. "The Talk to Me Like I Am a Human Being:" A Mixed Methods Analysis of Hepatitis Care Experience at Syringe Exchange Programs

Yesenia Aponte-Melendez^{*1}, Pedro Mateu-Gelabert¹, Chunki Fong¹, Benjamin Eckhardt², Shashi Kapadia³, Kristen Marks³, Alicia Rodriguez¹, Melinda Pai³

¹CUNY Graduate School of Public Health, ²NYU Langone Health, ³Weill Cornell Medicine

T50. Barriers and Facilitators to COVID-19 Vaccination Among People Who Inject Drugs in San Diego County

Chad Valasek¹, Heather Pines², Samantha Streuli¹, Maria Luisa Mittal¹, Steffanie Strathdee¹, Carlos Vera¹, Alicia Harvey-Vera¹, Angela Bazzi^{*1}

¹University of California - San Diego, ²San Diego State University

T51. Behavioral Health Benefits of Virtual Native American Talking Circles Group Sessions: Understanding the Impact of Peer Support Groups During COVID-19

Steven Steine¹, Anne Skinstad^{*1}

¹University of Iowa

T52. Best Practices for Substance Misuse Research Education Programs to Promote Diversity, Equity, and Inclusion

Chantae Ciceron^{*1}, Micah Johnson¹

¹University of South Florida

T53. Concurrent Sleep-Motivated Non-Medical Use of Prescriptions and Substance Use: A Latent Class Analysis

Alyssa Falise^{*1}, Carolin Hoeflich¹, Catherine Striley¹, Catalina Lopez-Quintero¹

¹University of Florida

T54. Internalized Stigma Among Legal-System Involved Women in Substance Use Disorder Treatment

Verlin Joseph^{*1}, David Moniz-Lewis¹, Dylan Richards¹, Matthew Pearson², Jason Luoma³, Katie Witkiewitz¹

¹University of New Mexico, ²Center on Alcohol, Substance Use, and Addictions (CASAA), ³Portland Psychotherapy Clinic, Research, and Training Center

T55. Leaving the Military in the Context of Mental Health Problems: Does It Increase Risk for Drug Use?

Bonnie Vest^{*1}, Rachel Hoopsick², D. Lynn Homish¹, Gregory Homish¹

¹State University of New York at Buffalo, ²University of Illinois Urbana-Champaign

T56. Major Depressive Episodes Among U.S. Adults Who Use Kratom (*Mitragyna Speciosa*): Concurrent Substance Use Patterns and Sociodemographic Differences

Carolin Hoeflich^{*1}, Alyssa Falise¹, Sara Nutley¹, Catherine Striley¹

¹University of Florida

T57. Perceived Link Between COVID-19 and Substance Use and Mental Health: Findings From Men Who Have Sex With Men Who Use Substances Visiting Sexually Transmitted Infection Clinics in Southeast U.S. Cities

Tanja Laschober¹, Mary Hatch¹, Melissa Ertl^{*2}, Margaret Paschen-Wolff³, Lynette Wright¹, Daniel Feaster⁴, C. Mindy Nelson⁴, Susan Tross⁵

¹University of Washington, Addictions, Drug and Alcohol Institute, ²Columbia University and New York State Psychiatric Institute, HIV Center for Clinical and Behavioral Studies, ³Columbia University Medical Center, ⁴University of Miami Miller School of Medicine, ⁵Columbia University

T58. Racial Differences in the Association Between Family Functioning and Substance Use Disorder Treatment Completion Among Justice-Involved Adolescents

Deja Wilson^{*1}, Micah Johnson¹

¹University of South Florida

T59. Racial Discrimination, Historical Trauma, Racial Microaggressions and Polysubstance Use in Black Young Adults

Chantel Ebrahimi^{*1}, Lillian Polanco-Roman¹, Alexandria Bauer², Tanya Saraiya³, Denise Hien⁴

¹The New School, ²Rutgers University, ³Medical University of South Carolina, ⁴Rutgers Center of Alcohol and Substance Use Studies, Graduate School of Applied and Professional Psychology

T60. Resilience During the COVID-19 Pandemic Among Persons Who Use Non-Injected Heroin and Cocaine: Resistance to Injecting, Stable Mental Health, and Reduced Heroin and Cocaine Use

Don Des Jarlais*¹, Chenziheng (Allen) Weng¹, Jonathan Feelemyer¹, Anneli Uuskula², Courtney McKnight¹
¹New York University School of Global Public Health, ²University of Tartu

T61. Substance Use Trajectories Among Urban College Students: Associations With Symptoms of Stress, Anxiety, and Depression Before and During COVID-19

Laura Brandt*¹, Nishanthi J. Anthonipillai², Teresa López-Castro², Robert Melara², Adriana Espinosa²
¹Columbia University Irving Medical Center and New York State Psychiatric Institute, ²The City College of New York

T62. The Impact of COVID-19 on Mental Health and Substance Use Outcomes Among Queer Women of Color: A Scoping Review

Lovelyne Julien*¹, Lesia M. Ruglass², Aimee Campbell³
¹The New School, ²The City College of New York, CUNY, ³Columbia University Irving Medical Center and New York Psychiatric Institute

T63. Types of Traumatic Experiences in Drug Overdose-Related Deaths: An Exploratory Latent Class Analysis

Judy Hong¹, Constanza de Dios*¹, Jessica Balderas¹, Sarah Tonkin², Robert Suchting¹, Consuelo Walss-Bass¹, Thomas Meyer³
¹The University of Texas Health Science Center at Houston, ²University at Buffalo, ³University of Texas Health Science Center

T64. Differences in Substance Class Use Among Driving Under the Influence of Drugs Events Using Real-Time Motor Vehicle Crash Data in the United States From 2019 to 2022

Nae Won*¹, Linda Cottler²
¹University of Florida, College of Medicine, ²University of Florida

T65. The Association Between Potentially-Traumatic Events and Cocaine, Cannabis, and Alcohol Use Differs by Race

Judy Hong*¹, Constanza de Dios¹, Adrienne Gilmore-Thomas¹, Emma Lathan-Powell¹, Jane Hamilton¹, Angela Heads¹
¹The University of Texas Health Science Center at Houston

T66. The Chemokine Antagonists Maraviroc and AMD3100 Reduce Opioid and Stimulant Choice in Rats

Briana Mason*¹, Gregory Collins¹
¹The University of Texas Health Science Center at San Antonio

T67. REL-1017 (Esmethadone; d-Methadone), a Rapid-Acting Antidepressant Has No Meaningful Opioid Abuse Liability in Nonclinical and Clinical Abuse Potential Studies

Jack Henningfield*¹, Glen Apseloff², Charles Gorodetzky³, Marco Pappagallo⁴, Megan Shram⁵, Sara De Martin⁶, Reginald Fant¹, Frank Vocci⁷, Frank Sapienza⁸, Thomas Kosten⁹, Jeff Huston², August Buchhalter¹, Judy Ashworth¹, Ryan Lanier¹, Francesco Bifari¹⁰, Franco Folli¹⁰, Sady Ribeiro⁴, Sergio Traversa⁴, Charles E. Inturrisi⁴, Paolo L. Manfredi⁴
¹Pinney Associates, Inc., ²Ohio Clinical Trials, ³Consultant in Pharmaceutical Medicine, ⁴Relmada Therapeutics, Inc., ⁵Altreos Research Partners, ⁶University of Padova, ⁷Friends Research Institute, ⁸The Drug and Chemical Advisory Group LLC, ⁹Baylor College of Medicine, MD Anderson Cancer Center, University of Houston, Michael E DeBakey VA Medical Center, ¹⁰University of Milano School of Medicine

T68. Racial and Ethnic Differences in Long-Term Outcomes After Randomization to Methadone or Buprenorphine/Naloxone Treatment for Opioid Use Disorder

Yuhui Zhu*¹, Sarah Clingan², Larissa Mooney³, Andrew Saxon⁴, Elizabeth Evans⁵, Yih-Ing Hser⁶
¹Semel Institute - UCLA, ²University of California, Los Angeles, ³David Geffen School of Medicine, University of California, Los Angeles, ⁴Veterans Affairs Puget Sound Healthcare System, ⁵University of Massachusetts Amherst, ⁶UCLA Integrated Substance Abuse Programs

T69. Self-Reported Substance Use With Clinician Interviewers Versus Computerized Surveys

Lauren Gorfinkel*¹, Dvora Shmulewitz², Malka Stohl³, Deborah Hasin²
¹The University of British Columbia, ²Columbia University, ³New York State Psychiatric Institute

T70. Sex Differences Among Individuals With Chronic Pain and Opioid Use Disorder Entering Methadone Maintenance Treatment

Olaniyi Olayinka*¹, Iain Carmichael², Marina Gaeta Gazzola³, Kimberly Dimeola⁴, Xiaoying Zheng⁵, Lynn Madden³, Mark Beitel⁶, Declan Barry⁶
¹Yale University School of Medicine, ²Brigham and Women's Hospital, Harvard Medical School, ³The APT Foundation, Yale School of Medicine, ⁴The APT Foundation, ⁵The APT Foundation and Yale College, ⁶The APT Foundation and Child Study Center, Yale School of Medicine

T71. Stimulant Use is Strongly Associated With Return to Opioid Use Following Initiation Onto Medications for Opioid Use Disorder

Canyon Foot*¹, P. Todd Korhuis¹, Judith Tsui², Sean Luo³, Ryan Cook¹
¹Oregon Health and Science University, ²University of Washington, ³Columbia University

T72. TRV734 as a Potential Medication for Opioid-Use Disorder: Protocol for a Dose-Finding Pilot and a Proof-Of-Concept Human Laboratory Study

Kirsten Smith*¹, Leigh Panlilio¹, Destiny Schriefer¹, Lorenzo Leggio¹, Karran Phillips², Kenzie Preston¹, Michael Kramer³, Michael Fossler³, David Epstein¹, Yavin Shaham²
¹National Institute on Drug Abuse, Intramural Research Program, ²National Institute of Drug Abuse, National Institutes of Health, ³Trevena, Inc.

T73. Why Stop a Good Thing? a Qualitative Study of Methadone Discontinuation in the First Year of Treatment for Opioid Use Disorder

Ashish Thakrar*¹, Jarratt Pytell², Kenneth Stoller³, Geetanjali Chander³
¹National Clinician Scholars Program, University of Pennsylvania, ²Addiction Medicine and General Internal Medicine Fellowships, Johns Hopkins University School of Medicine, ³Johns Hopkins University School of Medicine

T74. The Influence of COVID-19 on Treatment for Opioid Use Disorder Services in Rural Primary Care Settings: Patients' Perspectives

Sarah Clingan*¹, Maria Hanano¹, Stacy Calhoun¹, Allison Ober², Alex R. Dopp², Megan E. Curtis¹, Megan Black¹, Lin Chunqing¹, Melissa Salgado¹, Katie P. Osterhage³, Laura-Mae Baldwin³, Andrew Saxon⁴, Emily Hichborn⁵, Laurie S. Lester⁵, Lisa Marsch⁵, Larissa Mooney¹, Yih-Ing Hser¹
¹David Geffen School of Medicine, University of California, Los Angeles, ²RAND Corporation, ³University of Washington, ⁴Veterans Affairs Puget Sound Healthcare System, Seattle, ⁵Geisel School of Medicine at Dartmouth

T75. Trends in COVID-19 Testing, Infection, Vaccination and Housing Assistance Among People Who Inject Drugs in Los Angeles, California and Denver, Colorado During the First Year of the Pandemic

Rachel Ceasar¹, Karen Corsi², Jesse Goldshear¹, Patricia Wilkins², Kelsey Simpson¹, Eric Kovalsky², Karina Dominguez Gonzalez³, Ricky Bluthenthal^{*1}

¹University of Southern California, Keck School of Medicine, ²University of Colorado Denver School of Medicine, ³University of Southern California

T76. Understanding Opportunities and Challenges With Telemedicine-Delivered Buprenorphine During the COVID-19 Pandemic

Kristin Mattocks¹, David Moore², Dora Wischik², Christina Lazar², Marc Rosen^{*2}

¹U Mass Worcester/VA Central Western Mass, ²Yale University/VA Connecticut Healthcare System

T77. Women's Experiences in Injectable Hydromorphone and Diacetylmorphine Treatment Programs in Vancouver, Canada

Samara Mayer^{*1}, Jade Boyd², Ryan McNeil³

¹BC Centre on Substance Use and University of British Columbia, ²British Columbia Centre on Substance Use, ³Yale University School of Medicine

T78. "The Opposite of Addiction is Connection": Syringe Service Program Perspectives on Engaging People Who Use Drugs in Harm Reduction Services During the COVID-19 Pandemic

Elizabeth Austin^{*1}, Maria Corcorran¹, Madeline Frost², Elsa Briggs², Czarina Behrends³, Alexa Juarez¹, Noah Frank¹, Elise Healy¹, Stephanie Prohaska⁴, Paul LaKosky⁴, Shashi Kapadia⁵, David Perlman⁶, Bruce Schackman³, Don Des Jarlais⁷, Emily Williams², Sara Glick¹

¹University of Washington, ²University of Washington School of Public Health, ³Weill Cornell Medical College, ⁴Dave Purchase Project, North American Syringe Exchange Network, ⁵Weill Cornell Medical College, ⁶Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, ⁷New York University College of Global Public Health

T79. A Pilot Randomized Clinical Trial Examining Buspirone as an Adjunctive Medication During Buprenorphine-Assisted Supervised Opioid Withdrawal

Cecilia Bergeria^{*1}, Hongjun Tan², Denis Antoine¹, Elise Weerts¹, Andrew Huhn¹, J. Greg Hobelmann³, Kelly Dunn¹

¹Johns Hopkins University School of Medicine, ²Penn State University, ³Ashley Treatment Center

T80. A Randomized Controlled Trial of an Online Training to Reduce Primary Care Clinicians' Stigma Toward People With Opioid Use Disorder

Stephanie Hooker^{*1}, Lauren Crain¹, Amy LaFrance¹, Konadu Fokuo², Gavin Bart³, Rebecca Rossom¹

¹HealthPartners Institute, ²University of Illinois Chicago, ³University of Minnesota

T81. Analyzing Whether Social-Emotional Resources Attenuate the Relationship Between Adverse Childhood Experiences and Opioid Misuse Among Justice-Involved Adolescents

Tyre McDowell^{*1}, Chamanthi Konidala¹, Micah Johnson¹

¹University of South Florida

T82. Best Practices for Drug Testing During Medication for Opioid Use Disorder (MOUD) Treatment Over Telemedicine

Omeid Heidari^{*1}, Shoshana Aronowitz², Abigail Winiker¹, Sarah Pollock¹, Shereen Sodder¹, Karin Tobin¹

¹Johns Hopkins Bloomberg School of Public Health, ²University of Pennsylvania

T83. Buprenorphine Misuse in Opioid Use Disorders: Subgroups, Motivations, and Opioid Demand

Alexandra Goslow¹, Allison Tegge², Roberta Freitas-Lemos^{*3}, Devin Tomlinson³, William Craft³, Angela DeVeough-Geiss⁴, Howard Chilcoat⁴, Warren Bickel³

¹Virginia Tech Carilion School of Medicine, ²Virginia Tech Carilion Research Institute, ³Fralin Biomedical Research Institute at Virginia Tech Carilion, ⁴Indivior, Inc.

T84. Changes In Substance Use Behaviors Among Those Who Use Opioid Analgesics

Stevan Severtson^{*1}, Joshua Black¹, Janetta Iwanicki¹, Richard Dart²

¹Rocky Mountain Poison and Drug Safety, ²Rocky Mountain Poison and Drug Center

T85. City Streetscapes and Neighborhood Profiles of Fatal Opioid Overdoses Among Unstably-Housed People Who Use Drugs

Elizabeth Nesoff^{*1}, Douglas Wiebe¹, Silvia Martins²

¹Perelman School of Medicine University of Pennsylvania, ²Columbia University

T86. Enhancing Social Determinants of Health Among People With Opioid Use Disorder on Buprenorphine

Irene Pericot-Valverde^{*1}, Erik Ortiz², Ashely Coleman², Trisha Melling², Quang Pham², Marc Burrows³, Sherry Riggins², Carrie Baldwin², Michelle Bublitz², Jiajing Niu¹, Angelica Perez¹, Moonseong Heo¹, Alain Litwin¹

¹Clemson University, ²Prisma Health, ³Challenges Inc

T87. Experiences With Treatment for Opioid Use Disorder and Substance Use During the COVID-19 Pandemic Among People Who Use Opioids: A Web-Based Survey

Elizabeth Saunders^{*1}, Grace Janzow², Cassandra Harding², Lisa Marsch¹, Jacob Borodovsky¹, Zev Schuman-Olivier²

¹Geisel School of Medicine at Dartmouth, ²Cambridge Health Alliance

T88. Federal Policy Changes and Buprenorphine Treatment Capacity in the US: An Interrupted Time Series Analysis

Hannah Knudsen^{*1}

¹University of Kentucky

T89. Gabapentin Levels Impact on Successful Transition to Injectable Naltrexone

Michael Mancino^{*1}, Jeff Thostenson¹, Azizi Ray¹, Joseph Guise¹, Edward Nunes², Alison Oliveto¹

¹University of Arkansas for Medical Sciences, ²Columbia University and New York State Psychiatric Institute

T90. Impact of Telemedicine on Retention in Medications for Opioid Use Disorder (MOUD) Treatment With Buprenorphine in the Times of COVID-19 Pandemic: A Retrospective Chart Review

Jagdeep Kaur^{*1}, Irakli Mania², Raghavendra Tirupathi², Lakshmi Polavarapu³

¹University of California, Davis, ²Keystone Health Rural Center, ³Saddler Health Center

T91. Naloxone Provision and Overdose Prevention Education for Patients with Opioid Use Disorder in Four Urban Emergency Departments

Kathryn Hawk^{*1}, Marek Chawarski¹, Patrick O'Connor¹, E. Jennifer Edelman¹, Shara Martel¹, Patricia Owens¹, Edouard Coupet¹, Lauren Whiteside², Ethan Cowan³, Lynne Richardson³, Michael Lyons⁴, Caroline Freiermuth⁴, Richard Rothman⁵, David Fiellin¹, Gail D'Onofrio¹

¹Yale University School of Medicine, ²University of Washington, ³Icahn School of Medicine at Mount Sinai,

⁴University of Cincinnati, ⁵Johns Hopkins University School of Medicine

T92. *OPENing Hearts and Minds: Lessons Learned in the Implementation and Facilitation of a Weekly Online Opioid Use Disorder Educational Series*

John Lauckner¹, Michelle Lofwall², Laura Fanucchi³, Christopher Cook*¹, Sharon Walsh², Devin Oller³

¹University of Kentucky, Substance Use Priority Research Area, ²University of Kentucky, Center on Drug and Alcohol Research, ³University of Kentucky, College of Medicine

T93. *Opioid Knowledge Test: Identifying Knowledge Gaps Regarding Opioids Among College Students, Researchers, and Treatment Providers*

Frank Schwebel*¹, Margo Villarosa-Hurlocker², Matthew Pearson¹, Susan Baumgardner³, Jon Houck⁴, Addictions Research Team¹

¹Center on Alcohol, Substance Use and Addictions (CASAA), ²University of New Mexico, ³Colorado State University, ⁴Mind Research Network

T94. *Open Board*

T95. *Effects of Dimethylfumarate on Morphine Withdrawal Symptoms and In Vivo Neurochemistry in Morphine-Dependent Mice: A Behavioral and Proton Magnetic Resonance Spectroscopy Study*

Marc Kaufman*¹, Tao Song¹, Xiaopeng Song¹, Joseph Anderson¹, Edward Meloni², Fei Du¹, Carol Paronis²

¹McLean Hospital, Brain Imaging Center, ²McLean Hospital, Harvard Medical School

T96. *Analysis of Stimulant Prescriptions, Drug-Related Poisonings, and Treatment Retention Among Patients Receiving Buprenorphine for Opioid Use Disorder.*

Carrie Mintz*¹, Kevin Xu¹, Ned Presnall², Sarah Hartz¹, Frances Levin³, Jeffrey Scherrer⁴, Laura Bierut¹, Richard Gruzca⁴

¹Washington University School of Medicine, ²Washington University in St Louis, ³Columbia University Irving Medical Center/ New York State Psychiatric Institute, ⁴St. Louis University School of Medicine

T97. *Transcriptomic Hallmarks of Genetic Knockdown of the 5-HT_{2A} Receptor in Rat Medial Prefrontal Cortex: Implications for Understanding Psychedelic Actions*

Juliana Giacomini*¹, Christina Merritt², Jacqueline Silva², Dennis Sholler³, George Golovko², Jonathan Hommel², Noelle Anastasio², Kathryn Cunningham²

¹UTMB Center for Addiction Research, ²University of Texas Medical Branch, ³Johns Hopkins University School of Medicine

WEDNESDAY, JUNE 15, 2022

POSTER SESSION 4

W1. *Alterations in Diurnal Cortisol Related to Cannabis Use Disorder and Recent Marijuana Use: A Pilot in-Field, Within-Person Intensive Monitoring Study*

Stephanie Wemm*¹, Lucas Harrison¹, Marshall Tate¹, Rajita Sinha¹

¹Yale School of Medicine

W2. *Assessing the Utility of the Cannabis Use Disorder Identification Test - Revised (CUDIT-R) in a Sample of Medical and Non-Medical Cannabis Using Veterans*

Matthew Myers*¹, Dara Ganoczy², Kipling Bohnert³

¹Michigan State University College of Human Medicine, ²VA Government, ³University of Michigan and Department of Veterans Affairs

W3. Associations Between Maternal Prenatal Cannabis Exposure and Adolescent Cognitive Outcomes From the ABCD Study

Maria Poblete*¹, Stephanie Lake², Ziva Cooper³

¹Semel Institute for Neuroscience and Human Behavior at UCLA, ²University of California, Los Angeles,

³UCLA Cannabis Research Initiative

W4. Effect of COVID-19 on Cannabis Use and Motivation to Quit Among a Community Sample of Cannabis Users: A Time Series Analysis

Catherine Psaras*¹, Sarah Cousins¹, Joshua Hakimian¹, Maria Hanano¹, Yih-Ing Hser¹, Larissa Mooney¹

¹University of California, Los Angeles, David Geffen School of Medicine

W5. Exploring the Role of Female Gender Discrimination on Problematic Cannabis Use With Race as Moderator

Devin Whitt*¹, Tamika Zapolski¹

¹Indiana University- Purdue University Indianapolis

W6. Gender Differences in Cannabis Use Disorder Symptoms: A Network Analysis

Emese Kroon*¹, Alessandra Mansueto¹, Lauren Kuhns¹, Francesca Filbey², Reinout Wiers¹, Janna Cousijn³

¹University of Amsterdam, ²University of Texas at Dallas, ³Erasmus University Rotterdam

W7. Open Board

W8. Patterns of Tobacco and Cannabis Use in Australia: A Latent Class Analysis and Health-Related Correlates

Carmen Lim*¹, Janni Leung¹, Shannon Gravely², Coral Gartner³, Vivian Chiu¹, Tianze Sun¹, Jack Chung¹, Daniel Stjepanović¹, Jason Connor¹, Roman Scheurer⁴, Wayne Hall¹, Gary Chan¹

¹National Centre for Youth Substance Use Research, The University of Queensland, ²University of Waterloo,

³NHMRC Centre of Research Excellence on Achieving the Tobacco Endgame, The University of Queensland,

⁴Queensland Centre for Mental Health Research, The Park Centre for Mental Health Research

W9. Social Network Analysis of Young Adults' Cannabis Use Before and During the COVID-19 Pandemic

Graham DiGuseppi*¹, Ekaterina Fedorova², Stephen Lankenau², Jordan Davis¹, Bridgid Conn³, Carolyn Wong⁴

¹University of Southern California, ²Drexel University, Dornsife School of Public Health, ³Children's Hospital

Los Angeles, ⁴Children's Hospital Los Angeles and University of Southern California

W10. The Association Between Workplace Drug Use Policies and Current Drug Use Among Low-Income Workers: Findings From the National Survey on Drug Use and Health

Rachel Hoopsick*¹, Jaqueline Carrillo¹, Michael Knipp¹, Gregory Homish²

¹University of Illinois Urbana-Champaign, ²State University of New York at Buffalo

W11. The Association Between Cannabis Use Disorder and Co-Occurring Anxiety and Depression

Sarah Cousins*¹, Yuhui Zhu², Huiying Guo², Joshua Hakimian², Tram Nguyen², Maria Hanano², Yih-Ing Hser², Larissa Mooney²

¹Semel Institute for Neuroscience and Human Behavior at UCLA, ²David Geffen School of Medicine, University of California, Los Angeles

W12. The Lateral Habenula: A Critical Crossroad for the Brain's Negative and Positive Valence Systems

Kristen Platt*¹, Francesca Filbey¹

¹The University of Texas at Dallas

W13. Age Differences in Patterns of Cannabis and Other Drug Use Within a Cohort of Medical Cannabis Patients in Pennsylvania

Ekaterina Fedorova¹, Janna Ataiants¹, Allison Mitchell¹, Stephen Lankenau*¹

¹Drexel University Dornsife School of Public Health

W14. An Exploration of Multivariate Symptom Clusters of Cannabis Use Disorder in Young Adults

Lindy Howe*¹, Allen Bailey¹, Polly Ingram¹, Peter Finn¹

¹Indiana University

W15. Cannabis Practices of Gender Minority and Cisgender Young Adults Recruited Through Social Media

Cara Struble*¹, Jacob Borodovsky¹, Mohammad Habib², Deborah Hasin³, Ofir Livne⁴, Claire Walsh⁵, Efrat Aharonovich⁵, Dvora Shmulewitz³, Alan Budney¹

¹Geisel School of Medicine at Dartmouth, ²Dartmouth College, ³Columbia University, ⁴Columbia University Mailman School of Public Health, ⁵Columbia University and New York State Psychiatric Institute

W16. Chronic Relief: Exploring the Use and Impact of Cannabis in the Setting of Chronic Pain Among Black American Pain Patients in Los Angeles

Dilara Üsküp*¹, Jazzlyne Hudson²

¹Semel Institute for Neuroscience and Human Behavior at UCLA, ²University of California, Los Angeles

W17. Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use in Reducing Family Members' Distress: Preliminary Assessment of Efficacy

Mary Grace Shinnors¹, Eleanor Sultana¹, Andrea Wood¹, Roger Weiss², Dost Öngür², Kim Mueser³, James Hudson², Julie McCarthy*²

¹McLean Hospital, ²McLean Hospital, Harvard Medical School, ³Boston University

W18. Empirically Derived Patterns of Motivation, Readiness, and Confidence to Stop or Reduce Cannabis Use Among Treatment-Interested Adolescents and Emerging Adults

Kathryn Gex*¹, Kyle Walters¹, Rachel Tomko¹, Kevin Gray¹

¹Medical University of South Carolina

W19. Exploring Trajectories of Days of Cannabis Use Among Young Adults: A Novel Mixed Methods Study

Stephen Lankenau*¹, Ekaterina Fedorova¹, Janna Ataiants¹, Bridgid Conn², Carolyn Wong³

¹Drexel University Dornsife School of Public Health, ²Children's Hospital Los Angeles, ³Children's Hospital Los Angeles and University of Southern California

W20. Longitudinal Examination of Obsessive Passion for Cannabis Use Among College Undergraduate Students

Yitong Xin*¹, Brooke Arterberry², Corrine M. Schwarting², Stacey B. Armstrong¹, Erin Bonar³, Alan K. Davis¹

¹The Ohio State University, ²Iowa State University, ³University of Michigan

W21. Pharmacokinetic and Pharmacodynamic Effects of Hemp-Derived Topical Cannabidiol (CBD) Products

Tory Spindle*¹, Hayleigh Tilton¹, Spencer Lin¹, Edward Cone¹, Ruth Winecker², Eric Welsh³, Lynn Wagner³, Ron Flegel⁴, Ryan Vandrey¹

¹Johns Hopkins University School of Medicine, ²RTI International, ³Department of Defense, ⁴Substance Abuse and Mental Health Services Administration

W22. The Effects of Stress and Cues on Craving for Cannabis

Leslie Lundahl*¹, Mark Greenwald¹

¹Wayne State University School of Medicine

W23. Use of Pain Medication and Cannabis by Age Groups Before and After Legalization of Cannabis: An Investigation of Trends From 2017 to 2019 in a Representative Sample of Canada

Karina Thiessen*¹, Karling R. Luciani¹, Thomas Wen-Chi Chao¹, Christian Schütz¹

¹University of British Columbia

W24. Anxiety in a Placebo-Controlled Pharmacotherapy Trial for Adolescent Cannabis Use Disorder

Daniel Hashemi*¹, Nathaniel Baker¹, Rachel Tomko¹, Kevin Gray¹

¹Medical University of South Carolina

W25. Assessing Cannabis Use Disorder in Primary Care: Psychometric Performance of a Substance Use Symptom Checklist

Theresa Matson*¹, Kevin Hallgren², Malia Oliver¹, Gwen Lapham¹, Emily Williams³, Katharine Bradley¹

¹Kaiser Permanente Washington Health Research Institute, ²University of Washington, ³Veterans Affairs Puget Sound Health Services Research and Development

W26. Delta-8 THC Use in US Adults: Sociodemographic Characteristics and Correlates

Ofir Livne*¹, Alan Budney², Jacob Borodovsky², Claire Walsh³, Dvora Shmulewitz⁴, David Fink³, Cara Struble⁵, Mohammad Habib⁶, Efrat Aharonovich⁷, Deborah Hasin⁴

¹Columbia University Mailman School of Public Health, ²Geisel School of Medicine at Dartmouth, ³New York State Psychiatric Institute, ⁴Columbia University, ⁵Dartmouth Medical School, ⁶Dartmouth College, ⁷Columbia University and New York State Psychiatric Institute

W27. Marijuana Craving as a Predictor of Subjective Marijuana Effects

Ciara Cannoy*¹, Mark Greenwald¹, Leslie Lundahl²

¹Wayne State University, ²Wayne State University School of Medicine

W28. Mental Health and Life Events in Adolescents With Substance Use Disorders in the United States

Ryan Sultan*¹, Frances Levin², Alex Zhang³

¹Columbia University, College of Physicians and Surgeons, ²Columbia University Irving Medical Center/ New York State Psychiatric Institute, ³Columbia University

W29. Natural Reward Processing in Adults With Cannabis Use Disorder

Brian Sherman*¹, Zoe Brasher², Aimee McRae-Clark¹, Brett Froeliger³

¹Medical University of South Carolina, ²University of California, Los Angeles, ³University of Missouri

W30. Patterns of Substance Use and Mental Health Profiles Among Pregnant Women

Mary Mitchell*¹, Mishka Terplan¹, Jennifer Brooks¹, George Akinwolere¹, Katrina Mark²

¹Friends Research Institute, ²University of Maryland School of Medicine

W31. Population Patterns Linking Adolescent Risk-Taking and Substance Use

Brenden Tervo-Clemmens*¹, Zuena Karim², Sehyr Khan³, Randi Schuster¹, Jodi Gilman¹, Anne Eden Evins¹

¹Harvard Medical School, Massachusetts General Hospital, ²University of Texas at Austin, ³Wellesley College

W32. The Reddit Cannabis Subjective Highness Scale: Applying Natural Language Processing to Inform Cannabis Use Measurement

Meredith Meacham^{*1}, Michael Gilbert², Alicia Nobles³, Johannes Thru⁴

¹University of California San Francisco, ²Independent, ³University of California San Diego, ⁴Johns Hopkins Bloomberg School of Public Health

W33. Validity of DSM-5 Cannabis Use Disorder Severity Levels in Adults With Problematic Substance Use

David Fink^{*1}, Dvora Shmulewitz¹, Malki Stohl¹, Zachery Mannes², Melanie Wall³, Deborah Hasin²

¹New York State Psychiatric Institute, ²Columbia University, ³Columbia University and NYSPI

W34. Cannabinoids in Plasma by LC-MS/MS: Application to Specimens From Youths With HIV

Cynthia Coulter¹, Christine 9-Delta Analytical LLC^{*1}, Bernard Fischer², Guglielmo Venturi², Maureen Goodenow³, John Sleasman²

¹9-Delta Analytical LLC, ²Duke University, ³maureen.goodenow@nih.gov

W35. Cannabis Predictors of Neurocognitive Outcomes in Adolescents and Young Adults After 3-Week Abstinence Period

Elizabeth Stinson^{*1}, Julia Harris¹, Krista Lisdahl¹

¹University of Wisconsin-Milwaukee

W36. Chronic Oral Dosing of Cannabidiol (CBD) With And Without Low Doses Of Delta-9-Tetrahydrocannabinol (THC)

David Wolinsky^{*1}, Austin Zamarripa¹, Tory Spindle¹, Edward Cone¹, Ruth Winecker², Ron Flegel³, David Kuntz⁴, Ryan Vandrey¹

¹Johns Hopkins University School of Medicine, ²RTI International, ³Substance Abuse and Mental Health Services Administration, ⁴Clinical Reference Laboratory

W37. Health Conditions as Predictors of Longitudinal Groups of Medicinal Cannabis Use During the Legalization of Recreational Cannabis in Los Angeles

Janna Ataiants^{*1}, Carolyn Wong², Bridgid Conn², Ekaterina Fedorova¹, Omolola Odejimi², Stephen Lankenau¹

¹Drexel University Dornsife School of Public Health, ²Children's Hospital Los Angeles and University of Southern California

W38. Impaired Behavioral Insight During a Probabilistic Drug Vs. Non-Drug Reinforcer Choice Task in Severe Cannabis Use Disorder: Associations With Cannabis-Related Problem Awareness and Motivation to Change

Brandon Schermitzler^{*1}, Scott Moeller², Stephanie Wemm³, Richard Macatee¹

¹Auburn University, ²Stony Brook University School of Medicine, ³Yale School of Medicine

W39. Medical Cannabis Use During Peri- And Postmenopause: A Survey Study

Mary Dahlgren^{*1}, Celine El-Abboud¹, Kelly Sagar¹, Rosemary Smith², Ashley Lambros², Staci Gruber¹

¹McLean Hospital, Harvard Medical School, ²McLean Hospital

W40. Perceptions About Prenatal Cannabis Use in Postpartum Women With and Without a Personal History of Cannabis Use

Anna Wiese^{*1}, Nancy Jallo¹, Lisa Brown¹, Judy Chang², Nicole Karjane¹, Carl Wolf¹, Robert Balster¹, Divya Sharma¹, Enkelejda Ngjelina¹, Dace Svikis¹

¹Virginia Commonwealth University, ²University of Pittsburgh

W41. Open Board

W42. The Estimated Effect of Prenatal Cannabis Exposure on Neonatal Birth Outcomes

Alyssa Vanderziel*¹, James Anthony¹, Omayma Alshaarawy²

¹Michigan State University, ²Michigan State University College of Human Medicine

W43. Open Board

W44. Optimism Bias for Drug and Nondrug-Related Life Events in People With Opioid Use Disorder

Emmanuel Alvarez*¹, Julia Kong², Sahar Hafezi², Darla Bonagura², Anna Konova²

¹Rutgers Robert Wood Johnson Medical School, ²UBHC, and Brain Health Institute, Rutgers University – New Brunswick

W45. Open Board

W46. Patient Perspectives on the Intersection of Social Relationships, Medication for Opioid Use Disorder, and the Criminal Justice System

Lynn Madden*¹, Ruthanne Marcus², Kim Hoffman³, Marina Gaeta², Mark Beitel², Anthony Eller², Lindsay Oberleitner⁴, David Oberleitner⁵, Declan Barry⁶

¹APT Foundation, ²Yale Medical School, ³Oregon Health Sciences University, ⁴Oakland University William Beaumont School of Medicine, ⁵University of Bridgeport, ⁶Yale Medical School; APT Foundation

W47. Post-Traumatic Stress Symptoms After Childbirth Among Women in Outpatient Treatment for Opioid Use Disorder

Michelle Eglovitch*¹, Anna Beth Parlier-Ahmad¹, Allison Williams¹, Dace Svikis¹, Caitlin Martin¹

¹Virginia Commonwealth University

W48. Prescription Drug Monitoring Programs and Opioid-Related Arrests in the United States: Associations With Law Enforcement Agency Data Access and Operation in 1990-2016

Erin Annunziato*¹, Silvia Martins¹, Pia Mauro¹

¹Columbia University

W49. Racial Differences in the Impact of Trauma on Opioid Misuse Among Justice-Involved Adolescents

Ohemaa Peprah-Asante*¹, Gina Micciche¹, Micah Johnson¹

¹University of South Florida

W50. Remifentanyl Dose Ranging in Individuals With Physical Opioid Dependence and Opioid Use Disorder

Joshua Lile*¹, Joseph Alcorn¹, Shanna Babalonis¹, Kevin Hatton¹, Hays Lon¹, Abner Rayapati¹, Craig Rush¹, William Stoops¹, Michael Wesley¹

¹University of Kentucky, College of Medicine

W51. Responding to a Surge in Overdose Deaths: Perspectives From U.S. Syringe Services Programs

Madeline Frost*¹, Elizabeth Austin¹, Maria Corcoran², Elsa Briggs¹, Czarina Behrends³, Alexa Juarez², Noah Frank², Elise Healy², Stephanie Prohaska⁴, Paul LaKosky⁴, Shashi Kapadia³, David Perlman⁵, Bruce Schackman³, Don Des Jarlais⁶, Emily Williams¹, Sara Glick²

¹University of Washington School of Public Health, ²University of Washington, ³Weill Cornell Medical College, ⁴Dave Purchase Project, North American Syringe Exchange Network, ⁵Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, ⁶New York University, School of Global Public Health

W52. Resumption of Methadone Following Release From Incarceration Delays Reincarceration for Any Cause in Men Eligible to Continue Methadone Treatment in Connecticut Jails

Phil Marotta*¹, Adam Viera², Alissa Haas³, Laretta Grau², Robert Heimer²

¹Washington University in St. Louis, ²Yale University, ³University of Indiana Bloomington

W53. Retention on Treatment and Mortality of Opioid Use Disorder Patients After Methadone Take-Home Dosing Policy Change During COVID-19 Pandemic in Ukraine

Roman Ivasiy*¹, Samy Galvez¹, Lynn Madden³, Scott Farnum², Daniel J. Bromberg³, Iryna Pykalo⁴, Anna Meteliuk⁵, Zahedul Islam⁵, Frederick Altice¹

¹Yale University School of Medicine, ²APT Foundation, Inc., ³Yale School of Public Health, ⁴European Institute for Public Health Policy, ⁵Alliance for Public Health of Ukraine

W54. Risky Alcohol Use Among Patients Dispensed Opioid Medications: A Clinical Community Pharmacy Study

Gerald Cochran*¹, Elizabeth Charron¹, Jennifer Brown², Alina Cernasev³, Kenneth Hohmeier³, T. Winhusen²

¹University of Utah, ²University of Cincinnati, ³University of Tennessee

W55. Substance Use Patterns and Self-Ascribed Masculinity/Femininity Among Incarcerated Women With a Recent History of Opioid Misuse

Martha Tillson*¹, Matt Webster¹, Carrie Oser¹, Michele Staton²

¹University of Kentucky, ²University of Kentucky, College of Medicine

W56. The Association Between Exercise and Opioid Misuse: A Systematic Review

Whitney Cordoba-Grueso*¹, Paola Matthey-Mora¹, Maria Parker¹

¹Indiana University

W57. The Association Between Physical Therapist Advanced Orthopaedic Certification and Their Attitudes About Prescription Opioid Medication Misuse Management Practices: A Cross-Sectional Study

John Magel*¹, Mark Bishop², Gerald Cochran¹, Julie Fritz¹, Elaine Lonnemann³, Adam Gordon⁴

¹University of Utah, ²University of Florida, ³University of St. Augustine, ⁴University of Utah SoM and VASLCHCS

W58. Training, Development, and Implementation of Novel Peer Support Led Programs for Persons With Opioid Use Disorder (OUD)

Molly Gallivan*¹, Anna Ross², Amanda Fallin-Bennett³, Devin Oller⁴, Laura Fanucchi⁴, Christopher Cook¹, John Lauckner¹, Phoebe Wheeler-Crum², Shelley Elswick², Sharon Walsh⁵, Michelle Lofwall⁵

¹University of Kentucky, Substance Use Priority Research Area, ²Voices of Hope, ³University of Kentucky, College of Nursing; Voices of Hope, ⁴University of Kentucky, ⁵University of Kentucky, Center on Drug and Alcohol Research

W59. Open Board

W60. When Everyone's a Critic: How Social Factors Impact Individuals With Opioid Use Disorder and Influence Treatment Engagement

Emma Schweitzer*¹, Adelya Urmanche², Joshua Zhao³, Julia Kong⁴, Sahar Hafezi⁴, Anna Konova⁴

¹Rutgers University, ²Derner School of Psychology, Adelphi University, ³UBHC, Robert Wood Johnson Medical School, ⁴UBHC, and Brain Health Institute, Rutgers University – New Brunswick

W61. Open Board

W62. "I'm Clean And Sober, But Not Necessarily Free:" Motivations To Discontinue Treatment Among Patients On Long-Term Buprenorphine

Jessica Wyse^{*1}, Travis Lovejoy², Adam Gordon³, Katherine Mackey², Ben Morasco²

¹Oregon Health and Science University, ²VA Portland Health Care System, ³University of Utah SoM and VASLCHCS

W63. A Comparison of Treatment Outcomes Between Women Receiving and Not Receiving Medication for Opioid Use Disorder From a RCT of CBT4CBT for Women in Residential Treatment

Anna Parlier-Ahmad^{*1}, Sydney Kelpin², Caitlin Martin¹, Dace Svikis¹

¹Virginia Commonwealth University, ²Mayo Clinic

W64. A Novel Telehealth Model for Improved Retention in Opioid Use Disorder Treatment

Arthur Robin Williams^{*1}, Shosana Aronowitz², Ryan Gallagher³, Emily Behar³, Zack Gray³, Adam Bisaga¹

¹Columbia University, ²University of Pennsylvania School of Nursing, ³Ophelia Health

W65. Addressing Barriers to Buprenorphine Treatment Among People Experiencing Homelessness: The Provider Perspective

Emily A. Levine^{*1}, Kelly R. Knight², Leslie W. Suen³, Joseph A. Spillane¹, Maggie M. Chen¹, Ya Chi Angelina Liang¹, Carmen L. Masson¹

¹University of California, San Francisco, ²University of California, San Francisco and Center for Vulnerable Populations, ³University of California, San Francisco and San Francisco Veterans Affairs Medical Center

W66. COVID-Related Distress, Coping Motives, and Substance Use Among Women With a History of Sexual Assault During the COVID-19 Pandemic

Tosca Braun^{*1}, Wendee Wechsberg², Ana Abrantes¹

¹Butler Hospital, Alpert Medical School of Brown University, ²RTI International

W67. Characteristics Associated With Opioid Misuse Among At-Risk Adolescents

Oluchi Nwankwo^{*1}, Ethan Kusiak¹, Micah Johnson¹

¹University of South Florida

W68. Circumstances and Correlates of Providing Assistance With Someone's First Injection in the AIDS Linked to the Intravenous Experience Cohort, Baltimore, MD

Rachel Gicquelais^{*1}, Jacquie Astemborski², Dan Werb³, Elizabeth Collins¹, Gregory Kirk², Shruti H Mehta², Becky Genberg²

¹University of Wisconsin - Madison, ²Johns Hopkins Bloomberg School of Public Health, ³University of California, San Diego

W69. Contraceptive Use and Substance Use Disorder Treatment Utilization by Reproductive-Age Women Who Use Drugs in Rural Communities in the United States: A Cross-Sectional Survey

Ximena Levander^{*1}, Canyon Foot¹, Sara Magnusson², Ryan Cook¹, Jerel Ezell³, Judith Feinberg⁴, Vivian F. Go⁵, Kathryn Lancaster⁶, Elizabeth Salisbury-Afshar⁷, Gordon Smith⁴, Ryan Westergaard⁷, April Young⁸, Judith Tsui⁹, P. Todd Korthuis¹

¹Oregon Health and Science University, ²Comagine Health, Research and Evaluation, ³Cornell University, ⁴West Virginia University, ⁵Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, ⁶Ohio State University, ⁷University of Wisconsin - Madison, ⁸University of Kentucky, College of Public Health, ⁹University of Washington

W70. Creation of a Simple Microsimulation Model for Assessing the Impact of Treatment on Opioid Misuse in North Carolina

Kasey Jones*¹, Georgiy Bobashev¹

¹RTI International

W71. Developing a Core Outcomes Set (COS-OUD) for Opioid Use Disorder (OUD)-Related Research

Dikla Blumberg¹, Niranjan Karnik*², Kathryn Hefner³, John Marsden⁴

¹The Emmes Company, ²Rush Medical College of Rush University, ³Emmes Data and Statistics Center, NIDA CTN, ⁴Institute of Psychiatry, Psychology and Neuroscience, King's College London

W72. Developing an Integrated Behavioral Treatment for Women With Opioid Use Disorder and Posttraumatic Stress Disorder: Patient and Provider Perspectives

Tanya Saraiya*¹, Kathleen Brady¹, Sudie Back¹

¹Medical University of South Carolina

W73. Effects of Adjunct Gabapentin on Treatment Outcomes During an Outpatient Buprenorphine Taper

Azizi Ray*¹, Jeff Thostenson¹, Joseph Guise¹, Edward Nunes², Michael Mancino¹, Alison Oliveto¹

¹University of Arkansas for Medical Sciences, ²Columbia University and New York State Psychiatric Institute

W74. Examination of Sociodemographic Trends in Opioid Overdose Emergency Department Visits in Diverse Counties in New York State, 2010-2019

Navin Sanichar*¹, Sharifa Z. Williams², Helen-Maria Lekas², Shannon M. Monnat³, Dessa K. Bergen-Cico⁴, Natalie Crawford⁵, Crystal Fuller Lewis²

¹Nathan S. Kline Institute, ²Center for Research on Cultural and Structural Equity in Behavioral Health, Nathan S. Kline Institute for Psychiatric Research, ³Lerner Center for Public Health Promotion, Syracuse University, ⁴Syracuse University, ⁵Rollins School of Public Health, Emory University

W75. Examining Gender Differences in the Relationship Between Social Bonds and Opioid Misuse Treatment Completion Among Justice-Involved Adolescents

Enya Vroom*¹, Zahra Akbari², Skye Bristol², Elzbieta Wiedbusch², James-Angelo Suarez², Micah Johnson²

¹University of Florida, ²University of South Florida

W76. Feasibility and Acceptability of Harm Reduction Vending Machines in Philadelphia

Emily Loscalzo*¹, Linden Lalley-Chareczko¹, Rachel French², Nicholas Cardamone², Ali Tarhini³, Winna Mowenn⁴, Rebecca Stewart²

¹Philadelphia FIGHT Community Health Centers, ²University of Pennsylvania, ³Thomas Jefferson University, ⁴La Salle University

W77. HEALing Transitions: Training and Development of Opioid Use Disorder (OUD) Linkage and Retention Nurse/Social Work Care Navigator Programs

Christopher Cook*¹, Michelle Lofwall², Sharon Walsh², Katrina Nickels³, Jamie Cody⁴, Laura Fanucchi²

¹University of Kentucky, Substance Use Priority Research Area, ²University of Kentucky, Center on Drug and Alcohol Research, ³University of Kentucky, ⁴Bluegrass Care Navigators

W78. Houselessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT

Marissa Justen*¹, Jennifer Scodes², Martina Pavlicova³, Tse-Hwei Choo⁴, Manesh Gopaldas⁵, Angela Haeny¹, Onumara Opara⁵, Taeho Greg Rhee⁶, John Rotrosen⁷, Edward Nunes², Kathryn Hawk⁸, E. Jennifer Edelman¹
¹Yale University School of Medicine, ²Columbia University and NYSPI, ³Columbia University, ⁴Columbia University Mailman School of Public Health, ⁵New York State Psychiatric Institute, ⁶University of Connecticut School of Medicine, ⁷New York University School of Medicine, ⁸Yale University

W79. Incubation of Conditioned Opioid Withdrawal Avoidance in Methadone-Dependent Male and Female Rats

Jonathan Chow*¹, Jules M. Chabot¹, Rutsuko Ito², Yavin Shaham¹
¹IRP/NIDA/NIH, ²University of Toronto

W80. Monovalent and Bivalent Vaccination Strategies to Protect Against Deliberate and Accidental Exposure to Carfentanil and Mixtures of Carfentanil and Fentanyl in Rats

Bethany Crouse*¹, Mariah Wu², Valeria Gradinati¹, Andrew Kassick³, Daihyun Song², Saadyah Averick⁴, Scott Runyon⁵, Sandra Comer⁶, Marco Pravetoni¹
¹University of Minnesota Medical School, ²University of Minnesota, ³Allegheny-Singer Research Institute Center for Neurosciences Research, ⁴AHN, ⁵RTI International, ⁶Columbia University and NYSPI

W81. Open Label Trial of Lofexidine-Assisted Non-Opioid Induction Onto Naltrexone Extended-Release Injection for Opioid Use Disorder

John Mariani*¹, Cale Basaraba², Martina Pavlicova³, Daniel Alschuler², Daniel Brooks², Amy L. Mahony², Christina Brezing¹, Nasir Naqvi³, Frances Levin⁴
¹Columbia University and New York Psychiatric Institute, ²NYSPI, ³Columbia University, ⁴Columbia University Irving Medical Center/ New York State Psychiatric Institute

W82. Opioid Use Disorder (OUD) and Treatment for Opioid Problems Among OUD Symptom Subtypes

Emily Miller*¹, Angela DeVeauugh-Geiss², Howard Chilcoat²
¹Virginia Commonwealth University, ²Indivior, Inc.

W83. Overdose Fatalities in Maryland Jurisdictions and Implementation of Overdose Prevention Strategies

Catherine Tomko*¹, Saba Rouhani¹, Ryoko Susukida¹, Himani Byregowda¹, Taylor Parnham¹, Masoumeh Amin-Esmaeili¹, Kristin Schneider¹, Lyra Cooper¹, Marianne Gibson², Ju Nyeong Park³, Teresa Heath², Robin Rickard², Christine Boyd⁴, Renee Johnson¹
¹Johns Hopkins Bloomberg School of Public Health, ²Opioid Operational Command Center, Maryland Department of Health, ³Alpert Medical School, Brown University, ⁴Maryland Department of Health

W84. Pain in Recovery From Opioid Use Disorder: The Importance of Acute and Chronic Pain

William Craft*¹, Allison Tegge¹, Anne Le Moigne², Angela DeVeauugh-Geiss², Howard Chilcoat², Warren Bickel¹
¹Fralin Biomedical Research Institute at Virginia Tech Carilion, ²Indivior, Inc.

W85. Preclinical Profiling of the Ampakine HJC0122 as a Novel Therapeutic for Opioid Use Disorder

Ashley Smith*¹, Jimin Xu¹, Kathryn Cunningham¹, Jia Zhou¹, Noelle Anastasio¹
¹University of Texas Medical Branch

W86. Retail Pharmacy Naloxone Distribution and Overdose Mortality in Rhode Island, Massachusetts, and New York City, 2016-2018

Jake Morgan*¹, Christina Freibott², Ali Jalali³, Philip Jeng³, Alexander Walley¹, Avik Chatterjee¹, Traci Green⁴, Michelle Nolan⁵, Benjamin Linas¹, Brandon Marshall⁶, Sean Murphy³

¹Boston University School of Medicine, ²Boston University School of Public Health, ³Weill Cornell Medical College, ⁴Heller School for Social Policy and Management, Brandeis University, ⁵Columbia University Mailman School of Public Health, ⁶Brown University School of Public Health

W87. Self-Management Strategies and Utilization of Medications for Opioid Use Disorder: A Qualitative Systematic Review

Scott Farnum*¹, Declan Barry², Erica Cannata¹, Lynn Madden¹

¹APT Foundation, Inc., ²Yale University School of Medicine

W88. Sleep Architecture of OUD Patients: A Comparison of Watchpat 300 and NPSG

Vartika Parashar*¹, Mohammad Sibai², Gail Koshorek², Josh Smith², Mark Greenwald³, Timothy Roehrs²

¹Henry Ford Hospital, ²Henry Ford Health System, ³Wayne State University

W89. Telehealth Visits Support Buprenorphine Induction During the Covid-19 Pandemic

Lindsey Hammerslag*¹, Svetla Slavova¹, Philip Westgate¹, Michelle Lofwall², Patricia Freeman¹, Jeffery Talbert³

¹University of Kentucky, ²University of Kentucky, College of Medicine, ³University of Kentucky College of Pharmacy

W90. The Heroin Hug: Opioids Acutely Produce Feelings of Being Secure and Loved

Nina Christie*¹, John Monterosso¹

¹University of Southern California

W91. The Path Home Trial: A Comparative Effectiveness Study of Optimal Intervention Strategies for Perinatal Opioid Use Disorder in Rural Kentucky

Hilary Surratt*¹, Karen Fawcett¹, Jason Joy¹, Sara Kuhl¹, Hayley Powell¹, Brandon Schanbacher¹, John Bauer¹, Arnold Stromberg¹, Wendy Hansen¹

¹University of Kentucky

W92. The Relationship Between Resilience Phenotypes and Psychological Functioning in Individuals With Opioid Use Disorder

Suky Martinez*¹, Albert Garcia-Romeu², Freymon Perez¹, Jermaine Jones³

¹Columbia University Vagelos College of Physicians and Surgeons, ²Johns Hopkins University School of Medicine, ³Columbia University Irving Medical Center

W93. Trends in Opioid and Stimulant Treatment Admissions and Overdose Mortality in American Rural and Urban Areas

Huyen Pham*¹, Yuhui Zhu¹, Larissa Mooney², Yih-Ing Hser²

¹Semel Institute - UCLA, ²David Geffen School of Medicine, University of California, Los Angeles

W94. Two Novel Classes of Opioid Analogs: Discriminative Stimulus and Antinociceptive Effects

Michael Gatch*¹

¹University of North Texas Health Science Center

W95. What is Success in Treatment for Opioid Use Disorder? Perspectives of Physicians and Patients in Primary Care Settings

Robert Levy*¹, Tanner Nissly¹, Mary Lonergan-Cullum¹, Stephanie Hooker²
¹University of Minnesota, Medical School at Minneapolis, ²Health Partners

W96. "I Feel Like I'm Floating in Limbo": Understanding the Impacts of the COVID-19 Pandemic on Persons Who Use Illicit Opioids in Arizona

Kaylin Sweeney*¹, Seol Ki¹, Natasha Mendoza¹, Raminta Daniulaityte¹
¹Arizona State University

W97. Kratom Use Among Pregnant and Postpartum Individuals With Substance Use Disorders

Justin Bowman¹, Miao Lai¹, Jasmin Charles², Adam Gordon², Marcela Smid*²
¹University of Utah School of Medicine, ²University of Utah Health

W98. Umbilical Cord Homogenate Assay to Estimate Prenatal Kratom Exposure

Marcela Smid¹, Joseph Worden*², Gerald Cochran³, Melissa Hughs⁴, Aidin O'Brien⁴, Gwendolyn McMillin⁴
¹University of Utah Health, ²University of Utah School of Medicine, ³University of Utah, ⁴ARUP Lab

W99. The Controlled Substances Act Regulations on Schedule I Researcher Registrations and the Need to Investigate New Substances of Abuse

Theresa Carbonaro*¹, Srihari Tella², Terry Boos²
¹Drug Enforcement Administration, ²The United States Department of Justice

W100. Drug Overdose Deaths in the United States and Brazil Between 2000 and 2018: A Comparison Analysis of Sociodemographics and Intentionality

Marina Bianco¹, Vitor Tardelli², Emily Brooks³, Kelsy Areco¹, Adalberto Tardelli¹, Paulo Bandiera-Paiva¹, Luis Segura³, João Castaldelli-Maia⁴, Silvia Martins⁵, Thiago Fidalgo*¹
¹Universidade Federal de São Paulo, ²Universidade Federal de São Paulo/Centre for Addiction and Mental Health - University of Toronto, ³Columbia University Mailman School of Public Health, ⁴Medical School, University of São Paulo, ⁵Columbia University

DIGITAL POSTER PRESENTATIONS

Evaluating Loneliness and Binge Drinking Through a COVID-19 Follow-Up Survey Among Women in a Community Engagement Program in North Central Florida

Alyssa Berger*¹, Linda Cottler¹
¹University of Florida

Reproductive History and Outcomes in the Young Women Arrested for Methamphetamine Use in Taiwan

Chuan-Yu Chen*¹, I-An Wang², Rosetta Siew¹, An-Jou Chen¹
¹National Yang Ming Chiao Tung University, ²Center of Neuropsychiatric Research, National Health Research Institutes

A Spatial Science Approach to Inform Delivery of a Smartphone-Based Smoking Cessation Intervention

Amanda Luken*¹, Michael Desjardins¹, Johannes Thrul¹
¹Johns Hopkins Bloomberg School of Public Health

Building Organizational Capacity and Expertise to Treat Tobacco Dependence Within Behavioral Health Treatment Centers: A Qualitative Study of “Champion” Trainees’ Perspectives of a Train-The-Trainer Program

Isabel Martinez Leal*¹, Jayda Martinez¹, Virmarie Correa-Fernandez¹, Maggie Britton¹, Tzuan Chen¹, Vijay Nitturi¹, Kelli Drenner¹, Bryce Kyburz², Teresa Williams², Kathleen Casey², Marcel de Dios¹, Ezemenari Obasi¹, Lorraine Reitzel¹

¹University of Houston, ²Integral Care

Development and Process Evaluation of an Educational Intervention to Support Primary Care Based Sparing of Opioid Analgesics for Pain From New or Ongoing Non-Cancer Causes Among Opioid Naïve Patients

Shawna Narayan¹, Stefania Rizzardo², Ian Cooper³, Michee Ana Hamilton¹, Malcolm Maclure¹, Rita McCracken¹, Jan Klimas*¹

¹University of British Columbia, ²Ryerson University, ³University of Alberta

Leveraging SARS-CoV-2 Vaccination Efforts Through Latino MSM Drug Use and Sexual Networks

Mariano Kanamori*¹, Alfonso Yepes¹, Edda Rodriguez¹, Ariana Johnson¹, Cho-Hee Shrader², Kyle Self¹, Lacey Cracker¹, Nonie Kalra¹, Stephen Fallon³, Steven Safren⁴, John Skvoretz⁵

¹Miller School of Medicine, University of Miami, ²ICAP at Columbia University, ³Latinos Salud, ⁴University of Miami, ⁵University of Central Florida

AUTHOR INDEX

Acheson, Liam	52	Black, Joshua	63
Acri, Jane	27	Bluthenthal, Ricky	80
Adan, Fatumastar	71	Boggis, Jesse	60
Addicott, Merideth	61	Bonner, Courtney	22, 50
Akbari, Zahra	63	Brandt, Laura	17, 78
al'Absi, Mustafa	34	Braun, Tosca	89
Alexander, Karen	68	Bristol, Skye	49
Alexandre, Jean-Marc	74	Brown, Kanila	63
Allen, Alicia	65	Brown, Randall	66
Allen, Diamond	65	Browne, Felicia	21, 22
Alshaarawy, Omayma	24	Browne, Thom	39
Alvarez, Emmanuel	87	Burduli, Ekaterina	45, 46
Ana, Elizabeth Santa	24	Burlew, A. Kathleen	20
Angelone, Leonardo	26, 31	Burwell, Scott	31, 70
Annunziato, Erin	87	Bushnell, Greta	47
Ansell, Emily	43	Butler, Devin	38
Antoine, Denis	29	Buttram, Mance	25
Aponte-Melendez, Yesenia	76	Byrne, Kaileigh	31, 32
Appel, Nathan	27	Cadet, Techna	66
Apsley, Hannah	72	Cain, Gloria	20
Aquino, Joao De	60	Cannoy, Ciara	85
Arnold, Rachel	75	Carbonaro, Theresa	93
Aronson, Ian	71	Carney, Tara	22
Ashrafioun, Lisham	68	Caro, Yohanka	51
Ataiaants, Janna	86	Carpenter, Kenneth	39
Athamneh, Liqa	73	Carreiro, Stephanie	31, 70
Austin, Elizabeth	80	Carroll, Marilyn	53
Bahji, Anees	56	Carson, Ian	63
Bailey, Amelia	75	Chatterjee, Biswadip	48
Baillet, Emmanuelle	62	Chen, An-Jou	66
Baldwin, Aileen	70	Chen, Chuan-Yu	93
Barrington-Trimis, Jessica	23	Chen, Lian-Yu	52
Bart, Gavin	36	Chen, Ling	58
Bazan, Carolyn	76	Chen, Ren-Hao	49
Bazzi, Angela	66, 76	Cheng, Hui	61
Beams, Ryan	27	Chilcoat, Howard	19
Bedillion, Margaret	43	Choi, Jenny	27
Beeler-Stinn, Sara	74	Chou, Jessica	39
Behrends, Czarina	66	Chow, Jonathan	91
Belfer, Inna	15	Christie, Nina	92
Bello, Mariel	59	Ciceron, Chantae	77
Bennett, Allyson	36	Claypool, Sarah	68
Berger, Alyssa	93	Clingan, Sarah	79
Bergeria, Cecilia	80	Cochran, Gerald	88
Bernal, Kristen	63	Colledge, Samantha	66
Berro, Lais	25, 26	Comer, Sandra	36
Bhatia, Devika	64	Conrad, Christopher	70
Bhatraju, Elenore	67	Cook, Christopher	82, 90
Bidwell, L. Cinnamon	24	Cook, Ryan	73
Bierut, Laura	14, 46	Cooper, Hannah	30

AUTHOR INDEX

Cooper, Ziva	23	Filbey, Francesca	35, 38
Cordoba-Grueso, Whitney	88	Fink, David	86
Cottler, Linda	27	Fitzgerald, Nicole	28, 76
Coulter, Cynthia	86	Fitzpatrick, Ben	70
Cousijn, Janna	35	Flannagan, Kerry	60
Cousins, Sarah	83	Fleming, Taylor	51
Craft, William	91	Foot, Canyon	79
Crouch, Taylor	72	Foster, Katrina	21
Crouse, Bethany	91	Franken, Ingmar	37, 38
Crump, Alisha	61	Franklin, Teresa	37
Cuttler, Carrie	24	Freeman, Patricia	34
Dahlgren, Mary	86	Freitas-Lemos, Roberta	61, 81
Dakwar, Elias	42	French, Rachel	57
Davis, Alan	65	Frost, Madeline	87
Davis, Danielle	62	Funada, Masahiko	50
de Dios, Constanza	78	Funmaker, George	40
de Martell, Sierra Castedo	70	Fuoco, Morgan Justice	18
Denis, Cecile	69	Fuster, Daniel	48
Dennis, Michael	40, 41	Gaalema, Diann	29
Des Jarlais, Don	78	Gallivan, Molly	88
DeWitt, Haley	49	Galloway, Gantt	50
Dickerson, Daniel	40	Gannon, Meghan	46
Dickson, Megan	73	Garcia-Romeu, Albert	42
DiGuseppi, Graham	83	Gatch, Michael	92
Dobbins, Robert	68	Gelberg, Lillian	64
D'Onofrio, Gail	33	Gentry, Brooks	21
Dugosh, Karen	72	Gex, Kathryn	84
Dunbar, Joi	51	Giacomini, Juliana	82
Duncan, Alexandra	29	Gicquelais, Rachel	89
Dunn, Kelly	23	Gilmore-Thomas, Adrienne	72
Dwyer, Candice	62	Glass, Joseph	18
Ebrahimi, Chantel	77	Go, Vivian	30
Edmiston, Jeffery	60	Gonzalez, Angela	54
Eglovitch, Michelle	87	Gorfinkel, Lauren	79
Eisman, Andria	59	Gould, Robert	25, 26
Ekhtiari, Hamed	16, 17	Gray, Frank	67
Eller, Anthony	57	Gray, Joy	74
Elliott, Amy	69	Greenwald, Mark	41
Ellis, Jennifer	75	Griffith, Kevin	65
Ellis, Matthew	25	Griffiths, Paul	39
Engel, Shaydel	59	Gruber, Staci	16
Ertl, Melissa	76, 77	Grundmann, Oliver	22, 23
España, Rodrigo	26	Gryczynski, Jan	56
Evans-Polce, Rebecca	61	Gueguen, Maëlle	57
Fahey, Margaret	44	Guerin, Alexandre	52
Falise, Alyssa	77	Gupta, Abhishek	48
Farnum, Scott	92	Gust, Steve	39
Feelemyer, Jonathan	54	Gutkind, Sarah	58
Feinstein, Marc Jerome	61	Haeny, Angela	20
Fidalgo, Thiago	93	Hales, Tim	34

AUTHOR INDEX

Hamilton, Leah	75	Jenkins, Richard	30
Hammerslag, Lindsey	92	Jentsch, J. David	13
Hammond, David	35	Johnson, Carrie	40
Han, Benjamin	44	Jones, Abenaa	76
Han, Dae Hee	62	Jones, Jermaine	56
Hand, Dennis	45	Jones, Kasey	90
Haney, Margaret	43	Jordan, Ayana	20
Hanlon, Colleen	17	Jordan, Dephanie	20
Haque, Lamia	48	Joseph, Elizabeth	73
Hard, Gregory	74	Joseph, Verlin	77
Harlow, Alyssa	61	Joudrey, Paul	69
Harris, Julia	49	Julien, Lovelyne	78
Harris, Miriam	74	Justen, Marissa	91
Harrison, Katherine	75	Kalmin, Mariah	71
Harton, Moriah	69	Kaminsky, Stephen	21
Hashemi, Daniel	85	Kampman, Kyle	54
Hasin, Deborah	59	Kanamori, Mariano	94
Hatoum, Alexander	18	Karelitz, Joshua	61
Hawk, Kathryn	81	Karnik, Niranjana	90
Heidari, Omeid	80	Karns-Wright, Tara	69
Heil, Sarah	54	Katz, Brian	60
Heimer, Robert	57	Kaufman, Marc	82
Hennessy, Emily	41	Kaur, Jagdeep	81
Henningfield, Jack	23, 78	Kelly, John	41
Hermes, Gretchen	51	Kelpin, Sydney	57
Higgins, Stephen	13	Keyser-Marcus, Lori	42
Hill, Mandy	63	Khan, Maria	34
Hoadley, Ariel	57	Khoury, Dalia	52
Hoeflich, Carolin	77	Kiluk, Brian	75
Hoffman, Kim	75	Klemperer, Elias	67
Hoffman, Paula	27	Kleykamp, Bethea	44, 45
Hong, Judy	78	Klimas, Jan	94
Hooker, Stephanie	80	Knudsen, Hannah	81
Hoopsick, Rachel	83	Konsin, John	31
Hooten, W. Michael	21	Koob, George	12
Hoots, Jennifer	53	Korthuis, Todd	36, 37
Horta, Marilyn	44	Kral, Alex	64
Horton, Gabriella	53	Krause, Alexis	51
Howe, Lindy	84	Kroon, Emese	83
Huhn, Andrew	42	Kuhns, Lauren	35
Hunter, John	27	Kulak, Jessica	64
Hurd, Yasmin	16	Kundu, Soumya	18
Hyves, Kelly	73	Lacy, Ryan	29
Ingersoll, Karen	47	Laffont, Celine	56
Ivasiy, Roman	88	LaForge, Kate	55
Iwanicki, Janetta	25	Lambert, Laura	62
Jain, Raka	48, 49	Lane, Scott	41
James, Morgan	42	Lankenau, Stephen	84
Janes, Amy	16	Lapham, Gwen	18
Javanbakht, Marjan	58	LaValley, Christina	53

AUTHOR INDEX

Leal, Isabel Martinez	94	McCarty, Dennis	36
Lee, Dustin	54	McClure, Erin	37
Lee, Enoch	72	McCuistian, Caravella	20
Lee, Joshua	34	McCurdy, Christopher	23
Lee, Juhan	62	McDowell, Tyre	80
Leganes-Fonteneau, Mateo	42	McNeil, Ryan	67
Lent, Michelle	56	Meacham, Meredith	86
LeSage, Mark	67	Melling, Trisha	32
Levander, Ximena	36, 37, 89	Mericle, Amy	65
Levine, Emily A.	89	Miller, Emily	91
Levin, Frances	14	Miloslavich, Krista	49
Levy, Robert	93	Mintz, Carrie	82
Lile, Joshua	87	Mitchell, Mary	85
Lim, Carmen	83	Molfenter, Todd	15
Livne, Ofir	85	Monico, Laura	74
Li, Xinhua	21	Moody, Raymond	48
Logan, Ryan	33	Moran, Lauren	53
Lopez, Marsha	27	Morgan, Jake	92
Lorenzetti, Valentina	35	Morochnik, Michelle	53
Loscalzo, Emily	90	Morris, Paul	28
Lu, Thanh	52	Moses, Tabitha	68
Luciani, Karling R.	71	Mulvey, Kevin	39
Luken, Amanda	93	Myers, Matthew	82
Lundahl, Leslie	85	Myers, Ursula	24
Luo, Sean	58	Nawrocik-Madrid, Acacia	50
Lutz, Miranda	62	Nayak, Amit	59
Macatee, Richard	43	Nelson, Douglas	70
Mackesy-Amiti, Mary	68	Nesoff, Elizabeth	81
Madden, Lynn	15, 87	Nguyen, Trang	54
Magel, John	88	Nielsen, Suzanne	56
Mahoney, James	73	Nisbett, Kenisha	65
Mancino, Michael	81	Nordeck, Courtney	72
Manke, Hayley	50	Novak, Matthew	63
Mannes, Andrew	27	Nugent, Fereshteh	34
Mannes, Zachary	55	Nwankwo, Oluchi	89
Mariani, John	91	Ochalek, Taylor	68
Marotta, Phil	88	Odom, Gabriel	17
Marra, Ashton	45	Okafor, Emeka	59
Martin, Caitlin	55	Olayinka, Olaniyi	79
Martinez, Suky	92	Oliveto, Alison	71
Marton, Jennifer	67	Ompad, Danielle	65
Mason, Briana	78	Ondersma, Steven	24, 47
Matson, Theresa	85	Onigbogi, Olanrewaju	72
Mauro, Pia	60	Oswald, Lynn	34
Maust, Donovan	47	Palamar, Joseph	50
Maxwell, Andrea	50	Palzes, Vanessa	65
Mayer, Samara	80	Panicker, Sangeeta	36
McCabe, Andrew	28, 61	Pantazopoulos, Harry	32, 33
McCabe, Sean Esteban	52	Parashar, Vartika	92
McCarthy, Julie	39, 84	Parker, Maria	19, 68

AUTHOR INDEX

Parlier-Ahmad, Anna	89	Serre, Fuschia	71
Parvaz, Muhammad	38	Setnik, Beatrice	51
Patton, Thomas	67	Severtson, Stevan	81
Peckham, Andrew	64	Shah, Samay	76
Peng, Kah-Whye	21	Shearer, Riley	54
Peoples, JaNiene	64	Sherman, Brian	85
Peprah-Asante, Ohemaa	87	Shoptaw, Steve	37
Pericot-Valverde, Irene	31, 32, 81	Shover, Chelsea	19, 20
Peters, Erica	29	Shrestha, Roman	53
Pfister, Brian	66	Shulman, Matisyahu	65
Pham, Huyen	92	Sibai, Mohammad	57
Philbin, Morgan	58	Siew, Rosetta	50
Pho, Mai	30	Sigmon, Stacey	33, 34
Platt, Kristen	83	Silwal, Anita	56
Poblete, Maria	83	Simpson, Kelsey	55
Polak, Kathryn	47	Sitar, Siara	64
Preiss, Alexander	71	Skinstad, Anne	77
Psaras, Catherine	83	Smid, Marcela	93
Rabinowitz, Jill	49	Smith, Ashley	91
Rains, Alex	72	Smith, Crystal	46
Rai, Tekendra	76	Smith, Danielle	76
Raleigh, Michael	55	Smith, Doug	40, 41
Ramirez, Miranda	53	Smith, Keisha	74
Randall-Thompson, Jovita	29	Smith, Kirsten	22, 23, 79
Ray, Azizi	90	Smith, Lia	28
Reich, Jeffrey	27, 69	Song, Daihyun	70
Reji, Angitha	49	Sorg, Barbara	32, 33
Reynolds, Maureen	24	Soto, Claradina	40
Ridenour, Ty	71	Spindle, Tory	84
Rosen, Marc	80	Stack, Erin	73
Roth, Prerana	32	Stark, Haidyn	62
Rowlett, James	35	Steele, Vaughn	37, 38
Roy, Payel	56	Stewart, Jennifer	58
Sacco, Paul	39	Stinson, Elizabeth	86
Salisbury-Afshar, Elizabeth	15	Stoltman, Jonathan	45
Sanichar, Navin	90	Stoops, William	12, 13, 41
Santo, Thomas	69	Stopka, Thomas	30
Saraiya, Tanya	90	Stoudt, Matthew	26
Satterfield, Jason	70	Streck, Joanna	60
Saunders, David	63	Strickland, Justin	19
Saunders, Elizabeth	81	Struble, Cara	84
Schermitzler, Brandon	86	Suarez, James-Angelo	63
Schmeichel, Brooke	42	Sugarman, Dawn	63
Schmid, Laura	74	Sullivan, Ryan	48
Schwab, Nathan	55	Sultan, Ryan	85
Schwarting, Corrine M.	48	Sung, Young-Hoon	54
Schwebel, Frank	82	Sunshine, Jacob	31
Schweitzer, Emma	88	Surratt, Hilary	92
Seow, Tricia	42	Svikis, Dace	38, 47
Serafine, Katherine	13	Sweeney, Kaylin	93

AUTHOR INDEX

Takano, Ayumi	52	Ward, Sara Jane	16
Tang, Victor	48	Wartko, Paige	18
Tardelli, Vitor	70	Washio, Yukiko	22
Taxman, Faye	15	Weaver, Victoria	69
Taylor, Linh	67	Webster, Matt	64
Teale, Tanisse	72	Wechsberg, Wendee	21, 22
Tegge, Allison	19, 69	Wemm, Stephanie	43, 82
Terplan, Mishka	50	White, David	21
Tervo-Clemmens, Brenden	85	Whitt, Devin	83
Thabaleh, Ammar	73	Wiedbusch, Elzbieta	49
Thakrar, Ashish	79	Wiese, Anna	86
Thiessen, Karina	85	Wiley, Jenny	15, 16
Thraillkill, Eric	61	Wiley, Rhiannon	59
Tien, Celine	26	Wilkerson, J. Michael	74
Tillson, Martha	73, 88	Williams, Arthur Robin	36, 37, 89
Toegel, Forrest	29	Wilson, Deja	77
Tomko, Catherine	91	Wilson-Poe, Adrienne	23, 24
Tomlinson, Devin	58	Winstanley, Erin	34
Tompkins, D. Andrew	68	Wirtz, Hailey	60
Tripathi, Richa	49	Wisor, Jonathan	33
Tsui, Judith	18	Witkiewitz, Katie	17
Üsküp, Dilara	84	Wolinsky, David	86
Vanderziel, Alyssa	87	Won, Nae	28, 78
Veliz, Philip	52	Worden, Joseph	93
Vergunst, Francis	64	Wright, Susan	17
Vest, Bonnie	77	Wyse, Jessica	89
Vest, Noel	20	Xin, Yitong	84
Vidot, Denise	28	Xu, Kevin	46, 53
Vincent, Robert	41	Yang, Allen	55
Vogel, Erin	59	Yang, Yang	65
Volkow, Nora	12	Yeager, Samantha	55
Vroom, Enya	90	Yeh, Yu-Hua	60
Wade, Natasha	58	Yi, Richard	19
Wahab, Suzaily	51	Young, April	30
Wallace, Alexander	62	Zamora, Joshua	51
Walsh, Claire	51	Zhu, Yuhui	79
Walsh, Sharon	33, 34	Zilverstand, Anna	17
Wang, Anna	28, 75	Zule, William	30, 57

2021-2022 DONORS

Judy Ashworth

Sudie Back

Jack Bergman

Qiana Brown

Kathleen Bucholz

Alan Budney

F. Ivy Carroll

Sandra Comer

Andrew Coop

Ziva Cooper

Richard De La Garza

Kelly Dunn

Linda Dwoskin

Linda Dykstra

Loretta Finnegan

Albert Garcia-Romeu

Ellen Geller

Charles Gorodetzky

Margaret Haney

Deborah Hasin

Angela Heads

Sarah Heil

Frederic Hopf

Jesse Howard

Amy Janes

Jermaine Jones

Scott Lane

Frances Levin

Scott Lukas

Wendy Lynch

Bertha Madras

Deborah Mash

Rick Mees

Tasha Perdue

Marco Pravetoni

James Rowlett

Sidney Schnoll

Stacey Sigmon

Maxine Stitzer

William Stoops

Eric Strain

Yung-Fong Sung-Holtzman

Dace Svikis

Michael Taffe

Judith Tsui

Wendee Wechsberg

Erin Winstanley

George Woody

SAVE THE DATE

85TH ANNUAL

SCIENTIFIC MEETING

SHERATON DENVER DOWNTOWN
JUNE 17-21, 2023



The College *on* Problems
of Drug Dependence